<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005288.pub3" GROUP_ID="MENSTR" ID="246704062514042870" MERGED_FROM="" MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-13 10:19:39 +1200" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="XZ 1011" REVMAN_SUB_VERSION="5.0.5" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Chinese herbal medicine for primary dysmenorrhoea</TITLE>
<CONTACT MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="17383" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiaoshu</FIRST_NAME><LAST_NAME>Zhu</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>x.zhu@uws.edu.au</EMAIL_1><EMAIL_2>mszhuxiaoshu@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Complementary Medicine Research</DEPARTMENT><ORGANISATION>School of Biomedical and Health Science, University of Western Sydney</ORGANISATION><ADDRESS_1>Building 24, Campbelltown Campus, Locked Bag 1797</ADDRESS_1><ADDRESS_2>Penrith South DC</ADDRESS_2><CITY>Sydney</CITY><ZIP>1797</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 4620 3338</PHONE_1><FAX_1>61 2 4620 3792</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="17383" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Xiaoshu</FIRST_NAME><LAST_NAME>Zhu</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>x.zhu@uws.edu.au</EMAIL_1><EMAIL_2>mszhuxiaoshu@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Center for Complementary Medicine Research</DEPARTMENT><ORGANISATION>School of Biomedical and Health Science, University of Western Sydney</ORGANISATION><ADDRESS_1>Building 24, Campbelltown Campus, Locked Bag 1797</ADDRESS_1><ADDRESS_2>Penrith South DC</ADDRESS_2><CITY>Sydney</CITY><ZIP>1797</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 4620 3338</PHONE_1><FAX_1>61 2 4620 3792</FAX_1></ADDRESS></PERSON><PERSON ID="10564" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Michelle</FIRST_NAME><LAST_NAME>Proctor</LAST_NAME><POSITION>Editor, Cochrane Menstrual Disorders and Subfertility Group</POSITION><EMAIL_1>michelleproctor@clear.net.nz</EMAIL_1><EMAIL_2>michelle.proctor@corrections.govt.nz</EMAIL_2><URL>research/cochrane</URL><ADDRESS><DEPARTMENT>Psychological Service</DEPARTMENT><ORGANISATION>Department of Corrections</ORGANISATION><ADDRESS_1>PO Box 302457</ADDRESS_1><ADDRESS_2>North Harbour</ADDRESS_2><CITY>Auckland</CITY><ZIP>1310</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9448 3208</PHONE_1><FAX_1>+64 9 3035969</FAX_1></ADDRESS></PERSON><PERSON ID="16922" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Alan</FIRST_NAME><LAST_NAME>Bensoussan</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>a.bensoussan@uws.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Center for Complementary Medicine Research</DEPARTMENT><ORGANISATION>University of Western Sydney</ORGANISATION><ADDRESS_1>Narellan Road</ADDRESS_1><ADDRESS_2>Campbelltown</ADDRESS_2><CITY>Sydney</CITY><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 977 26363</PHONE_1><FAX_1>+61 2 977 26820</FAX_1></ADDRESS></PERSON><PERSON ID="0E01D92082E26AA2005EE6A64BAAF399" ROLE="AUTHOR"><FIRST_NAME>Emily</FIRST_NAME><LAST_NAME>Wu</LAST_NAME><POSITION>Chinese Medicine Practitioner</POSITION><EMAIL_1>emilywu@fastmail.com.au</EMAIL_1><ADDRESS><DEPARTMENT>Traditional Chinese Medicine</DEPARTMENT><ORGANISATION>Emily Wu Traditional Chinese Medicine Clinic</ORGANISATION><ADDRESS_1>4 Nelson Rd</ADDRESS_1><CITY>Lindfield</CITY><ZIP>2070</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 9415 6910</PHONE_1></ADDRESS></PERSON><PERSON ID="14621" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Caroline</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Smith</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>caroline.smith@uws.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Complementary Medicine Research</DEPARTMENT><ORGANISATION>The University of Western Sydney</ORGANISATION><ADDRESS_1>Locked Bag 1797</ADDRESS_1><CITY>Penrith South DC</CITY><ZIP>1797</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 4620 3777</PHONE_1><FAX_1>+ 61 2 9772 6810</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-05 12:48:08 +1200" MODIFIED_BY="Julie  Brown " NOTES="&lt;p&gt;Minor update: 10/28/06&lt;/p&gt;" NOTES_MODIFIED="2008-05-05 12:48:08 +1200" NOTES_MODIFIED_BY="Julie  Brown ">
<UP_TO_DATE>
<DATE DAY="14" MONTH="12" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>


</WHATS_NEW>
<HISTORY MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="12" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Minor edits made outcomes unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:15:28 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="5" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Menstrual Disorders and Subfertility Group</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>University of Western Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-13 10:18:24 +1200" MODIFIED_BY="jane clarke">
<SUMMARY>
<TITLE>Chinese herbal medicine may help reduce menstrual pain.</TITLE>
<SUMMARY_BODY>
<P>Dysmenorrhoea is a very common complaint that refers to painful menstrual cramps in abdomen. Primary dysmenorrhoea refers to pain of an unknown cause (i.e. no medical condition is identified). Nonsteroidal anti-inflammatory drugs or the contraceptive pill have been used successfully for treatment but more women are looking for non-drug therapies. Chinese herbal medicine has been used for centuries in China and it is currently used in public hospitals in China for the treatment of primary dysmenorrhoea. The review found promising evidence for the use of Chinese herbal medicine in reducing menstrual pain in the treatment of primary dysmenorrhoea, compared to conventional medicine such as NSAIDs and the oral contraceptive pill, acupuncture and heat compression. No significant adverse effects were identified in this review. However the findings should be interpreted with caution due to the generally low methodological quality of the included studies. <BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Conventional treatment for primary dysmenorrhoea has a failure rate of 20% to 25% and may be contraindicated or not tolerated by some women. Chinese herbal medicine may be a suitable alternative.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the efficacy and safety of Chinese herbal medicine for primary dysmenorrhoea when compared with placebo, no treatment, and other treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Menstrual Disorders and Subfertility Group Trials Register (to 2006), MEDLINE (1950 to January 2007), EMBASE (1980 to January 2007), CINAHL (1982 to January 2007), AMED (1985 to January 2007), CENTRAL (The Cochrane Library issue 4, 2006), China National Knowledge Infrastructure (CNKI, 1990 to January 2007), Traditional Chinese Medicine Database System (TCMDS, 1990 to December 2006), and the Chinese BioMedicine Database (CBM, 1990 to December 2006) were searched. Citation lists of included trials were also reviewed.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Any randomised controlled trials involving Chinese herbal medicine versus placebo, no treatment, conventional therapy, heat compression, another type of Chinese herbal medicine, acupuncture or massage. Exclusion criteria were identifiable pelvic pathology and dysmenorrhoea resulting from the use of an intra-uterine contraceptive device. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Quality assessment, data extraction and data translation were performed independently by two review authors. Attempts were made to contact study authors for additional information and data. Data were combined for meta-analysis using either Peto odds ratios or relative risk (RR) for dichotomous data or weighted mean difference for continuous data. A fixed-effect statistical model was used, where suitable. If data were not suitable for meta-analysis, any available data from the trial were extracted and presented as descriptive data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Thirty-nine randomised controlled trials involving a total of 3475 women were included in the review. A number of the trials were of small sample size and poor methodological quality. Results for Chinese herbal medicine compared to placebo were unclear as data could not be combined (3 RCTs). Chinese herbal medicine resulted in significant improvements in pain relief (14 RCTs; RR 1.99, 95% CI 1.52 to 2.60), overall symptoms (6 RCTs; RR 2.17, 95% CI 1.73 to 2.73) and use of additional medication (2 RCTs; RR 1.58, 95% CI 1.30 to 1.93) when compared to use of pharmaceutical drugs. Self-designed Chinese herbal formulae resulted in significant improvements in pain relief (18 RCTs; RR 2.06, 95% CI 1.80 to 2.36), overall symptoms (14 RCTs; RR 1.99, 95% CI 1.65 to 2.40) and use of additional medication (5 RCTs; RR 1.58, 95% CI 1.34 to 1.87) after up to three months of follow-up when compared to commonly used Chinese herbal health products. Chinese herbal medicine also resulted in better pain relief than acupuncture (2 RCTs; RR 1.75, 95% CI 1.09 to 2.82) and heat compression (1 RCT; RR 2.08, 95% CI 2.06 to 499.18). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The review found promising evidence supporting the use of Chinese herbal medicine for primary dysmenorrhoea; however, results are limited by the poor methodological quality of the included trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-13 10:18:24 +1200" MODIFIED_BY="jane clarke">
<BACKGROUND MODIFIED="2008-05-13 10:17:41 +1200" MODIFIED_BY="jane clarke">
<P>Dysmenorrhoea is a common gynaecological complaint among adolescent girls and women of reproductive age and refers to the occurrence of painful cramps in the lower abdominal region during menstruation. It is usually classified into two subcategories: primary dysmenorrhoea occurs in the absence of an identifiable pathological condition (<LINK REF="REF-Lichten-1987" TYPE="REFERENCE">Lichten 1987</LINK>); when the period pain is associated with organic pathology such as endometriosis, it is defined as secondary dysmenorrhoea (<LINK REF="REF-Dawood-2006" TYPE="REFERENCE">Dawood 2006</LINK>).</P>
<P>Primary dysmenorrhoea characteristically begins at or shortly after (six to 12 months) menarche, which coincides with the occurrence of the regular ovulatory cycle. Pain usually develops within hours of the start of menstrual bleeding and peaks as the flow becomes heaviest during the first day or two of the cycle (<LINK REF="REF-Dawood-2006" TYPE="REFERENCE">Dawood 2006</LINK>).</P>
<P>Period pain can have a significant impact on women's lives. Dysmenorrhoea can affect as many as 50% of women of reproductive age (<LINK REF="REF-Daniels-2002" TYPE="REFERENCE">Daniels 2002</LINK>) although, using different measurement methods and study populations, prevalence estimates vary from 60% to 85% of adolescent girls (<LINK REF="REF-Banikarim-2000" TYPE="REFERENCE">Banikarim 2000</LINK>; <LINK REF="REF-Burnett-2005" TYPE="REFERENCE">Burnett 2005</LINK>; <LINK REF="REF-Harlow-1996" TYPE="REFERENCE">Harlow 1996</LINK>; <LINK REF="REF-Vicdan-1996" TYPE="REFERENCE">Vicdan 1996</LINK>). A survey undertaken by the University of Western Australia has highlighted the high prevalence and impact of primary dysmenorrhoea as a significant public health problem that requires attention (<LINK REF="REF-Hillen-1999" TYPE="REFERENCE">Hillen 1999</LINK>).</P>
<P>Period pain can lead to an absence from school or work (<LINK REF="REF-French-2005" TYPE="REFERENCE">French 2005</LINK>). In the US alone, it was estimated that in the mid 1980s 600 million hours were lost from work, which led to an economic loss of two billion dollars; in today's dollars this figure would be much higher (<LINK REF="REF-Dawood-1984" TYPE="REFERENCE">Dawood 1984</LINK>).</P>
<P>The aetiology or cause of primary dysmenorrhoea has been the source of some debate. Experimental and clinical research has identified the over-production of uterine prostaglandins and vasopressin as contributing factors to the painful cramps (<LINK REF="REF-Dmitrovic-2003" TYPE="REFERENCE">Dmitrovic 2003</LINK>; <LINK REF="REF-Ekstrom-1992" TYPE="REFERENCE">Ekstrom 1992</LINK>). Oestrogens can stimulate the release of vasopressin and this effect is counteracted by progesterones (<LINK REF="REF-Forsling-1985" TYPE="REFERENCE">Forsling 1985</LINK>), which indicates that an imbalance in ovarian hormones may be involved in dysmenorrhoea (<LINK REF="REF-Hauksson-1987" TYPE="REFERENCE">Hauksson 1987</LINK>).</P>
<P>Principal pharmacological therapies include drugs that inhibit prostaglandins, such as non-steroidal anti-inflammatory drugs (NSAIDs); or that regulate hormones, such as the oral contraceptive pills (OCPs). NSAIDs reduce myometrial activity (contraction of the uterus) by inhibiting prostaglandin F2 (PGF2) synthesis and reducing vasopressin secretion. This may effectively reduce menstrual pain. The OCPs suppresses ovulation and thins the endometrial lining which in turn reduces menstrual fluid volume along with the amount of prostaglandins produced, thus reducing uterine contractions any associated pain (<LINK REF="REF-Creatsas-1990" TYPE="REFERENCE">Creatsas 1990</LINK>; <LINK REF="REF-Ekstrom-1992" TYPE="REFERENCE">Ekstrom 1992</LINK>). These drugs provide no long-term relief as the treatment relieves symptoms on an episode-by-episode basis only.</P>
<P>The failure rate of NSAIDs is often 20 to 25% (<LINK REF="REF-Dawood-1985" TYPE="REFERENCE">Dawood 1985</LINK>) and these drugs may be contraindicated or not tolerated by some women (<LINK REF="REF-Taylor-2002" TYPE="REFERENCE">Taylor 2002</LINK>). In addition, gastrointestinal side effects can be particularly troublesome (<LINK REF="REF-Daniels-2002" TYPE="REFERENCE">Daniels 2002</LINK>; <LINK REF="REF-Singh-1998" TYPE="REFERENCE">Singh 1998</LINK>; <LINK REF="REF-Strom-1996" TYPE="REFERENCE">Strom 1996</LINK>). Surgical interruption of the pelvic nerve pathways can be used in women who do not respond to medical treatment but, as yet, there is no strong evidence of long-term efficacy of this method (<LINK REF="REF-Proctor-2005" TYPE="REFERENCE">Proctor 2005</LINK>). Emerging documents suggest many women are seeking for alternatives to conventional medicine including herbal medicine (<LINK REF="REF-Proctor-2001" TYPE="REFERENCE">Proctor 2001</LINK>).<BR/>
<BR/>Chinese herbal medicine (CHM) has been used for centuries in China. Recently, the practice of CHM has significantly permeated a broad cross-section of the Western community (<LINK REF="REF-Bensoussan-1996" TYPE="REFERENCE">Bensoussan 1996</LINK>). A key primary requirement of traditional treatment with CHM is that the treatment needs not only to be tailored at the outset to the individual but should also be modified at different stages of the patient's recovery or illness. This is one of the underpinning theoretical constructs of traditional Chinese medicine (TCM) and a number of related complementary therapies. In this way, a second and distinct diagnostic process is required, as illness labelling (and therefore the treatment process) differs from conventional medical approaches.</P>
<P>CHM is currently used in public hospitals in China for the treatment of primary dysmenorrhoea. Case studies suggest that CHM may be effective in treating primary dysmenorrhoea; herbs may improve general well being and also reduce recurrence of the condition over a three-month of follow-up period (<LINK REF="STD-Deng-2003" TYPE="STUDY">Deng 2003</LINK>). However, the evidence describing the safety and efficacy of CHM for the treatment of primary dysmenorrhoea is important and there is a need for a systematic review of the available literature.</P>
<P>This review aims to identify randomised controlled trials (RCTs) of CHM as treatment for women with primary dysmenorrhoea in order to establish the efficacy and safety of CHM.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy and safety of CHM in the treatment of primary dysmenorrhoea when compared with a placebo, no treatment, conventional medical treatments (for example NSAIDs), heat compression or other TCM therapy (such as acupuncture, Chinese massage). </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Any RCTs involving CHM for the treatment of primary dysmenorrhoea were considered for inclusion in the review. It was intended to include only phase-one data from any cross-over trials in meta-analysis but no such trials were found. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women in the trials needed to meet the following inclusion criteria for the trial to be included in the review: <BR/>* be of reproductive age; <BR/>* have primary dysmenorrhoea, i.e. individuals with no identifiable pelvic pathology as indicated by pelvic examination, ultrasound scans and laparoscopy; or women self reporting a diagnosis of primary dysmenorrhoea; <BR/>* have primary dysmenorrhoea (self reported) during the majority of the menstrual cycles or for three consecutive menstrual cycles; <BR/>* take hormones or NSAIDs for the management of primary dysmenorrhoea. </P>
<P>Exclusion criteria: <BR/>* women with identifiable pelvic pathology as revealed by a physical or gynaecological examination; <BR/>* women with dysmenorrhoea resulting from intra-uterine device (IUD) use. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any RCTs involving CHM as treatment for primary dysmenorrhoea. Interventions could include but were not limited to the following: <BR/>* any Chinese herbal medicine versus placebo for primary dysmenorrhoea; <BR/>* any Chinese herbal medicine versus no treatment for primary dysmenorrhoea; <BR/>* any Chinese herbal medicine versus conventional therapy (e.g. NSAIDs or OCPs) for primary dysmenorrhoea; <BR/>* one type of Chinese herbal medicine versus another type of CHM for primary dysmenorrhoea; <BR/>* any Chinese herbal medicine versus acupuncture or massage for primary dysmenorrhoea. </P>
<P>
<I>Change from protocol </I>
<BR/>Searches for trials identified a trial comparing CHM with heat compression (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>). The original protocol for this review did not include this intervention. However, this trial was included in the review to ensure that a full comparison of treatments could be made. </P>
<P>Note <BR/>* Detailed interventions might include, but were not limited to, a single Chinese herb or Chinese herbal formulae that were either fixed formulae or tailored formulae. <BR/>* The routes of administration of interventions included, but were not limited to, oral or external use. <BR/>* The forms of administration involved, but were not limited to, herbal decoctions, herbal extract such as powders, herbal pills or tablets or plasters containing herbs. <BR/>* Co-interventions included OCPs or NSAIDs. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>At least one of the following primary outcomes was measured for a trial to be included. Data from each of the following outcomes were recorded, where available. </P>
<P>
<B>Primary outcomes</B> </P>
<P>1. Reduction in pain (i.e. menstrual pain) that occurred only during the intervention or occurred during the intervention and was maintained for more than two consecutive menstrual cycles - measured by a visual analogue scale (VAS), or other validated scales, or measured as dichotomous outcomes. </P>
<P>2. Overall reduction in symptoms (other menstruation-related symptoms) that occurred only during the intervention or occurred during the intervention and was maintained for more than two consecutive menstrual cycles - measured by changes in dysmenorrhoeic symptoms, treatment effectiveness that was either self reported or observed or other similar measures. <BR/>
<BR/>3. Adverse effects - measured by any relevant incident and duration of any side effects. </P>
<P>
<B>Secondary outcomes <BR/>
</B>
<BR/>1. Laboratory tests (where changes occurred only during the intervention or occurred during the intervention and were maintained for more than two consecutive menstrual cycles) - measured by changes in a biomedical test (i.e. PGF2, oxytocin, vasopressin, oestrogen progesterone or another substance). </P>
<P>2. Use of additional medication - measured as the proportion of women requiring no analgesics and continued routine activities. </P>
<P>3. Satisfaction of treatment as reported by patients - measured as the proportion of women who reported improvements or satisfaction, or both, with their treatment. </P>
<P>4. Quality of life - measured by a validated scale, for example SF 36. </P>
<P>
<I>Change from protocol</I>
<BR/>The laboratory tests were removed at the review stage, as required by the Cochrane Menstrual Disorders and Sub-fertility Group (MDSG). </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-13 09:58:07 +1200" MODIFIED_BY="jane clarke">
<P>The Cochrane MDSG search strategy was adopted. Reports which described (or might describe) RCTs of CHM in the treatment of primary dysmenorrhoea were obtained using the following search strategy.</P>
<P>(1) The MDSG Specialised Register of controlled trials was searched for any trials with primary dysmenorrhoea or dysmenorrhoea in the title, abstract or keyword sections.</P>
<P>(2) The following electronic databases were searched from their inception to the date given:<BR/>Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2006, Issue 4), MEDLINE (1950 to January week 2 2007), EMBASE (1980 to January week 2 2007), CINAHL (1982 to January week 1 2007), AMED (1985 to January week 1 2007).</P>
<P>The keywords used for MEDLINE and other English language databases see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. MeSH words were adapted as necessary for other databases.</P>
<P>Search results</P>
<P>CENTRAL: eleven references found, four relevant (<LINK REF="STD-Deng-2003" TYPE="STUDY">Deng 2003</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Song-2005" TYPE="STUDY">Song 2005</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>).<BR/>MEDLINE: thirty-seven references found, six were RCTs (<LINK REF="STD-Deng-2003" TYPE="STUDY">Deng 2003</LINK>; <LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Song-2005" TYPE="STUDY">Song 2005</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).<BR/>EMBASE: seventy references found, two were RCTs (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).<BR/>CINAHL: nineteen references found, none of them was relevant.<BR/>AMED: ten references found, one was a RCT (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>).</P>
<P>The search of English language databases identified a number of duplicated references from the search of the Chinese databases (see below); however, three studies published in English were relevant (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).</P>
<P>(3) Three electronic Chinese databases were examined. These were the China National Knowledge Infrastructure (CNKI) (1990 to January week 1 2007), Traditional Chinese Medicine Database System (TCMDS) (1990 to December 2006) and Chinese BioMedicine Database (CBM) (1990 to December 2006). The search identified a large number of trials on the use of CHM in the treatment of primary dysmenorrhoea. However, search results from the individual databases overlapped significantly. Only search results from CNKI were reported in this review given it is regarded as having wide coverage with full paper access.</P>
<P>The keywords used for the Chinese language databases research see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>The search of the CNKI identified five hundred and sixty-six references; thirty-six of these were RCTs.</P>
<P>(4) The reference lists of all included studies or relevant review articles were screened for further relevant papers.</P>
<P>(5) The authors of significant papers and other experts in the field were contacted to ask if they knew of other relevant published or unpublished material for this review.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Selection of studies</B> </P>
<P>The selection of trials for inclusion in the review, or exclusion from the review, was performed by two review authors (XZ and MP), based on employing the search strategy described previously. Since the majority of references were published in Chinese, two bilingual review authors (XZ and EW) translated the reports and extracted data onto hard copy data sheets independently. </P>
<P>
<B>Quality assessment and data extraction </B>
</P>
<P>All assessments on the quality of trials and further data extraction were performed independently by two review authors (XZ and MP). Any discrepancies were to have been resolved by a third review author (AB or CS) however this was not necessary due to the lack of discrepancies. Additional information on the trial methodology or actual original trial data were sought from the principal author of those trials which appeared to meet the eligibility criteria but where aspects of methodology were unclear or where the data were in a form unsuitable for meta-analysis. </P>
<P>Letters were sent to the authors of four included studies and seventeen excluded studies to request additional information on trial methodology for clarification or original trial data if the data in the reports were in a form unsuitable for meta-analysis. The authors would like to thank Dr Stephen Kennedy, Dr Hua Liu and Dr Neirong Li for responding to the request for further information about their trials. Replies have not yet been received from the other studies. Letters were not sent to some contact authors of studies as recent addresses for the authors could not be located. </P>
<P>When data were extracted for some included trials for the outcome of "reduction of pain" (measured as the number of women with reduced pain compared to the total number of women in the treatment group), only women who reported a complete reduction in pain were counted as having reduced pain. For example, if a treatment group of 100 women were measured for intensity of pain using either complete reduction (n = 50), moderate reduction (n = 30), minimal reduction (n = 10) or no reduction (n=10), then only the number of women who reported complete reduction (n = 50) were included in meta-analysis as having experienced a reduction in pain (n = 50/100). The same approach was used for the outcome of "overall reduction in symptoms". </P>
<P>All trials were assessed for methodological quality using the Jadad scale (as below).</P>
<P>Methodological quality assessment (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) </P>
<P>* Was the assigned treatment adequately concealed prior to allocation? <BR/>* Were the outcomes of patients who withdrew or were excluded after allocation described and included in an 'intention-to-treat' analysis? <BR/>* Were the withdrawals less than 15% of the study population? <BR/>* Were the inclusion and exclusion criteria for entry clearly defined? <BR/>* Were the treatment and control groups comparable at entry? <BR/>* Were the women blinded to assignment status following allocation (if trial design allowed it)? <BR/>* Were the treatment providers blinded to assignment status (if trial design allowed it)? <BR/>* Were the care programmes, other than the trial options, identical? <BR/>* Were there any checks to ensure compliance with treatment? <BR/>* Were the outcome assessors blind to assignment status? <BR/>* Were the outcome measures used clearly defined? <BR/>* Were the accuracy, precision and observer variation of the outcome measures adequate? <BR/>* Was the timing of the outcome measures appropriate? <BR/>* Were the outcome measures clearly reported? </P>
<P>Furthermore, allocation concealment was scored according to the categories used by the Cochrane Collaboration: allocation concealment was adequate (A), unclear (B), inadequate (C) or allocation concealment was not used (D). The reviewers followed the protocol for defining allocation concealment categories as set by the Cochrane MDSG, that is allocation based on odd or even hospital numbers, alternation, day of week and similar methods were regarded as non-randomised. These studies were, therefore, excluded from the review rather than being classified as C. Other aspects are reported in the 'Methodological quality of included studies' section of the review, such as: use of blinding, use of intention-to-treatment analysis, numbers lost to follow up, trial design and adherence to treatment protocols. </P>
<P>
<B>Analysis </B>
</P>
<P>Statistical analysis was performed in accordance with the guidelines developed by the Cochrane MDSG. Where possible, intention-to-treat data were extracted from trials and used in the analysis. </P>
<P>Statistical analysis was performed using the Review Manager software (<LINK REF="REF-RevMan-2002" TYPE="REFERENCE">RevMan 2002</LINK>). For dichotomous data, relative risk (RR) and associated 95% confidence interval (CI) were calculated using a fixed-effect model. Weighted mean difference (WMD) and 95% CI were calculated for continuous data using a fixed-effect model.</P>
<P>For two trials (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>), data could not be extracted for meta-analysis. The data from these trials were included as descriptive data and were still considered in the results of the review (<I>see</I> Additional tables such as <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>).</P>
<P>Three of the included trials set up more than two comparisons. Two trials had two experimental groups versus one control group (placebo or NSAIDs); the experimental groups were merged for analysis of data accordingly in the graph (<LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>). The third trial had one experimental group against two control groups, which was taken into account in the analysis (<LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>). <BR/> <BR/>Statistical heterogeneity between trials was tested using a standard chi-squared test. Inconsistency across trials included in meta-analysis was measured using I<SUP>2</SUP>. This describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error. As a general rule, I<SUP>2</SUP> values of up to 25% provide evidence of low heterogeneity, a value of 50% is considered moderate heterogeneity and 75% or above is considered as high heterogeneity. In the presence of significant heterogeneity, the causes of heterogeneity were examined by pre-specified sub-group analysis and also sensitivity analysis, if possible. Where sub-group analysis failed to explain the heterogeneity, then data were analysed using the random-effects model. </P>
<P>Sensitivity analysis was used to explore the influence of high quality trials (defined as A category) versus moderate and low quality trials (defined as B or C), as well as the effects of analysing by intention-to-treat, on the effect size. If heterogeneity could not be explained by these pre-specified analyses then meta-analysis was to be performed using a random-effects model. The intention-to-treat analysis was not used as appropriate data were not always available. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-13 10:18:24 +1200" MODIFIED_BY="jane clarke">
<P>Using the search strategy described above, thirty-nine RCTs involving treatment for primary dysmenorrhoea with CHM were identified.</P>
<P>
<B>Trials excluded from the review</B>
</P>
<P>A total of twenty-six trials were excluded from the review, for the following reasons:</P>
<UL>
<LI>Three trials included participants with either primary or secondary dysmenorrhoea and separate data were not reported.</LI>
<LI>Four trials did not mention randomisation.</LI>
<LI>One trial involved a combined intervention of CHM with acupuncture in the experimental group</LI>
<LI>Eighteen trials were not randomised (the numbers of women in each treatment arm were very different, for example 56 women in the herbal group versus 32 women in the control group, even though the word of randomisation was used in the reports). Attempts were made to contact the authors to clarify randomisation and allocation concealment, however no response was received.</LI>
</UL>
<P>
<BR/>
<I>See</I> the 'Characteristics of excluded studies' table for more information.</P>
<P>
<B>Trials included in the review </B>
</P>
<P>The review included thirty-nine RCTs, all of which were of parallel design see<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> .</P>
<P>Most of the studies were conducted in mainland China, except one was conducted in Taiwan, one in Japan and another one in the Netherlands. Thirty-six of the included trials were published in Chinese and three were published in English (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>). <B>
<BR/>
</B>
<BR/>
<B>Participants </B>
</P>
<P>The inclusion and exclusion criteria for participation were quite explicit for the majority of included studies. Thirty-six out of the thirty-nine included trials were carried out in hospitals in mainland China and as a result, the diagnosis of primary dysmenorrhoea was confirmed through one of three methods; pelvic examination, ultra sound scans or laparoscopy. The trial conducted in Japan did not state the source of the participants. However, it indicated that a confirmed diagnosis of primary dysmenorrhoea was an inclusion criterion, although the method used for diagnosis was unclear (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>). The trial in Taiwan recruited students as participants (<LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>). It appeared that participants with a self report of primary dysmenorrhoea were included but it is unclear if this self report was medically confirmed (<LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).</P>
<P>
<B>Principle of herbal treatment </B>
</P>
<P>It is a common approach in the practice of CHM to use differentiated pattern(s) that is clusters of related symptoms to determine appropriate treatment. Research suggests that there are five or six different patterns in TCM diagnostics that may correspond to primary dysmenorrhoea as defined in western medicine. These decide the herbal formulation to be used in the trials or clinical practice (<LINK REF="REF-Luo-1986" TYPE="REFERENCE">Luo 1986</LINK>; <LINK REF="REF-SATCM-1995" TYPE="REFERENCE">SATCM 1995</LINK>; <LINK REF="REF-Xia-1994" TYPE="REFERENCE">Xia 1994</LINK>).</P>
<P>In this review, six of the included trials considered patterns of symptoms in conjunction with other factors determined by conventional western medicine in the inclusion criteria. There were another thirteen trials only considered a specific TCM diagnostic pattern (that pattern was only treated with a corresponding experimental herbal formula). In other words, nineteen of the included trials considered the traditional approach by making individualised treatment based on differentiated pattern(s) in TCM diagnosis.</P>
<P>The criteria for differentiating the patterns of symptoms in most included trials were referred to the Traditional Chinese Medicine Professional Statute: Criteria of diagnosis and therapeutic effect of diseases/syndromes, published by the State of Administration of Traditional Chinese Medicine, China (<LINK REF="REF-SATCM-1995" TYPE="REFERENCE">SATCM 1995</LINK>) A number of other references such as textbooks were supplemented (<LINK REF="REF-Luo-1986" TYPE="REFERENCE">Luo 1986</LINK>; <LINK REF="REF-Maciocia-1998" TYPE="REFERENCE">Maciocia 1998</LINK>; <LINK REF="REF-Xia-2000" TYPE="REFERENCE">Xia 2000</LINK>; <LINK REF="REF-ZCTCM-1991" TYPE="REFERENCE">ZCTCM 1991</LINK> ).</P>
<P>In accordance with the fundamental TCM philosophy (<LINK REF="REF-Maciocia-1998" TYPE="REFERENCE">Maciocia 1998</LINK>), the tailored approach was defined in this review as the prescription of an experimental formula or herb to a group of women who were diagnosed with a corresponding pattern as defined in TCM diagnostics; or when an experimental formula or herb was used but modified according to individualised clinical presentation in addition to the principal pattern; or the prescription of a series of experimental formulae was made that corresponded with each individualised diagnostic pattern.</P>
<P>In contrast, if an experimental formula or herb was applied to the eligible women regardless of TCM diagnostic patterns, and it was maintained throughout an entire course of intervention without alteration, treatment was then defined as the standardised approach.</P>
<P>The measurement of different patterns was mainly based on descriptive symptoms and signs. However, two trials used integrated numeric scales as assessment tools (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>).</P>
<P>
<B>Comparison and control groups<BR/>
</B>
<BR/>Included trials incorporated the following comparisons.<BR/>* Chinese herbal medicine versus placebo: three trials.<BR/>* Chinese herbal medicine versus no treatment: one trial.<BR/>* Chinese herbal medicine versus conventional therapy (for example NSAIDs or OCPs): fourteen trials.<BR/>* Chinese herbal medicine versus another type/formula of Chinese herbal medicine: eighteen trials.<BR/>* Chinese herbal medicine versus acupuncture: two trials.<BR/>* Chinese herbal medicine versus massage: no trial.<BR/>* Chinese herbal medicine versus heat compression: one trial.</P>
<P>The majority of trials compared two interventions; a placebo was seldom used as the control intervention.</P>
<P>Many included trials comparing herbal medicine with conventional therapy used non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin or ibuprofen. Oral contraceptive pills (OCPs) were also used in the control groups.</P>
<P>The most popular comparison agent was different composition, or another form of administration but the same composition, of herbal formula. In most cases, an over-the-counter, commonly used, patented formula or a single herb, considered as a natural health product in China, was compared with a self-designed formula.</P>
<P>Acupuncture with limited numbers of acupuncture points was also selected as a control therapy (<LINK REF="STD-Miao-2001" TYPE="STUDY">Miao 2001</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>). Heat compression using a hot water bottle was the comparison treatment in one trial (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>).</P>
<P>
<B>Herbal intervention in the experimental group</B>
</P>
<P>The majority of included trials used complicated formulae with more than five or six herbs. However, two included trials tested a single herb, either in the form of a decoction tea or as an herbal extraction (<LINK REF="STD-Niu-1996" TYPE="STUDY">Niu 1996</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).</P>
<P>Regardless of the variations in formulation, the herbs were mostly chosen from the following categories that are set out in the Chinese herbal pharmacopoeia and textbooks: herbs 'regulating the Qi and Blood', 'warming the Interior', 'tonifying the Kidney and Liver' and 'reinforcing Qi and Blood' (<LINK REF="REF-Bensky-2004" TYPE="REFERENCE">Bensky 2004</LINK>; <LINK REF="REF-NUTCM-2006" TYPE="REFERENCE">NUTCM 2006</LINK>).</P>
<P>The most frequently evaluated herbs were: <I>Danggui</I> (Angelicae sinensis Radix; Chinese angelica root), <I>Chuanxiong</I> (Chuanxiong Rhizoma; Szechuan lovage root), <I>Chishao </I>(Paeoniae Radix rubra; red peony root), <I>Baishao</I> (Paeoniae Radix alba; white peony root), <I>Yimucao</I> (Leonuri Herba; Chinese motherwort), <I>Puhuang</I> (Typhae Pollen; cattail pollen), <I>Wulingzhi </I>(Trogopterori Faeces, flying squirrel feces), <I>Niuxi </I>(Achyranthis bidentatae Radix; achyranthes root), <I>Danshen</I> (Salviae miltiorrhizae Radix; salvia root), <I>Chaihu</I> (Bupleuri Radix; Chinese thorowax root), <I>Xiangfu</I> (Cyperi Rhizoma; nut-grass rhizome), <I>Yanhusuo </I>(Corydalis Rhizoma; corydalis rhizome), <I>Aiye</I> (Artemisiae argy Folium; mugwort leaf), <I>Wuzhuyu</I> (Evodiae Fructus; evodia fruit), <I>Huixiang</I> (Foeniculi Fructus; fennel fruit), <I>Rougui</I> (Cinnamomi Cortex; cinnamon bark), <I>Dihuang</I> (Rehmanniae Radix; rehmannia root), <I>Gouqizi </I>(Lycii Fructus; lycium fruit), <I>Dangshen</I> (Codonopsis Radix; codonopsis root), <I>Baizhu</I> (Atractylodis macrocephalae Rhizoma; atractylodes rhizome) and <I>Gancao</I> (Glycyrrhizae Radix; liquorice root).</P>
<P>The dosages varied but most were within the standard ranges defined by the Chinese herbal pharmacopoeia (<LINK REF="REF-NUTCM-2006" TYPE="REFERENCE">NUTCM 2006</LINK>).</P>
<P>Traditional preparation of herbs, a cooked decoction, was used in many included trials. To avoid the inconvenience of the traditional cooking procedure, preparations of herbs in a form of pills, powders, or plasters (for external use) were also used in the included trials.</P>
<P>Most trials considered timing of the clinical intervention based on phase of menstrual cycle. Herbal interventions were usually introduced from five to seven days prior to the onset of menstruation and continued for a period of approximately 10 to 15 days, which was until the first or second day of menstruation or throughout the whole bleeding period. One trial specified that the herbs should be given three days prior to bleeding and continued for a period of five days (<LINK REF="STD-Yang-2005" TYPE="STUDY">Yang 2005</LINK>).<BR/>
<BR/>
<B>Outcome measures<BR/>
</B>
<BR/>Outcome measures of reduction in pain varied. Most included studies measured the pain intensity rating on an ordinal scale (for example, from poor to excellent) in combination with a dichotomous measure (for example, complete relief or ongoing pain). Pain relief was measured as the number of women with pain relief, reduced pain or no improvement compared with the total number of women in the treatment or control group; whether or not there was a relapse during the follow-up was also taken into consideration. The majority of trials that were conducted in mainland China fell into this group; which indicates such practice was compliant with the statute enacted by the State Administration of Traditional Chinese Medicine, People's Republic of China, for measuring therapeutic efficacy of herbs in the treatment of primary dysmenorrhoea (<LINK REF="REF-SATCM-1995" TYPE="REFERENCE">SATCM 1995</LINK>).<BR/>
<BR/>A continuous numerical scale such as a visual analogue scale was rarely used in mainland China, but was used in three included studies from other countries or regions (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>). Tseng and her colleagues used multiple scales to rate the degree of pain, such as the Short-form McGill Pain Questionnaire and the Menstrual Distress Questionnaire Short Form.</P>
<P>Associated menstrual symptoms analysed as overall reduction in symptoms in meta-analysis, were measured in a similar way as for reduction in pain in many included trials. Psychophysiological well being was assessed by two trials (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>).</P>
<P>Only eight out of thirty-nine included trials reported adverse effects. Seven trials (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Liu-2000" TYPE="STUDY">Liu 2000</LINK>; <LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>; <LINK REF="STD-Wang-2006a" TYPE="STUDY">Wang 2006a</LINK>; <LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>) provided a thorough report. For example, the number of incidents in both the experimental and control groups, the nature of an adverse event and how the adverse incident was dealt with, were reported in the trials. However, one trial ( <LINK REF="STD-Deng-2003" TYPE="STUDY">Deng 2003</LINK>) had incomplete data as it reported that there was no incident in the experimental group, but did not provide information on the control groups. One trial (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>) mentioned that headache was the most frequently reported side effect, with equal frequency in both experimental and control groups. The adverse effects were usually self reported. Four out of the thirty-nine included trials (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Li-2001" TYPE="STUDY">Li 2001</LINK>; <LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>) reported that the measures used were occurrence of signs or symptoms as self-report; laboratory tests such as blood and urine routine tests; electrocardiogram (EKG); and liver and renal function tests.</P>
<P>Five included trials gave detailed reports on the impact of herbs on biomedical parameters such as hormone levels; microcirculation morphology; and haemorheology (not reported in this review). One trial mentioned that laboratory tests were evaluated but did not provide any details (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>).</P>
<P>Ten out of the thrifty-nine included trials assessed requirements for additional medication in the way similar to the measurement of reduction in pain. One trial (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>) mentioned that rescue medication was recorded but no details were provided.</P>
<P>Only one trial assessed the outcome of satisfaction with treatment, as reported by the participants; no details were provided for meta-analysis (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>).</P>
<P>No trial assessed the outcome of self-reported quality of life.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>Allocation concealment and randomisation<BR/>
</B>
<BR/>Only two out of the included trials described adequate methods of randomisation and allocation concealment, receiving an allocation score of A (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). All other included trials received allocation scores of B or C as they did not either have clear descriptions of their method of allocation or their randomisation methods, or the methods they chose were inadequate. Poor compliance during clinical intervention was also noted (<LINK REF="STD-Huang-2000" TYPE="STUDY">Huang 2000</LINK>). </P>
<P>
<B>Blinding <BR/>
</B>
<BR/>Four included trials were single blinded (<LINK REF="STD-Li-2001" TYPE="STUDY">Li 2001</LINK>; <LINK REF="STD-Niu-1996" TYPE="STUDY">Niu 1996</LINK>; <LINK REF="STD-Song-2003" TYPE="STUDY">Song 2003</LINK>; <LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>); three trials were double blinded (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). The other included trials did not mention blinding at all. </P>
<P>Two included trials reported that there was no difference in appearance, taste, packaging, labelling nor coding between the placebo and the experimental herbal formula, to ensure that blinding was maintained (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). The trial conducted in Japen also used a placebo as a control but no details were given in the report as to similarity to the intervention formula (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>).</P>
<P>
<B>Power calculation</B> </P>
<P>Only one included trial mentioned power calculation and stated that no formal statistical sample size calculation was made because this was a pilot study; it estimated a sample size for future study (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>).<BR/> <BR/>
<B>Baseline similarity of comparison groups <BR/>
</B>
<BR/>Thirty-four included trials compared the treatment and control groups at baseline to ensure that they were comparable with respect to known prognostic factors; thirty-one out of thirty-four reported no statistically significant difference between the groups at baseline. </P>
<P>Nineteen out of the thirty-four trials considered the patterns in TCM in addition to age, duration of symptoms, history and severity as entry measures. Thirteen trials only considered one specific clinical pattern of primary dysmenorrhoea in TCM diagnosis. </P>
<P>Five included trials did not report on the baseline similarity of comparison groups. </P>
<P>
<B>Intention-to-treat (ITT) analysis and follow-up <BR/>
</B>
<BR/>Only two included trial clearly reported the number of drop-outs and withdrawals (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>), although ITT analysis was not implemented; nor was it used in the other included trials. One trial reported that the exclusion of data from analysis was due to poor compliance and incomplete data; nevertheless the information about drop-outs was unclear (<LINK REF="STD-Deng-2005" TYPE="STUDY">Deng 2005</LINK>). </P>
<P>Most included trials had two to three months of follow-up after the cessation of clinical intervention; four out of the thirty-nine included trials did not report on any further follow-up (<LINK REF="STD-Luo-2001" TYPE="STUDY">Luo 2001</LINK>; <LINK REF="STD-Qin-2003" TYPE="STUDY">Qin 2003</LINK>; <LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>; <LINK REF="STD-Wang-2006a" TYPE="STUDY">Wang 2006a</LINK>). </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>Reduction of pain <BR/>
</B>
<BR/>
<B>
<I>1) Reduction in pain - Chinese herbal medicine versus placebo</I>
</B>
</P>
<P>Three trials (166 women) compared CHM against placebo. </P>
<P>One trial (90 women) that set up two experimental herbal groups with slightly changed formulae (30 women in each group) was included in meta-analysis. The dichotomous data showed a statistically significant difference between the herbal intervention and placebo on reduction in pain (RR 5.59, 95% CI 0.32 to 97.87) (<LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). </P>
<P>One trial with a small sample size (36 women) ( <LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>) reported no statistically significant difference between the herbs and placebo in pain relief, although after the third cycle of intervention, 53% of women in the herbal groups reported less pain than usual compared with 26% in the placebo group. Results from meta-analysis for two outcomes measuring the maximal pain scores (Cmax) and total pain (area under the curve) (AUC) at the follow-up cycle showed no statistically significant difference between herbs and placebo (RR 1.00, 95% CI -17.95 to 19.95 and RR 12.00, 95% CI -54.76 to 78.76, respectively). More details are listed in the Additional table (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). </P>
<P>One trial reported data in a form which was unsuitable to be included in meta-analysis (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>). It found that CHM was significantly more effective than placebo through two treatment months and two months of follow-up (40 women; P &lt; 0.05 for the first treatment month, P &lt; 0.005 for subsequent months, <I>see </I> Additional table <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). </P>
<P>
<B>
<I>2) Reduction in pain - Chinese herbal medicine versus no treatment </I>
</B>
</P>
<P>One trial (130 women) (<LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>) compared the use of a single herb <I>Meiguihua </I>(Rosae rugosae Flosin, rosebud) in a form of tea, to no treatment. Multi-dimensional indicators including the Short-form of the McGill Pain Questionnaire (SF-MPQ), the Menstrual Distress Questionnaire Short Form (MDQ-SF), a Visual Analogue Scale for Anxiety (VASA), and a Perceived Stress Scale (PSS) were used. However, the results could not be included in meta-analysis. The trial reported no significant difference between rose tea and control for changes from baseline in any outcome measure after six months of treatment (mean difference in the SF-MPQ at six months was -1.76; VASA -0.04; perceived stress scale -1.58; MDQ-SF -1.44). The P values were not reported. However, when the adjustments for differences in age and the PSS scores at baseline were made, it found that rose tea improved all scores significantly more than control treatment for up to six months (P &lt; 0.001 for all scales). <I>See</I> Additional table <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>
<B>
<I>3) Reduction in pain - Chinese herbal medicine versus conventional therapy</I>
</B>
<I> </I>
</P>
<P>Fourteen included trials (1441 women) with a methodological quality score of B compared CHM against one of commonly used conventional therapies such as NSAIDs or OCPs. Data from all trials were suitable for meta-analysis, and the trials were divided into sub-groups according to the use of standardised formulae or tailored formulae. </P>
<P>Most trials assessed reduction in pain with the lasting effect during two or three cycles of follow-up. One trial measured an immediate efficacy of pain relief within 15 to 30 minutes of intervention, without follow-up evaluation (<LINK REF="STD-Wang-2006a" TYPE="STUDY">Wang 2006a</LINK>). </P>
<P>All these trials included at least one complex Chinese herbal formula in experimental group. </P>
<P>The results for this outcome showed significant heterogeneity (I<SUP>2</SUP> 81.7) that could not be accounted for by the herbal formula, trial quality or follow-up time. A random-effects model was used in meta-analysis. </P>
<P>Five trials (652 women) used the standardised treatment approach, which means a formula was given to participants regardless of diagnostic types of pattern in TCM. Overall results showed that standardised CHM provided significant improvement in pain relief with long-term efficacy when compared to conventional therapies (RR 2.28, 95% CI 0.88 to 5.94).</P>
<P>Nine trials (789 women) used the tailored approach where a formula was prescribed according to a correlating pattern. Results showed that the Chinese herbal formula tailored to individualised clinical pattern also provided significant improvements in pain relief for up to three months of follow-up (RR 2.13, 95% CI 1.70 to 2.66). </P>
<P>One trial (340 women) tested a herbal product which is commonly used sublingually for heart disorders such as angina pectoris, against oral administration of indomethacin. The results showed that the herbs were superior to indomethacin (RR 1.67, 95% CI 1.42 to 1.97) (<LINK REF="STD-Wang-2006a" TYPE="STUDY">Wang 2006a</LINK>). </P>
<P>The overall outcome from meta-analysis of fourteen included trials (1441 women) showed that the use of CHM resulted in a significant improvement in pain relief compared to conventional therapies (RR 1.99, 95% CI 1.52 to 2.60); in most cases, the benefit continued for up to three months of follow-up. <BR/> <BR/>
<B>
<I>4) Reduction in pain - Chinese herbal medicine (experimental) versus Chinese herbal medicine (OTC) </I>
</B>
</P>
<P>Eighteen included trials (1527 women) compared self-designed Chinese herbal formulae or a single herb with one of the commonly used OTC herbal health products. Data from all trials were suitable for meta-analysis. Sub-groups were set up for statistical analysis based on the type of formulation used (standard or tailored). </P>
<P>One trial had a methodological quality score of C; the other seventeen trials were scored as B for quality. </P>
<P>Seventeen out of the eighteen (1474 women) included trials used complex Chinese herbal formulae designed by the researchers, only one trial (53 women) used a single herbal ingredient (<LINK REF="STD-Niu-1996" TYPE="STUDY">Niu 1996</LINK>). </P>
<P>Five out of the eighteen trials (380 women) used self-designed formulae during an entire course of intervention, regardless of the individual clinical patterns, that is defined as a standardised approach in this review. The other fourteen included trials (1147 patients) also used self-designed formulae but the formulae were tailored throughout the treatment period based on a principal formula. </P>
<P>One out of the eighteen trials (60 patients), with a methodological quality score of C, had one experimental group which was used with herbal suppository in comparison with two different control groups both in a form of capsule for oral administration (one was a herbal health product , and the other was as the same herbal formula as used in the experimental group). The results from the comparison of experimental formula (same formula in both forms of suppository and capsules) and the control formula (capsules, different formula) showed no statistically significant difference (RR 0.92, 95% CI 0.43 to 1.99) (<LINK REF="STD-Wang-1996" TYPE="STUDY">Wang 1996</LINK>). In order to evaluate the efficacy of experimental formula, although the group used the same herbal formula in a form of capsule was defined as one of the control groups, the data were merged with the experimental group (in a form of suppository) for meta-analysis, since the same experiemental formula was tested. </P>
<P>Five trials, with a methodological quality score of B, compared a standard and self-designed formulae against an over-the-counter herbal product. These trials showed a statistically significant difference in favour of the self-designed formulae (RR 2.09, 95% CI 1.62 to 2.70). Twelve trials, with a methodological quality score of B, compared tailored formulae with an over-the-counter formula. These trials showed a statistically significant difference in favour of the tailored formulae (RR 2.13, 95% CI 1.80 to 2.51). </P>
<P>Overall, meta-analysis of eighteen trials (1527 women) showed that CHM provided pain relief for primary dysmenorrhoea for up to three months of follow-up (RR 2.06, 95% CI 1.80 to 2.36). </P>
<P>
<B>
<I>5) Reduction in pain - Chinese herbal medicine versus acupuncture</I>
</B>
<B> </B>
</P>
<P>Two trials (156 women) compared CHM against acupuncture. One used a standardised formula (<LINK REF="STD-Miao-2001" TYPE="STUDY">Miao 2001</LINK>) and the other trial used a tailored formula (<LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>). Overall results showed a statistically significant difference between CHM and acupuncture (RR 1.75, 95% CI 1.09 to 2.82). </P>
<P>
<B>
<I>6) Reduction in pain - Chinese herbal medicine versus massage</I>
</B>
</P>
<P>No data were available for this comparison </P>
<P>
<B>
<I>7) Reduction in pain - Chinese herbal medicine versus heat compression</I>
</B>
</P>
<P>One trial (55 women) compared CHM to heat compression. Results showed that CHM was significantly more effective for reduction in pain at three months of follow-up than applying a heat compress to the lower abdomen (RR 32.08, 95% CI 2.06 to 499.18). </P>
<P>
<B>Overall reduction in symptoms <BR/>
</B>
<B>
<I>
<BR/>1) Overall symptoms - Chinese herbal medicine versus placebo <BR/>
</I>
</B>
<B>
<BR/>
</B>Two trials (130 women) compared CHM against placebo. One trial (90 women) with two experimental herbal groups (30 women in each group with slightly changed formulae) was included in meta-analysis and showed statistically significant difference between the herbal intervention and placebo (RR 5.59, 95% CI 0.32 to 97.87) (<LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). </P>
<P>Another trial did not report direct results on this outcome (<I>see </I>Additional tables), but monitored depression associated with the menstrual pain. The trial reported no significant difference between groups or within groups in depression associated with the menstrual pain (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>). </P>
<P>
<B>
<I>2) Overall reduction in</I>
</B>
<B>
<I> </I>
</B>
<B>
<I>symptoms - Chinese herbal medicine versus no treatment <BR/>
</I>
</B>
<B>
<BR/>
</B>Only one trial had no treatment as a comparison (<LINK REF="STD-Tseng-2005" TYPE="STUDY">Tseng 2005</LINK>). The results could not be included in meta-analysis. There were no direct results available on this outcome, but it stated that when the adjustments for differences in age and the perceived stress scale scores at baseline were made, rosebud tea improved psychophysiologic well being significantly compared to placebo in scores using the Psychophysiologic Life Adaptation scale (PLAS) over time (P &lt;0.001 for all scales), <I>see </I>Additional table <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. </P>
<P>
<B>
<I>3) Overall reduction in symptoms - Chinese herbal medicine versus conventional therapy </I>
</B>
</P>
<P>There were six trials (482 women) that compared CHM with one of the commonly used conventional therapies such, as NSAIDs or OCPs. The trials reported dichotomous data and they were suitable for meta-analysis; although patients were split into sub-groups according to whether standardised or tailored formulas were used. In addition, the methodological quality score was taken into account for setting up the sub-groups.</P>
<P>One trial compared two different experimental herbal groups against a control group using pharmaceutical drugs including analgesics, NSAID, or in combination of OCPs. </P>
<P>The six trials (482 women) reported significant improvements in overall symptoms for CHM compared to conventional therapy for up to three months of follow-up (RR 2.17, 95% CI 1.73 to 2.73). This meta-analysis included one (58 women) of the eleven trials that compared a standard formula CHM to conventional medicine (RR 23.39, 95% CI 1.45 to 377.35); the other five trials (424 women) compared tailored formulae with conventional treatment (RR 2.00, 95% CI 1.59 to 2.52).</P>
<P>
<B>
<I>4) Overall reduction in symptoms - Chinese herbal medicine (experiment) versus Chinese herbal medicine (OTC) <BR/>
</I>
</B>
<B>
<BR/>
</B>Fourteen included trials (1167 women) evaluated one experimental Chinese herbal formulae or selected a single herb in comparison with one of the commonly used herbal products. The data were dichotomous and suitable for meta-analysis. The relevant sub-groups were also set up for appropriate statistical analysis in consideration of the type of formulation (standardised or tailored). They were all in a score of B for the trial quality. </P>
<P>Thirteen out of fourteen included trials (1114 women) used complex Chinese herbal formulae that were designed by the researchers; only one trial (53 women) experimented a single herbal ingredient (<LINK REF="STD-Niu-1996" TYPE="STUDY">Niu 1996</LINK>). </P>
<P>Four out of fourteen trials (320 women) used standardised formulae in experimental groups throughout the whole period of intervention, while the other ten included trials (847 women) tailored treatment individually based on principle formulae in experimental groups. </P>
<P>All of the trials (1167 women) found significant improvement in overall symptoms after up to three months of follow-up (RR 1.99, 95% CI 1.65 to 2.40). </P>
<P>
<B>
<I>5) Overall reduction in symptoms - Chinese herbal medicine versus acupunctur</I>
</B>
<B>e </B>
</P>
<P>No data were available for this comparison. </P>
<P>
<B>
<I>6) Overall reduction in symptoms - Chinese herbal medicine versus massage<BR/>
</I>
</B>
<B>
<BR/>
</B>No data were available for this comparison </P>
<P>
<B>
<I>7) Overall reduction in symptoms - Chinese herbal medicine versus heat compression <BR/>
</I>
</B>
<B>
<BR/>
</B>No data were available for this comparison</P>
<P>
<B>Adverse effects<BR/>
</B>
<B>
<I>
<BR/>1) Adverse effects - Chinese herbal medicine versus placebo </I>
</B>
<B>
<BR/>
</B>
<BR/>Three included trials (166 women) reported no serious adverse events in either the experimental or control groups. </P>
<P>Trial data were extracted and suitable for meta-analysis (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>; <LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>; <LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). One of the trials (36 women) reported that headache was the most frequently reported side effect and that there was no difference between the groups. However, meta-analysis showed a small statistical difference between the groups with more incidents occurring in the placebo group than in the herbal group (RR 0.81, 95% CI 0.61 to 1.07). There were no serious adverse events and no clinically relevant changes in laboratory values (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>). </P>
<P>
<B>
<I>2) Adverse effects - Chinese herbal medicine versus no treatment <BR/>
</I>
</B>
<B>
<BR/>
</B>No data were available for this comparison</P>
<P>
<B>
<I>3) Adverse effects - Chinese herbal medicine versus conventional therapy <BR/>
</I>
</B>
<BR/>Only two included trials (418 women) mentioned that adverse effects were monitored, with no incident reported in either the experimental or the control groups. </P>
<P>
<B>
<I>4) Adverse effects - Chinese herbal medicine (experiment) versus Chinese herbal medicine (OTC)<BR/>
</I>
</B>
<BR/>Two included trials (183 women) reported no adverse effects. Only one of the trials (120 women) had data that could be extracted (<LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>) for meta-analysis; the data were incomplete in the other trial, since the information on the control group was not provided (<LINK REF="STD-Deng-2003" TYPE="STUDY">Deng 2003</LINK>). </P>
<P>
<B>
<I>5) Adverse effects - Chinese herbal medicine versus acupuncture</I>
</B>
</P>
<P>No data were available for this comparison </P>
<P>
<B>
<I>6) Adverse effects - Chinese herbal medicine versus massage</I>
</B>
</P>
<P>No data were available for this comparison</P>
<P>
<B>
<I>7) Adverse effects - Chinese herbal medicine versus heat compression </I>
</B>
</P>
<P>One trial (55 women) reported no adverse effects in either the experimental or control groups; data could be extracted for meta-analysis (<LINK REF="STD-Zhang-2000" TYPE="STUDY">Zhang 2000</LINK>).</P>
<P>
<B>Use of additional medication</B>
<BR/>
<B>
<I>
<BR/>1) Use of additional medicines - Chinese herbal medicine versus placebo <BR/>
</I>
</B>
<B>
<BR/>
</B>Three trials (166 women) compared CHM against placebo. One trial (90 women) (<LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>) that set up two experimental herbal groups with slightly different formulae (30 women in each group) was included in meta-analysis, the results showed a statistically significant difference between the herbal intervention and placebo (RR 12.00, 95% CI 1.70 to 84.49). </P>
<P>Another included trial (40 women) reported results on this outcome in such a form that no numerical data could be extracted, nor were the data suitable for meta-analysis (<I>see </I>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Significant reduction in the use of pain-relieving medication while on the intervention and at follow-up was found in the herbal group (P &lt; 0.05; P &lt; 0.01, respectively). Significant reduction in the use of pain-relieving medication was found in the placebo group in the first intervention cycle only (P &lt; 0.01) (<LINK REF="STD-Kotani-1997" TYPE="STUDY">Kotani 1997</LINK>). </P>
<P>One trial (36 women) reported that it had assessed the amount of additional medication used; however, this trial did not report any detail for undertaking meta-analysis (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>). </P>
<P>
<B>
<I>2) Use of additional medicine - Chinese herbal medicine versus no treatment <BR/>
</I>
</B>
<B>
<BR/>
</B>No data were available for this comparison. </P>
<P>
<B>
<I>3) Use of additional medicine - Chinese herbal medicine versus conventional therapy</I>
</B>
<B> </B>
</P>
<P>Two trials (194 women) measured this outcome. One (132 women) used a tailored formula with up to three months of follow-up, and the other trial (62 women) used a standard formula with no follow-up. Overall results showed that the use of CHM resulted in a reduction in the use of additional pain-relieving medication (RR 1.58, 95% CI 1.30 to 1.93). </P>
<P>
<B>
<I>4) Use of additional medicine - Chinese herbal medicine (experiment) versus Chinese herbal medicine (OTC)</I>
</B>
</P>
<P>Five trials (402 women) including two trials (116 women) with standardised formulae, and three trials (286 women), used tailored formulae, all were with three months of follow-up. The results showed significant improvements - numbers of women did not require analgesics after the herbal intervention (RR 1.58, 95% CI 1.34 to 1.87). </P>
<P>
<B>
<I>5) Use of additional medicine - Chinese herbal medicine versus massage</I>
</B>
</P>
<P>No data were available for this comparison. </P>
<P>
<B>
<I>6) Use of additional medicine - Chinese herbal medicine versus heat compress</I>
</B>
</P>
<P>No data were available for this comparison. </P>
<P>
<B>Laboratory tests </B>
</P>
<P>Omitted from this review</P>
<P>
<B>Satisfaction from patients </B>
</P>
<P>No data were available for this outcome. One trial assessed the global assessment of treatment and reported the data were similar in both groups. However, no details were provided for meta-analysis (<LINK REF="STD-Kennedy-2006" TYPE="STUDY">Kennedy 2006</LINK>). </P>
<P>
<B>Quality of life</B>
</P>
<P>No data were available for this outcome</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The aim of this review was to assess the effectiveness of Chinese herbal therapy and its safety for the treatment of primary dysmenorrhoea. CHM has been used to treat women's conditions for hundreds of years; however, data on the administration of CHM in a rigorous scientific context is still lacking. </P>
<P>The review found promising evidence in the form of RCTs for the use of CHM in reducing menstrual pain in the treatment of primary dysmenorrhoea, with up to three months of effectiveness. No significant adverse effects were identified from the included studies in this review. <BR/> <BR/>
<B>Impact of an individualised approach to the routine practice of CHM</B>
</P>
<P>A key primary requirement of traditional treatment with CHM is that treatment needs to be tailored according to different patterns; these are of a description of selection of phenomena (symptoms and signs) that have a mutual relation with each other. Moreover, a pattern has individual variations and changes over time with different stages of illness.</P>
<P>For example, primary dysmenorrhoea, is a clinical diagnosis in Western medicine (WM) that can be classified into different patterns in TCM. Although lower abdominal pain associated with menstruation that occurs for more than three consecutive cycles is also acknowledged as the main symptom in TCM practice, TCM takes further interest in other associated complaints such as the nature of the pain, feeling of coldness, and whether pain is relieved by warmth, psychological status, and so on, all of which impact on the final TCM diagnosis. These associated symptoms form a syndrome with a distinct label, such as 'retention of Cold', or 'stagnation of Qi and Blood'. Treatment differs according to the identified and diagnosed syndrome.</P>
<P>Nineteen out of thirty-nine included trials considered an inclusion criterion in relation to the TCM diagnostic pattern(s), and another twenty-three trials considered the influence of the pattern(s) (for example, a pattern was only treated by one correlating experimental herbal formula). In other words, the majority of included trials paid a specific attention to the role of differentiated patterns defined in TCM diagnosis for primary dysmenorrhoea, because the patterns of primary dysmenorrhoea in TCM inform selection of treatment formulation. The patterns of 'stagnation of Qi &amp; Blood', 'retention of Cold', 'deficiency of the Kidney and Liver' were the common diagnostic classifications of primary dysmenorrhoea in TCM diagnosis. In addition, 'stagnation of Blood' was the fundamental aetiology and pathological condition for primary dysmenorrhoea in TCM. This was in agreement with the majority of published diagnostic protocols in TCM (<LINK REF="REF-Luo-1986" TYPE="REFERENCE">Luo 1986</LINK>; <LINK REF="REF-Maciocia-2004" TYPE="REFERENCE">Maciocia 2004</LINK>; <LINK REF="REF-SATCM-1995" TYPE="REFERENCE">SATCM 1995</LINK>; <LINK REF="REF-Xia-1994" TYPE="REFERENCE">Xia 1994</LINK>). </P>
<P>The selection of treatment formulae used in the trials in this review were mostly influenced by the TCM diagnostic process. Some trials used tailored formulae in accordance with the individual patterns. Because the nature of primary dysmenorrhoea is fairly straightforward in terms of the principal TCM diagnostic patterns, most tailored formulae were actually designed based on a principal formulation with limited modification throughout an entire course of herbal intervention. Some trials used a standard formula (including a single herb) across the whole period of clinical intervention, either because one diagnostic pattern of primary dysmenorrhoea was selected for this specific formula, or simply no consideration was given to the possible variation of diagnostic patterns.</P>
<P>Overall, twenty-three trials used modified experimental Chinese herbal formulae in order to fit the different TCM diagnostic patterns, or selected a standard formula based on a defined specific pattern, that is the individualised (tailored) treatment approach was employed. The results demonstrated promising evidence of effective pain relief for primary dysmenorrhoea. Whilst sixteen trials did not consider a possible variation in patterns, the results still demonstrated the effectiveness of CHM in pain reduction with statistical significance. </P>
<P>Japanese researchers stated that a favourable outcome for pain relief could only be achieved when TCM diagnostic patterns that inform the decision of selection of formulae were considered, so a tailored formula might be better than a standard formula (Kotani 1997). This may be becasue a complex formula designed for a relevant diagnostic pattern could possibly address multiaspects of imbalance in the body. This may also further explain why a single herb could only achieve limited therapeutic scopes, in contrast with a complicated formula, even the formula may be remained unchanged throughout an entire period of clinical intervention. </P>
<P>However, this review was unable to provide an explicit answer as to whether tailored treatment was more beneficial than standard formulae in the treatment of primary dysmenorrhoea.</P>
<P>
<B>Types of control interventions <BR/>
</B>
<BR/>Apart from the use of conventional types of control interventions, such as placebo, NSAIDs and OCPs, eighteen of the thirty-nine included trials compared two different Chinese herbal formulae. In general, both types of pharmaceutical and traditional Chinese herbal agents are available as over-the-counter (OTC) products in China, therefore a commonly used OTC herbal product was chosen for the comparison group. However, in an experimental group, it appeared that researchers and practitioners were reluctant to further explore commonly used herbal products, instead, exploring self-desgined formulae were of their interests. </P>
<P>
<B>Adverse effects</B>
</P>
<P>The attention to the safety of CHM in clinical practice was not addressed adequately in the reviewed trials. The measurement and report of adverse effects were poor; most trials neglected the fact that herbs are not risk free. Only eight out of the thirty-nine included trials mentioned some adverse effects in their reports. Only seven trials detailed the number of incidents not only in the experimental groups but also in the control groups. This allowed suitable data to be extracted for meta-analysis. </P>
<P>Generally, the reviewed trials reported that CHM for primary dysmenorrhoea were safe when compared with conventional medicines. However, the data were limited and more trials that monitor possible adverse effects are needed. </P>
<P>
<B>Herbal pharmacotherapeutic action </B>
</P>
<P>It is difficult to elucidate the pharmacotherapeutic action of CHM because the herbal formulae contain many potentially active compounds, many of which remain unknown. Nevertheless, some studies explored the potential mechanisms of action of CHM focusing mainly on the potential aetiology of primary dysmenorrhoea. It was requested by the Menstrual Disorders and Subfertility Group that the detailed laboratory results in relation to pharmacotherapeutic actions were removed from this Cochrane review.<B> <BR/>
</B>
<BR/>
<B>Further effort for understanding aetiology of primary dysmenorrhoea <BR/>
</B>
<BR/>In China, CHM has been used to treat dysmenorrhoea for centuries, with positive clinical responses. Clinical success is likely to be related to one of the TCM fundamental theories - 'stagnation of Blood' is the main pathological condition in primary dysmenorrhoea. To draw relevant parallels between contemporary medical sciences and TCM, four included trials attempted to reveal and explore the aetiology of primary dysmenorrhoea in the fields of endocrinology and neurology. </P>
<P>General haemorheology and vascular microcirculation effects were also investigated. Some studies stated that abnormalities were found in women with primary dysmenorrhoea. Such abnormalities included high levels of blood viscosity (BV), both at high and low shear rates. CHM from the category removing Blood stagnation was investigated and was found to improve the haemocytologic parameters as well as to improve period pain (<LINK REF="STD-Sun2004" TYPE="STUDY">Sun2004</LINK>). </P>
<P>
<B>Methodological weaknesses<BR/> </B>
<BR/>The methodological quality of many trials included in this review was poor calibre. Only three out of the thirty-nine trials clearly described their methods of randomisation and allocation concealment. The rest either did not state the methods or the methods were inadequate. </P>
<P>A consistent weakness of all the trials was their small sample size. Only one trial had more than one hundred participants. The small size reduces the likelihood of detecting any effect of an intervention in a single study, but given the similarities between studies, it makes meta-analysis of the data particularly valuable. </P>
<P>Placebo was seldom used in the trials (only three trials compared CHM with placebo). The lack of placebo trials affects the results, since typically a medicine's efficacy is established with placebo trials before comparisons are made with other drugs . With CHM this has not been the case. In addition, the lack of blinding in some trials had the potential to affect the results as it may give skewed results, if participants were aware of their treatment. </P>
<P>The measurement outcomes were generally subjective. Most of the trials collected the data by using descriptions of symptoms with no quantitative standards. Only four trials used numerical scales. </P>
<P>A possible publication bias has not excluded for this review as the majority of trials reported positive effects of CHM in the treatment of primary dysmenorrhoea. Funnel plots were used to investigate the possibility of publication bias, for the trials comparing CHM with conventional medicine. For the outcomes of pain reduction and overall symptom assessment (outcomes that are highly correlated), the funnel plots appear to be asymmetrical, which suggests a bias towards positive studies (<I>see</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). However, it remains unclear whether this bias is related solely to publication bias or whether it is an effect of poor methodological quality of the smaller trials. Conversely, funnel plots of the trials comparing CHM (experimental) with other CHM (OTC) appeared roughly symmetrical indicated less chance of publication bias in this group of trials (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> and <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Therefore, the existence of publication bias in the reviewed trials remains unclear. </P>
<P>Overall the review has found that an attempt towards evidence-based TCM practice has been made. However, more research trials with high quality design are needed. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The review found promising evidence from RCTs for the use of CHM in reducing menstrual pain associated with primary dysmenorrhoea, with up to three months of effectiveness. All available measures of effectiveness confirmed the overall superiority of CHM to placebo, no treatment, NSAIDs, OCPs, acupuncture and heat compression. No significant adverse effects were identified by this review. However, the small number and the low quality of included studies did not allow for any definite conclusion for their use in clinical practice. </P>
<P>In CHM practice, categories of herbs such as herbs 'regulating the Qi and Blood', 'warming the Interior', 'tonifying the Kidney and Liver' and 'reinforcing Qi and Blood' were most commonly used. The herbs may influence primary dysmenorrhoea through the effects on hormones and microcirculation haemorheology. <BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Overall, current weaknesses of trials included in this review such as poor methodological quality, lack of the use of placebo as the control comparison, no appropriate blinding and restricted language publication, which all require rectification. Therefore, the findings of this review should be interpreted with caution. In addition, more carefully designed, double-blinded, placebo-controlled randomised trials with large numbers of participants that use of CHM in the treatment of primary dysmenorrhoea are required. Biomedical evidence is also needed. Any adverse effect that is either symptomatic or biomedical needs to be investigated further. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>To Professor Chunxiang Zhou (Nanjing University of Traditional Chinese Medicine, China) and Professor Jin Yu (Fudan University, China) who advised on data searches in the Chinese literature and strategic planning at an early stage of the review. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Xiaoshu Zhu recently completed a randomised controlled trial of CHM for primary dysmenorrhoea. There are no other known potential conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Xiaoshu Zhu: conceptualised and wrote the protocol and review. <BR/>Michelle Proctor: commented on and assisted with structure and development of the review. <BR/>Alan Bensoussan: commented on and assisted with development of the protocol and review.<BR/>Emily Wu: assisted with data translation and extraction for the review. <BR/>Caroline Smith: commented on and assisted with development of the protocol.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2003" NAME="Deng 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng HX, Zhu NS, Wang CW, Qing HX, Xu YZ</AU>
<TI>Clinical observation on the use of Jia Wei Muo Jie Pian in the treatment of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Yi Ji Chu Yi Xue Za Zhi [Chinese Journal of Basic Medicine in Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>10</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2005" NAME="Deng 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng DM</AU>
<TI>Observation on the use of Jiang Ji Jiu in the treatment of dysmenorrhoea</TI>
<SO>Yi Xue Wen Xuan [Anthology of Medicine]</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>56970</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-1999" NAME="Fan 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fan J</AU>
<TI>The use of modified Huo Xue Zhen Tong Tang in the treatment of 50 cases of primary dysmenorrhoea</TI>
<SO>Shi Yong Zhong Yi Yao Za Zhi [Journal of Practical Traditional Chinese Medicine]</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>3</NO>
<PG>15-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-1997" NAME="Guo 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo WP, Zhang XK</AU>
<TI>The use of Tong Jing San in the treatment of 35 cases of primary dysmenorrhoea</TI>
<SO>Shi Yong Zhong Xi Yi Jie He Za Zhi [Practical Journal of Integration of Traditional Chinese Medicine with Western Medicine]</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>3</NO>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2000" NAME="Huang 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huang, G, Xu YH</AU>
<TI>Analysis of the use of Si Wuo Tang in the treatment of 58 cases of primary dysmenorrhoea</TI>
<SO>Nei Meng Gu Zhong Yi Yao [Journal of Inner Mongolia Traditional Chinese Medicine]</SO>
<YR>2000</YR>
<VL>4</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2000" NAME="Jiang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang H</AU>
<TI>Clinical observation on the use of Li Qi Huo Xue Tang in the treatment of severe cases of primary dysmenorrhoea</TI>
<SO>He Bei Zhong Yi [Hebei Journal of Traditional Chinese Medicine]</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>8</NO>
<PG>587</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kennedy-2006" NAME="Kennedy 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy S, Jin X, Zhong S, Magill P, Vliet T.V, et al</AU>
<TI>Randomised controlled trial assessing a traditional Chinese medicine remedy in the treatment of primary dysmenorrhoea</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>3</NO>
<PG>762-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotani-1997" NAME="Kotani 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naoki K, Tsutomu O, Ichiro S, Hiroshi H, Masatoshi M, Yasuhiro O, Akitomo M</AU>
<TI>Analgesic effect of a herbal medicine for treatment of primary dysmenorrhoea - a double-blind study</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>25</YR>
<VL>2</VL>
<PG>205-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1999" NAME="Li 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HB, Zhao GX, Wang LJ</AU>
<TI>Clinical research on the use of Fu Ke Qian Jin Pian in the treatment of primary dysmenorrhoea of a pattern of stagnation of Qi &amp; Blood</TI>
<SO>Hu Nan Zhong Yi Za Zhi [Hunan Journal of Traditional Chinese Medicine]</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>1</NO>
<PG>44-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2001" NAME="Li 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li NR, Jiang QH, Guo AX</AU>
<TI>The use of Tong Jing Wan in the treatment of 50 cases of primary dysmenorrhoea of pattern of 'retention of Cold and stagnation of Blood'</TI>
<SO>Shang Dong Zhong Yi Za Zhi [Shangdong Journal of Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>10</NO>
<PG>597-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2004" NAME="Li 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li ZP, Xu Y</AU>
<TI>The use of Nuan Gong Zhi Tong Tang in the treatment of 40 cases of primary dysmenorrhoea</TI>
<SO>Xin Zhong Yi [New Chinese Medicine]</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>4</NO>
<PG>58-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2000" NAME="Liu 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu XH</AU>
<TI>The use of combination of Chinese herbs with western drug in the treatment of 40 cases primary dysmenorrhoea</TI>
<SO>Shang Dong Yi Yao [Shangdong Journal of Medicine]</SO>
<YR>2000</YR>
<VL>40</VL>
<NO>10</NO>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2002" NAME="Liu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu SJ</AU>
<TI>Clinical observation on the use of Wen Tong Tang in the treatment of 30 cases of primary dysmenorrhoea</TI>
<SO>Zhong Yi Yao Xue Kan [Journal of Traditional Chinese Medicine &amp; Pharmacology]</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>4</NO>
<PG>463</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" NAME="Liu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu H, Mao XL</AU>
<TI>The use of Wen Jing Tang in combination of Xin Jie San in the treatment of 52 cases of primary dysmenorrhoea of a pattern of stagnation of Blood</TI>
<SO>Guang Zhou Yi Xue Yuan Xue Bao [Academic Journal of Guangzhou Medical College]</SO>
<YR>2003</YR>
<VL>31</VL>
<NO>3</NO>
<PG>81-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004" NAME="Liu 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu WP</AU>
<TI>Clinical observation on the external use of Chinese herbal medicine in the treatment of 45 cases of primary dysmenorrhoea of the pattern of retention of Cold and Blood stasis</TI>
<SO>Zhong Yi Wai Zhi Za ZHi [Journal of External Therapy of Traditional Chinese Medicine]</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2005" NAME="Liu 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu HM, Wang XX, Han YH, Yao JP, Jin FR</AU>
<TI>Analysis on the use of Wen Jing Zhi Tong Yin in the treatment of 60 cases of primary dysmenorrhoea of a patter of 'retention of Coldness and stagnation of Blood'</TI>
<SO>Shou Duo Yi Yao [Capital Medicine]</SO>
<YR>2005</YR>
<VL>3</VL>
<PG>47-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2002" NAME="Lu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu YM</AU>
<TI>Observation on the use of Fu Kang Bao in the treatment of primary dysmenorrhoea</TI>
<SO>Suzhou University Journal of Medical Science</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>3</NO>
<PG>328</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2001" NAME="Luo 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo FP, Li BQ</AU>
<TI>Clinical observation on the use of Tong Jing San in the treatment of primary dysmenorrhoea</TI>
<SO>Shang Dong Zhong Yi Za Zhi [Shangdong Journal of Traditional Chinese Medicine] Shang Dong Zhong Yi Za Zhi [Shangdong Journal of Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>6</NO>
<PG>338-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miao-2001" NAME="Miao 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miao F</AU>
<TI>The use of Niu Xi San in the treatment of 36 cases of primary dysmenorrhoea</TI>
<SO>Zhe Jiang Zhong Yi Xue Yuan Xue Bao [Academic Journal of Zhejing College of Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>1</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niu-1996" NAME="Niu 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niu Y, Hou LL, Wang SB, Yang LX</AU>
<TI>Observation on the use of Tie Xin Gan Cao in the treatment of dysmenorrhoea</TI>
<SO>Zhong Guo Yi Yao Xue Bao [China Journal of Chinese Medicine and Pharmacology]</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>18-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qin-2003" NAME="Qin 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qin XL, Lu SP, ZHou YM</AU>
<TI>Clinical observation on the use of Du Yi Wei Jiao Nang in the treatment of 60 cases of dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Yi Yao Xin Xi Zao Zhi [China Journal of Information of Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>6</NO>
<PG>60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2001" NAME="Shen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen YH</AU>
<TI>Clinical observation on the use of Wen Jing Jian Tong Jiao Nang in the treatment of 60 cases of primary dysmenorrhoea of a pattern of retention of Cold and Blood stasis</TI>
<SO>Hu Nan Zhong Yi Za Zhi [Hunan Journal of Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>2</NO>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2003" NAME="Song 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song RX, Yang YQ, Chen FH</AU>
<TI>The use of Tong Jing Jiao Nang in the treatment of 50 cases of primary dysmenorrhoea</TI>
<SO>Shang Dong Zhong Yi Za Zhi [Shangdong Journal of Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>7</NO>
<PG>404</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2006" NAME="Sun 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun, W.F., &amp; Liu, Y</AU>
<TI>Tiao Jing Ding Tong Tang in the treatment of 46 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Yi Ji Zheng [China Chinese Medicine Emergency Treatment]</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>12</NO>
<PG>1352-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun2004" NAME="Sun2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sun WH, Zhao L, Tian XP, Yang CQ, Li XH</AU>
<TI>Clinical observation on the use of Gui Zhi Fu Ling Wan in the treatment of 90 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Xi Yi Jie He Za Zhi [CJITWM]</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun2004-_x002d_2" NAME="Sun2004 -2" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sun WH, Zhao L, Tian XP, Yang CQ, Li XH</AU>
<TI>Clinical observation on the use of Gui Zhi Fu Ling Wan in the treatment of 90 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Xi Yi Jie He Za Zhi [CJITWM]</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>12</NO>
<PG>1121-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tseng-2005" NAME="Tseng 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tseng YF, Chen CH, Yang YH</AU>
<TI>Rose tea for relief of primary dysmenorrhoea in adolescents: a randomised controlled trial in Taiwan</TI>
<SO>Journal of Midwife &amp; Women's Health</SO>
<YR>2005</YR>
<VL>50</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1996" NAME="Wang 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SJ, Liu SQ, Luo SX, Guo RF</AU>
<TI>Laboratory research on the use of Tong Jing Ling suppository in the treatment of primary dysmenorrhoea of the pattern of retention of cold and stagnation of Qi</TI>
<SO>Liao Ning Zhong Yi Za Zhi [Liaoning Journal of Traditional Chinese Medicine]</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>7</NO>
<PG>332-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000b" NAME="Wang 2000b" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong L</AU>
<TI>The use of Bu Shen Hua Yu Tang in the treatment of 50 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Min Jian Liao Fa [China Folk Therapy]</SO>
<YR>2000</YR>
<VL>8</VL>
<NO>4</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" NAME="Wang 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X</AU>
<TI>The treatment of primary dysmenorrhoea in accordance with the differentiation of syndrome in Chinese medicine</TI>
<SO>Lin Chuang Lun Tan [China Medicine Bulletin]</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>3</NO>
<PG>33-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006a" NAME="Wang 2006a" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X G</AU>
<TI>Clinical observation on use of Su Xiao Jiu Xin Wan in the treatment of 340 cases of primary dysmenorrhoea</TI>
<SO>Lin Chuang He Shi Yan Yi Xue Za Zhi [Journal of Clinical and Laboratory Medicine]</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>7</NO>
<PG>969</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006b" NAME="Wang 2006b" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YH</AU>
<TI>Use of Tong Jing Ling in the treatment of 32 cases of primary dysmenorrhoea</TI>
<SO>Shan Xi Zhong Yi [Shan Xi Journal of Traditional Chinese Medicien]</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>6</NO>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" NAME="Wu 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu XM, Li H.J</AU>
<TI>Modified Dang Gui Shao Yao San in the treatment of 45 cases of primary dysmenorrhoea</TI>
<SO>Liao Ning Zhong Yi Yao Da Xue [Journal of Liao Ning University of TCM]</SO>
<YR>2006</YR>
<VL>8</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ye-2004" NAME="Ye 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ye LL</AU>
<TI>The use of Nv Jin Jiao Nang in the treatment of 30 cases of primary dysmenorrhoea</TI>
<SO>Shi Yong Zhong Yi Yao Za Zhi [Journal of Practical Traditional Chinese Medicine]</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>3</NO>
<PG>148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2003" NAME="Yu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu P, Li QC, Tan BL</AU>
<TI>Clinical observation of the use of Fu Mei Tong Jing Fang in the treatment of 35 cases of primary dysmenorrhoea of pattern of retention of Cold and Blood stasis</TI>
<SO>Xin Zhong Yi [New Chinese Medicine]</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>8</NO>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2000" NAME="Zhang 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J</AU>
<TI>Observation on the use of modified Si Wu Tang in the treatment of 35 cases of primary dysmenorrhoea</TI>
<SO>Yi Xue Wen Xuan [Anthology of Medicine]</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001" NAME="Zhang 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Q, Wan ZX</AU>
<TI>Clinical observation of the use of Chinese herbal medicine in the treatment of 60 cases of primary dysmenorrhoea</TI>
<SO>Shi Yong Zhong Yi Yao Za Zhi [Journal of Practical Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>17</VL>
<NO>5</NO>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2001" NAME="Zhu 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu YL, Li X</AU>
<TI>The use of Dang Gui Ai Ye Tang in the treatment of 78 cases of primary dysmenorrhoea</TI>
<SO>Jiang Su Zhong Yi [Jiangsu Journal of Traditional Chinese Medicine]</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>8</NO>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2002" NAME="Zhu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu LY</AU>
<TI>Observation on the use of Chines herbal medicine in the treatment of 70 cases of primary dysmenorrhoea</TI>
<SO>Ye Yu Jian Kang [Occupation and Health]</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>8</NO>
<PG>121-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2003" NAME="Zhu 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Y, Wang J</AU>
<TI>The use of Chinese herbal medicine Hua Yu Tong Mai Zhi Tong Tang in the treatment of 42 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Yi Yao Xin Xi Za Zhi [Chinese Journal Information on Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>10</VL>
<NO>9</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-1995" NAME="Chen 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen ZL</AU>
<TI>The use of Tong Jing Yao Fang in the treatment of 78 cases of primary dysmenorrhoea</TI>
<SO>Nan Jing Zhong Yi Yao Da Xue Xue Bao [Academic Journal of Nanjing University of Traditional Chinese Medicine ]</SO>
<YR>1995</YR>
<VL>11</VL>
<NO>6</NO>
<PG>47-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2000" NAME="Du 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du CY</AU>
<TI>Clinical observation on the use of modified Jia Wei Shi Xiao San in the treatment of 68 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Min Zu Min Jian Yi Yao Za Zhi [China Journal of Folk Medicine]</SO>
<YR>2000</YR>
<VL>44</VL>
<PG>135-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" NAME="Huang 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang L</AU>
<TI>Observation on the use of self-designed formula Tong Jing Zhi Tong Tang in the treatment of 56 cases of primary dysmenorrhoea</TI>
<SO>Zhong Yi Yao Dao Bao [Guiding Journal of Traditional Chinese Medicine]</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>7</NO>
<PG>36, 44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ji-2001" NAME="Ji 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ji XM, Dong CM, Yuan LH, Xu XH</AU>
<TI>Clinical anaylsis on the use of Dan Shen Tong/Tanshinone in the treatment of 203 cases of primary dysmenorrhoea</TI>
<SO>Journal of Chinese Physician</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>6</NO>
<PG>476</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2005" NAME="Li 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li PJ, Zhang YM</AU>
<TI>A clinical report on use of Yang Xue Tiao Jing He Ji for 200 cases of dysmenorrhoea</TI>
<SO>Zhong Hua Shi Yong Zhong Xi Yi Za Zhi [Chinese Journal of the Practical Chinese and Modern Medicine]</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>6</NO>
<PG>784</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liao-2002" NAME="Liao 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liao W, Wang CW</AU>
<TI>Clinical observation on the use of Jia Wei Muo Jie Pian in the treatment of primary dysmenorrhoea</TI>
<SO>Shi Yong Zhong Yi Yao Za Zhi [Journal of Practical Traditional Chinese Medicine]</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>2</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004" NAME="Lin 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin H</AU>
<TI>Analysis on the clinical efficacy of the use of Gui Zhi Fu Ling Jiao Nang in the treatment of gyneocological conditions</TI>
<SO>Zhong Guo Ji Ceng Yi Yao [Chinese Journal of Primary Medicine and Pharmacy]</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>12</NO>
<PG>1509</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2006" NAME="Liu 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y.Z</AU>
<TI>Tong Jing Tang in combination with Wu Ji Bai Feng Wan in the treatment of 60 cases of primary dysmensorrhoea</TI>
<SO>He Nan Zhong Yi [He Nan TCM]</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>8</NO>
<PG>52-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miao-2006" NAME="Miao 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miao Q</AU>
<TI>Clinical observation on modified Tao Hong Si Wu Tang in the treatment of primary dysmenorrhoea</TI>
<SO>Zhong Yi Yao Xue Kan [Journal of Traditional Chinese Medicine &amp; Pharmacology]</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>10</NO>
<PG>1926</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ni-2004" NAME="Ni 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ni GL, Zhang QY, Sheng W, Shi MJ, Han M</AU>
<TI>Therapeutic efficacy of An Gong Ding Tong Wan in the treatment of primary dysmenorrhoea and its microcirculation disturbance</TI>
<SO>He Bei Bei Fang Xue Yuan Xue Bao [Journal of Hebei North University]</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>5</NO>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2003" NAME="Pan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan CP</AU>
<TI>The use of Tiao Jing Zhi Tong Fan in the treatment of 76 cases of primary dysmenorrhoea</TI>
<SO>Guan Xi Zhong Yi Yao [Guanxi Journal of Traditional Chinese Medicine &amp; Pharmacology]</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>3</NO>
<PG>47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2003" NAME="Shi 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi JH, Yin JH, Jin QY, Xue LN, Wang XX, Hou XM, Ji CH</AU>
<TI>Clinical research on use of Tong Jing Ling in the treatment of primary dysmenorrhoea</TI>
<SO>Hebei Zhong Yi [Hebei J TCM]</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>4</NO>
<PG>250-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2005" NAME="Song 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song ZM, Xin SM, Luo MY, Sun SZ, Ha XX, Zhu LP</AU>
<TI>Clinical observation on the use of Tong Jing Lin Ke Li in the treatment of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Xi Yi Jie He Za Zhi [CJITWM]</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>7</NO>
<PG>608</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2005" NAME="Sun 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Li YQ, Song HX</AU>
<TI>Clinical observation on the use of Tao Hong Shi Xiao Zhi Tong Tang in the treatment of 30 cases of primary dysmenorrhoea</TI>
<SO>Si Chuan Zhong Yi [Journal of Sichuan of Traditional Chinese Medicine]</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>4</NO>
<PG>61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2000a" NAME="Wang 2000a" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H, Bei HW, Chang H, Wu XZ, Sun G</AU>
<TI>Clinical research on the use of series capsule Tiao Jing Mie Tong in the treatment of primary dysmenorrhoea</TI>
<SO>He Bei Zhong Yi Za Zhi [Hebei Journal of Traditional Chinese Medicine]</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>2</NO>
<PG>99-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" NAME="Wang 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang CL</AU>
<TI>The use of Wen Jing Huo Xue San in the treatment of 150 cases of primary dysmenorrhoea</TI>
<SO>Zhong Guo Zhong Yi Ji Zheng [China Chinese Medicine Emergency Treatment]</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>4</NO>
<PG>311</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2000" NAME="Wei 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei B, Wu J</AU>
<TI>Injection of Honghua in the treatment of 90 cases of primary dysmenorrhoea</TI>
<SO>Zhong Yao Cai [Chinese Herbs]</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>7</NO>
<PG>430-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2002" NAME="Wu 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu JF</AU>
<TI>The use of Tong Jing Fan in the treatment of 50 cases of primary dysmenorrhoea</TI>
<SO>Zhe Jiang Zhong Yi Xue Yuan Xue Bao [ Academic Journal of Zhejiang College of Traditional Chinese Medicine]</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>4</NO>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2005" NAME="Wu 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu P</AU>
<TI>The use of modified self-designed formula in the treatment of 60 cases of primary dysmenorrhoea</TI>
<SO>Bei Jing Zhong Yi Za Zhi [Beijing Journal of Traditional Chinese Medicine]</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>222-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2000" NAME="Xu 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu JY, Yan XJ, Ma GX</AU>
<TI>Clinical observation on the use of Gui Xin Xiang Cao Tang in the treatment of 60 cases of primary dysmenorrhoea</TI>
<SO>Ning Xia Yi Yao [Ning Xia Medical Journal]</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>7</NO>
<PG>435</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2005" NAME="Yang 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang CQ, Yuan J</AU>
<TI>The use of modified Tiao Gan Tang in the treatment of 40 cases of primary dysmenorrhoea</TI>
<SO>He Nan Zhong Yi [Henan Traditional Chinese Medicine]</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>2</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" NAME="Zhang 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang AL</AU>
<TI>Clinical observation on the use of Chinese herbs with a principle of 'reinforcing body and warming meridians for removing blood stasis' in the treatment of 50 cases of primary dysmenorrhoea</TI>
<SO>Jiang Su Zhong Yi [Jiangsu Journal of Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>1</NO>
<PG>25-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-Y-2003" NAME="Zhang Y 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang Y, Li ZP</AU>
<TI>The use of Wen Jing San Han Tang in the treatment of 30 cases of dysmenorrhoea</TI>
<SO>Shang Xi Zhong Yi [Shanxi Journal of Traditional Chinese Medicine]</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>5</NO>
<PG>401-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006" NAME="Zhao 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao C</AU>
<TI>Clinical observation on use of Hua Yu Tong Jing Jiao Nang in the treatment of 318 cases of primary dysmenorrhoea</TI>
<SO>Zhong Yi Yao Guan Li [Chinese Journal of Management in Chinese Medicine]</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>10</NO>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhen-1996" NAME="Zhen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhen C, Xu J, Xu HX, Wei Y</AU>
<TI>Clincial and laboratory research on use of Tong Jing Ting Tea in the treatment of primary dysmenorrhoea of the pattern of retention of cold and blood stasis</TI>
<SO>Zhong Guo Zhong Yi Yao Ke Ji [China Chinese Medicine Scientific Technology]</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhen-2002" NAME="Zhen 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhen C, Xu J, Zhang ZH</AU>
<TI>The use of Tong Jing Ting in the treatment of primary dysmenorrhoea of a pattern of 'retention of cold and blood stasis'</TI>
<SO>Hunan Guiding Journal of TCMP</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>5</NO>
<PG>269</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke">
<REFERENCE ID="REF-Banikarim-2000" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Banikarim 2000" TYPE="JOURNAL_ARTICLE">
<AU>Banikarim C, Chacko M , Kelder S</AU>
<TI>Prevalence and impact of dysmenorrhea on hispanic female adolescents</TI>
<SO>ARCH Pediatra Adolesc Med</SO>
<YR>2000</YR>
<VL>154</VL>
<PG>1226-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bensky-2004" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Bensky 2004" TYPE="BOOK">
<AU>Bensky D, Clavey S, Stoger E</AU>
<SO>Chinese herbal medicine: materia medica</SO>
<YR>2004</YR>
<PB>Eastland Press, Inc.</PB>
<CY>Seattle</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bensoussan-1996" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Bensoussan 1996" TYPE="BOOK">
<AU>Bensoussan A, Myers SP</AU>
<SO>Towards a safer choice: the practice of traditional Chinese medicine in Australia</SO>
<YR>1996</YR>
<PB>Sydney, University of Western Sydney</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burnett-2005" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Burnett 2005" TYPE="JOURNAL_ARTICLE">
<AU>Burnett MA, Antao V , Feldman K, Grenville A , Lea, R et al</AU>
<TI>Prevalence of primary dysmenorrhoea in Canada</TI>
<SO>J Obstet Gynaecol Can</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>8</NO>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creatsas-1990" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Creatsas 1990" TYPE="JOURNAL_ARTICLE">
<AU>Creatsas G, Delugeoroglou E, Zachari A, Loutradis D, Papadimitriou, Miras K et al</AU>
<TI>Prostaglandins: PGF2a, PGF2, 6-keto-PGF1a and TXB2 serum levels in dysmenorrheic adolescents before, during and after treatment with oral contraceptives</TI>
<SO>European Journal of Obstetrics, Gynaecology, and Reproductive Biology</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>3</NO>
<PG>292-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Daniels-2002" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Daniels 2002" TYPE="JOURNAL_ARTICLE">
<AU>Daniels SE, Talwalker S, Torri S, Snabes MC, Recher DP, Verburg KM</AU>
<TI>Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhoea</TI>
<SO>The American College of Obetetricians and Gynaecologists</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>2</NO>
<PG>350-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1984" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Dawood 1984" TYPE="JOURNAL_ARTICLE">
<AU>Dawood M</AU>
<TI>Ibuprofen and dysmenorrhoea</TI>
<SO>American Journal of Medicine</SO>
<YR>1984</YR>
<VL>77</VL>
<NO>1A</NO>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-1985" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Dawood 1985" TYPE="JOURNAL_ARTICLE">
<AU>Dawood M</AU>
<TI>Dysmenorrhoea</TI>
<SO>Pain and Analgesia</SO>
<YR>1985</YR>
<VL>84</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawood-2006" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Dawood 2006" TYPE="JOURNAL_ARTICLE">
<AU>Dawood MY</AU>
<TI>Primary dysmenorrhoea</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>108</VL>
<NO>2</NO>
<PG>428-441</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dmitrovic-2003" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Dmitrovic 2003" TYPE="JOURNAL_ARTICLE">
<AU>Dmitrovic R, Branimir P, Cvitkovic-Kuzmic A, Strelec M, Kereshi T</AU>
<TI>Severity of symptoms in primary dysmenorrhoea - a doppler study</TI>
<SO>European Journal of Obstetrics and Gynaecology and Reproductive Biology</SO>
<YR>2003</YR>
<VL>107</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekstrom-1992" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Ekstrom 1992" TYPE="JOURNAL_ARTICLE">
<AU>Ekstrom P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G</AU>
<TI>Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment: effect on uterine contractility</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99</VL>
<NO>8</NO>
<PG>680-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forsling-1985" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Forsling 1985" TYPE="JOURNAL_ARTICLE">
<AU>Forsling M, Stromberg P, Akerland M</AU>
<TI>Effect of ovarain steroids on vasopressin secretion</TI>
<SO>Journal of Endocrinology</SO>
<YR>1985</YR>
<VL>92</VL>
<NO>1</NO>
<PG>47-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-French-2005" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="French 2005" TYPE="JOURNAL_ARTICLE">
<AU>French L</AU>
<TI>Dysmenorrhoea</TI>
<SO>American Family Physician</SO>
<YR>2005</YR>
<VL>71</VL>
<NO>2</NO>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harlow-1996" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Harlow 1996" TYPE="JOURNAL_ARTICLE">
<AU>Harlow SD, Park M</AU>
<TI>A longitudinal study of the risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1996</YR>
<VL>103</VL>
<NO>11</NO>
<PG>1134-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauksson-1987" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Hauksson 1987" TYPE="JOURNAL_ARTICLE">
<AU>Hauksson A, Akerland M, Forsting M, Kingahl H</AU>
<TI>Plasma concentration of vasopressin and a prostagalandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with combined oral contraceptive</TI>
<SO>Journal of Endocrinology</SO>
<YR>1987</YR>
<VL>115</VL>
<PG>355-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hillen-1999" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Hillen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hillen TIJ, Grbavac SL, Johnston PJ, Straton JA, Keogh JM</AU>
<TI>Primary dysmenorrhoea in young western Australian women: prevalence, impact and knowledge of treatment</TI>
<SO>Journal of Adolescent Health</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>1</NO>
<PG>40-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lichten-1987" MODIFIED="2008-05-05 12:48:12 +1200" MODIFIED_BY="Julie A Brown" NAME="Lichten 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lichten EB</AU>
<TI>Surgical treatment of primary dysmenohrroea with laparoscopic uterine nerve ablation</TI>
<SO>Reproductive Medicine</SO>
<YR>1987</YR>
<VL>987</VL>
<NO>32</NO>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luo-1986" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Luo 1986" TYPE="BOOK">
<AU>Luo YK</AU>
<SO>Gynecology in Traditional Chinese Medicine</SO>
<YR>1986</YR>
<PB>Shanghai Science and Technology Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maciocia-1998" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Maciocia 1998" TYPE="BOOK">
<AU>Maciocia, G</AU>
<SO>The Foundations of Chinese Medicine: A Comprehensive Text for Acupuncturists and Herbalists</SO>
<YR>1998</YR>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maciocia-2004" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Maciocia 2004" TYPE="BOOK">
<AU>Maciocia G</AU>
<SO>Diagnosis in Chinese Medicine: A Comprehensive Guide</SO>
<YR>2004</YR>
<PB>Churchill Livingstone: Elsevier Science</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NUTCM-2006" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="NUTCM 2006" TYPE="BOOK">
<AU>Nanjing University of Traditional Chinese Medicine,</AU>
<SO>Chinese Materia Medica Pharmacopoeia</SO>
<YR>2006</YR>
<PB>Shanghai Scientific and Technology Press</PB>
<CY>Shanghai</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Proctor-2001" MODIFIED="2008-05-06 14:27:59 +1200" MODIFIED_BY="jane clarke" NAME="Proctor 2001" TYPE="COCHRANE_REVIEW">
<AU>Proctor ML, Murphy PA</AU>
<TI>Herbal and dietary therapies for primary and secondary dysmenorrhoea (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-05-06 14:27:59 +1200" MODIFIED_BY="jane clarke">
<IDENTIFIER MODIFIED="2008-05-06 14:27:59 +1200" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE="10.1002/14651858.CD002124 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Proctor-2005" MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke" NAME="Proctor 2005" TYPE="COCHRANE_REVIEW">
<AU>Procotor ML, Farquhar CM, Sinclair OJ, Johnson NP</AU>
<TI>Surgical interruption of pelvic nerve pathways for primary dysmenorrhoea (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke">
<IDENTIFIER MODIFIED="2008-05-06 14:29:15 +1200" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE="10.1002/14651858.CD001896.pub2  "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2002" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="RevMan 2002" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan) (Computer program) Version 4.2 for Windows</TI>
<YR>2002</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Oxford, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SATCM-1995" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="SATCM 1995" TYPE="UNPUBLISHED">
<AU>State Administration of Traditional Chinese Medicine, P.R. China</AU>
<TI>Traditional Chinese Medicine Professional Statute: Criteria of diagnosis and therapeutic effect of diseases/syndromes</TI>
<SO>Government document</SO>
<YR>1995</YR>
<PG>65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh-1998" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Singh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Singh G, Ramey D</AU>
<TI>NSAID-induced gastrointestinal complications: The ARAMIS perspective -1997</TI>
<SO>Arthritis, Rheumatism, and Aging Medical Information Sydtem. Journal of Pheumatol Suppl</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>8-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strom-1996" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Strom 1996" TYPE="JOURNAL_ARTICLE">
<AU>Strom BL, Berlin JA, Kinman JL, Sptiz PW, Hennessy S, Feldman H</AU>
<TI>Parenteral ketorolac and risk of gastrointestinal and operative site bleeding: A postmarking surveillance study</TI>
<SO>Journal of American Medicine Association</SO>
<YR>1996</YR>
<VL>275</VL>
<PG>376-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2002" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Taylor 2002" TYPE="JOURNAL_ARTICLE">
<AU>Taylor D, Miaskowski C, Kohn J</AU>
<TI>A randomised clinical trial of the effectiveness of an acupressure device (relief brief) for managing the symptoms of dysmenorrhoea</TI>
<SO>The Journal of Alternative and Complementary Medicine</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>3</NO>
<PG>357-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vicdan-1996" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Vicdan 1996" TYPE="JOURNAL_ARTICLE">
<AU>Vicdan K , Kukner S , Darakoglu T, Ergin T, Keles G, Gokmen O</AU>
<TI>Demographic and epidemiologic features of female adolescents in Turkey</TI>
<SO>Journal of Adolescent Health</SO>
<YR>1996</YR>
<VL>18</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-1994" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Xia 1994" TYPE="BOOK">
<AU>Xia G</AU>
<SO>Clinical Gynecology in Traditional Chinese Medicine</SO>
<YR>1994</YR>
<PB>People's Health Press</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2000" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="Xia 2000" TYPE="BOOK">
<AU>Xia G</AU>
<SO>Chinese medicine diagnosis and treatment in the management of menstrual disorders</SO>
<YR>2000</YR>
<PB>People's Health Press</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ZCTCM-1991" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NAME="ZCTCM 1991" TYPE="BOOK">
<AU>Zhejiang College of Traditional Chinese Medicine</AU>
<SO>A Handbook of Traditional Chinese Gynecology</SO>
<YR>1991</YR>
<PB>Blue Poppy Press</PB>
<CY>Boulder</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-13 10:17:37 +1200" MODIFIED_BY="jane clarke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-05-13 10:17:37 +1200" MODIFIED_BY="jane clarke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Deng-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number<BR/>Experimental: 33 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 16-33,<BR/>Control: 15-33</P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Jia Wei Muo Jie Pian) vs OTC (Yue Yue Shu) </P>
<P>Jia Wei Muo Jie Pian: Xue Jie (Sanguis Draconis), Mo Yao (Myrrha), Pu Huang (Pollen Typhae), Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), San Leng (Rhizoma Sparganii Stoloniferi), Er Zhu (Rhizoma Curcumae Ezhu) etc. 4 tablets, tid. 2 weeks prior to bleeding till 1st day of cycle</P>
<P>Yue Yue Shu: 1 sachet (10g), bid. 1 week prior to bleeding till 1st day of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain<BR/>Experimentalerimental : <BR/>Casess of cure: 19/33<BR/>Casess of improvement: 7/33<BR/>Casess of response: 5/33<BR/>Casess of no response: 2/33<BR/>Total effectiveness: 93.94% </P>
<P>Controlrol<BR/>Cases of cure: 7/30<BR/>Cases of improvement: 8/30<BR/>Cases of response: 9/30<BR/>Cases of no response: 6/30<BR/>Total effectiveness: 80.00% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Cases of cure: 19/33<BR/>Cases of improvement: 7/33<BR/>Cases of response: 5/33<BR/>Cases of no response: 2/33<BR/>Total effectiveness: 93.94% </P>
<P>Control:<BR/>Cases of cure: 7/30<BR/>Cases of improvement: 8/30<BR/>Cases of response: 9/30<BR/>Cases of no response: 6/30<BR/>Total effectiveness: 80.00% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, pain scores reduced to 0, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, other symptoms disappeared or reduced, no need to take pain relieving medication, the pain scores after intervention reduced less than 1/2 of the scores before intervention. </P>
<P>Response: abdominal pain reduced, other symptoms improved, pain relieving medication needed, the pain scores after intervention reduced between 1/2 to 4/3 of the scores before intervention. </P>
<P>No response: abdominal pain, or other symptoms not changed at all. </P>
<P>3. Adverse effect: stated, but no statement for the Controlrol group</P>
<P>4. Lab tests: <BR/>unstated </P>
<P>5. Use of additional medication: stated. </P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Deng-2005">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration:3-5 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 70 women<BR/>Control: 70 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-37 ys. </P>
<P>History: stated </P>
<P>TCM Pattern: both groups were diagnosed as 'retention of cold', 'stagnation of Qi and blood', 'deficiency of liver and kidney', 'retention of dampness and heat'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Folker formula (Jiang Ji Jiu) vs OTC ( Tian Qi Tong Jing Jiao Nang) </P>
<P>Jiang Ji Jiu: rice wine 200ml, Sheng Jiang (Rhizoma Zingiberis Officinalis Recens) 200 g, Ai Ye (Folium Artemisiae Argyri) 200 g, Yi Mu Cao (Herba Leonuri Herterophylli) 50 g, Hen 1000 g, modification of formula may be required. Stewing all ingredients, taking the soup and the chicken meat, one dose for 3 days. 3 days prior to bleeding, no chicken soup during menstruation, then started it again on day 2 of cycle for 6 days</P>
<P> Tian Qi Tong Jing Jiao Nang: 6 pills, tid. 2 days prior to bleeding for 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate &amp; Casess of cure: 44.3%, 31/70<BR/>Rate &amp; Casess of improvement: 51.4%, 36/70<BR/>Rate &amp; Casess of no response: 4.3%, 3/70</P>
<P>Cont:<BR/>Rate &amp; Cases of cure: 21.4%, 15/70<BR/>Rate &amp; Cases of improvement: 67.1%, 47/70<BR/>Rate &amp; Cases of no response: 11.4%, 8/70</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, but relapse during 3 cycles of follow up.</P>
<P>No response: abdominal pain and other symptoms not changed at all.</P>
<P>2. Overall symptoms: <BR/>unstated </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fan-1999">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 50 women<BR/>Control: 48 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-26 y </P>
<P>History: stated </P>
<P>TCM Pattern: specified, 'stagnation of blood Qi and blood, ','retention of cold', 'deficiency of kidney deficiency'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Huo Xue Zhen Tong Tang) vs indomethacin + Atropome </P>
<P>Huo Xue Zhen Tong Tang: <BR/>Pu Huang (Pollen Typhae) 15 g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 15 g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 30 g, Dan Shen (Radix Salviae Miltrorrhizae) 12 g, <BR/>Hong Hua (Flos Carthami Tinctorii) 12 g, Bai Shao (Radix Paeoniae Latiflorae) 30-45 g, <BR/>Chai Hu (Radix Bupleuri) 12 g. <BR/>Modification might be required. Herbal decoction, one dose/day, 5 days prior to bleeding for a period of 7 days </P>
<P>Indomethacin: 25mg, tid. Atropome: 0.3 mg, tid. 20 th days of cycle for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 58.00%, 29/50<BR/>Rate and Cases of improvement: 42.00%, 21/50<BR/>Rate and Cases of no response: 0%, 0/50<BR/>Total effectiveness: 100%</P>
<P>Control:<BR/>Rate and Cases of cure: 35.42%, 17/48<BR/>Rate and Cases of improvement: 43.75%, 21/48<BR/>Rate and Cases of no response:0%, 0/48<BR/>Total effectiveness: 79.17%</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 58.00%, 29/50<BR/>Rate and Cases of improvement: 42.00%, 21/50<BR/>Rate and Cases of no response: 0%, 0/50<BR/>Total effectiveness: 100%</P>
<P>Control:<BR/>Rate and Cases of cure: 35.42%, 17/48<BR/>Rate and Cases of improvement: 43.75%, 21/48<BR/>Rate and Cases of no response:0%, 0/48<BR/>Total effectiveness: 79.17%</P>
<P>Criteria<BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, but relapse during 3 cycles of follow up.</P>
<P>No response: abdominal pain and and other symptoms changed at all.</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Guo-1997">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised - method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 35 women<BR/>Control: 31 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-26 years </P>
<P>History: stated </P>
<P>TCM Pattern: unspecified, but mentioned the common reasons as 'stagnation of blood Qi and blood, retention of cold' etc</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Tong Jing San) vs OTC formula (Yue Yue Shu) </P>
<P>Tong Jing San: Xue Jie (Sanguis Draconis), Rou Gui (Cortex Cinnamomi Cassiae), in a ratio of 3:1 and a form of powder, 3 g, bid. Mixed and dissolve with warm water. starting 24 hours prior to bleeding till 3rd day of cycle</P>
<P>Yue Yue Shu (powder): 10g, bid. 1 week prior to bleeding till day 3 of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 24/35 <BR/>Cases of improvement: 7/35<BR/>Cases of response: 3/35<BR/>Cases of no response: 1/35<BR/>Total effectiveness: 97.14% </P>
<P>Control:<BR/>Cases of cure: 9/31<BR/>Cases of improvement: 9/31<BR/>Cases of response: 11/31<BR/>Cases of no response: 1/31<BR/>Total effectiveness: 93.55% </P>
<P>Significant difference between the two groups in the total efficacy P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Cases of cure: 24/35 <BR/>Cases of improvement: 7/35<BR/>Cases of response: 3/35<BR/>Cases of no response: 1/35<BR/>Total effectiveness: 97.14% </P>
<P>Control:<BR/>Cases of cure: 9/31<BR/>Cases of improvement: 9/31<BR/>Cases of response: 11/31<BR/>Cases of no response: 1/31<BR/>Total effectiveness: 93.55% </P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, and other symptoms disappeared or reduced, capable of working without pain relieving medication. </P>
<P>Response: abdominal pain reduced, and other symptoms improved, capable of working with pain relieving medication. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Huang-2000">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated </P>
<P>Trial design: parallel</P>
<P>Parallel performance: No</P>
<P>Duration: 2 cycle of intervention + 2 cycles of follow up </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 33 women<BR/>Control: 25 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-33 ys </P>
<P>History: unstated </P>
<P>TCM Pattern: unspecified, only common patters were 'stagnation of Qi and blood in the channels' and 'retention of cold in the channels'.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self -designed formula (modified Si Wuo Tang) vs Indomethacin </P>
<P>Modified Si Wu Tang based on patterns. <BR/>Stagnation of Qi and Blood: <BR/>Dang Gui (Radix Angelicae Sinensis) 15 g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 10 g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 10 g, <BR/>Shu Di (Radix Rehmanntae Glutinosae Conquitae) 10 g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 10 g, <BR/>Tao Ren (Semen Persicae) 15 g, <BR/>Hong Hua (Flos Carthami Tinctorii) 10 g</P>
<P>Retention of Cold and Blood Stasis: <BR/>Dang Gui (Radix Angelicae Sinensis) 15 g, Chuan Xiong (Radix Ligustici Chuanxiong) 10 g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 10 g, <BR/>Shu Di (Radix Rehmanntae Glutinosae Conquitae) 10 g, <BR/>Tao Ren (Semen Persicae) 15 g, <BR/>Hong Hua (Flos Carthami Tinctorii) 10 g <BR/>Gui Zhi (Ramulus Cinnamomi Cassiae) 6 g, <BR/>Wu Zhu Yu (Fructus Evodiae Rutaecorpae) 6 g</P>
<P>Herbal decoction, one dose/day, as soon as bleeding started, for a period of 3 days</P>
<P>Indomethacin: 25mg, as soon as bleeding started, for a period of 3 days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 10/33<BR/>Cases of improvement: 18/33<BR/>Cases of no response: 5/33<BR/>Total effectiveness: 92.4%</P>
<P>Control:<BR/>Cases of cure: 2/25<BR/>Cases of improvement: 17/25<BR/>Cases of no response: 6/25<BR/>Total effectiveness: 76% </P>
<P>Criteria<BR/>Cure: abdominal pain disappeared. no relapse during 2 cycles of follow up </P>
<P>Improvement: abdominal pain reduced, but relapse during 2 cycles of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: <BR/>unstated </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jiang-2000">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 40 women<BR/>Control: 36 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-25 years </P>
<P>History: stated </P>
<P>TCM Pattern: unspecified, but the common pattern was 'stagnation of Qi and blood with retention of cold'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Li Qi Huo Xue Tang) vs Indomethacin </P>
<P>Li Qi Huo Xue Tang: <BR/>Di Huang (Radix Rehmanniae Glutinosae) 12 g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 12 g, Ge Gen (Radix Puerariae) 12 g, <BR/>Dang Gui (Radix Angelicae Sinensis) 10 g, Chi Shao (Radix Paeoniae Rubrae) 10 g, Ze Lan (Herba Lycopi Lucidi) 10 g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 10 g, <BR/>Hu Lu Ba (Semen Trigonellae Foeni-graeci) 10 g, Dan Shen (Radix Salviae Miltrorrhizae) 15 g, <BR/>Wu Yao (Radix Linderae Strychnifoliae) 6 g, Sha Ren (Fructus Amomi) 6 g, <BR/>Wu Zhu Yu (Fructus Evodiae Rutaecorpae) 5 g <BR/>Herbal decoction, one dose daily, starting from 3 days prior to bleeding till bleeding ended, plus OCT (Wu Ji Bai Feng Wan) started as soon as bleeding stopped for a period of 10 days</P>
<P>Indomethacin: 25mg, bid. 3 days before bleeding till bleeding ended</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 37.5%, 15/40<BR/>Rate and Cases of improvement: 52.5%, 21/40<BR/>Rate and Cases of no response: 10%, 4/40<BR/>Total effectiveness: 90.0%</P>
<P>Control:<BR/>Rate and Cases of cure: 30.5%, 11/36<BR/>Rate and Cases of improvement: 41.7%, 15/36<BR/>Rate and Cases of no response: 27.8%, 10/36<BR/>Total effectiveness: 72.2%%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.05 </P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 37.5%, 15/40<BR/>Rate and Cases of improvement: 52.5%, 21/40<BR/>Rate and Cases of no response: 10%, 4/40<BR/>Total effectiveness: 90.0%</P>
<P>Control:<BR/>Rate and Cases of cure: 30.5%, 11/36<BR/>Rate and Cases of improvement: 41.7%, 15/36<BR/>Rate and Cases of no response: 27.8%, 10/36<BR/>Total effectiveness: 72.2%%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.05 </P>
<P>Criteria:<BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, but relapse during 3 cycles of follow up.</P>
<P>No response: abdominal pain and other symptoms not changed at all.</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kennedy-2006">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised - method stated (computer-generated opaque sealed envelope)</P>
<P>Blinding: double blinded</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 1 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 17 women<BR/>Control: 19 women</P>
<P>Drop-outs/withdrawals: stated 3 dropped out before randomisation, 2 dropped out after randomisation due to either irregular menstruation or personal reasons. Their data were excluded (no intention-to-treatment performed) </P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 18-45 years </P>
<P>History: unstated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula vs Placebo</P>
<P>Self-designed formula: Dang Gui (Radix Angelicae Sinensis), Bai Shao (Radix Paeoniae Latiflorae), Chi Shao (Radix Paeoniae Rubrae), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), in a ration of approximately 1:1.5:1</P>
<P>Placebo: sugar beet fiber and maltodextrin indistinguishable in appearance </P>
<P>Both groups took 3 tablets, bid, 2 days prior to bleeding for a period of 7 days</P>
<P>Rescue medication: Ibuprofen, 200 mg, 6 tablets/day maximum </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>VAS, more details in the additional table </P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: stated, measured by hematological and biochemical tests. No details provided. </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: stated, no details provided.</P>
<P>6. Satisfaction from patients: stated, no details provided. </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Additional results in the additional table. </P>
<P>Sample size calculation was mentioned but no formal statistic estimation was performed.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kotani-1997">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: double blind </P>
<P>Trial design: parallel </P>
<P>Duration: 2 cycles of observation + 2 cycles of intervention + 2 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 20 women <BR/>Control: 20 women </P>
<P>Drop-outs/withdrawals: unstated </P>
<P>Diagnosis of dysmenorrhoea: unstated</P>
<P>Age: 14-45 </P>
<P>History: unstated </P>
<P>TCM Pattern: stated, only included 'stagnation blood', 'deficiency', 'yin', and 'cold'. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Classic Chinese formula (Tao Hong Si Wuo San) vs placebo</P>
<P>Tao Hong Si Wuo San: <BR/>Dang Gui (Angelicae sinensis radix) <BR/>Chi Shao (Paeoniae rubrae radix) <BR/>Fu Ling (Sclerotium poriae cocos) <BR/>Cang Zhu (Atractylodis lanceae rhizoma) <BR/>Ze Xie (Alismatis rhizoma) <BR/>Chuan Xiong (Chuanxiong rhizoma) <BR/>(in a ratio of 3:4:4:4:4:3)</P>
<P>Placebo: no details </P>
<P>Both groups took study materials 7.5g, daily, for two cycles. </P>
<P>Rescue medication: Diclofenac sodium 25 mg, 4 tablets/day maximum</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reduction in pain <BR/>Visual analogue scale (VAS)</P>
<P>Reduction in depression <BR/>Zung self-rating depression scale </P>
<P>Reduced consumption of pain relieving medication </P>
<P>Improved biomedical parameters (FSH, LH, Prolactin, Estradiol, Blood count, Hepatic and renal function tests at each cycle). No data assessed </P>
<P>Adverse Effects <BR/>Self report from subjects: None Experimentalerienced adverse effects. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Results listed in the additional table</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-1999">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated </P>
<P>Trial design: parallel</P>
<P>Parallel performance: yes</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 44 women<BR/>Control: 36 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-45</P>
<P>History: stated </P>
<P>TCM Pattern: stated, 'stagnation of Qi and Blood'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Fu Ke Qian Jin Pian) vs OTC Chinese herbal formula (Tian Qi Jiao Nang) </P>
<P>Fu Ke Qian Jin Pian: no details stated</P>
<P>Tian Qi Jiao Nang: no details stated</P>
<P>Both group took 5 tablets of each study material, tid. 4-5 days prior to bleeding till day 2 of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 13/44<BR/>Cases of improvement: 23/44<BR/>Cases of response: 5/44<BR/>Cases of no response: 3/44<BR/>Total effectiveness: 93.2% </P>
<P>Control:<BR/>Cases of cure: 10/36<BR/>Cases of improvement: 17/36<BR/>Cases of response: 5/36<BR/>Cases of no response: 4/36<BR/>Total effectiveness: 88.9% </P>
<P>No significant difference between the Experimentalerimental and Controlrol groups P&gt;0.05<BR/>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/> Experimental: <BR/>Cases of cure: 13/44<BR/>Cases of improvement: 23/44<BR/>Cases of response: 5/44<BR/>Cases of no response: 3/44<BR/>Total effectiveness: 93.2% </P>
<P>Control:<BR/>Cases of cure: 10/36<BR/>Cases of improvement: 17/36<BR/>Cases of response: 5/36<BR/>Cases of no response: 4/36<BR/>Total effectiveness: 88.9% </P>
<P>No significant difference between the Experimentalerimental and Controlrol groups P&gt;0.05<BR/>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, and other symptoms disappeared or reduced. </P>
<P>Response: abdominal pain reduced, and other symptoms improved. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: </P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear how women assigned to different groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: single blinded </P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 50 women<BR/>Control: 50 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental:15-35, <BR/>Control: 15-33 </P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Tong Jing Wan) vs OTC Chinese herbal formula (Yuan Hu Zhi Tong Pian) </P>
<P>Tong Jing Wan: Xiao Hui Xiang (Fructus Foeniculi Vulgaris), Rou Gui (Cortex Cinnamomi Cassiae), San Qi (Radix Notoginseng), Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), Pu Huang (Pollen Typhae), Chen Xiang (Lignum Aquitariae), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Mu Xiang (Radix Aucklandiae Lappae), Bai Zhu (Rhizoma Atractylodis Macrocephalae), made as a form of pills in certain ratio. 2g, tid</P>
<P>Yuan Hu Zhi Tong Pian: 5 tablets, tid</P>
<P>Both groups started from 5 days prior to bleeding till day 2 of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 68.0%, 34/50<BR/>Rate and Cases of improvement: 10%, 5/50<BR/>Rate and Cases of response: 12%, 6/50<BR/>Rate and Cases of no response: 10%, 5/50<BR/>Total effectiveness: 90% </P>
<P>Control:<BR/>Rate and Cases of cure: 20%, 10/50<BR/>Rate and Cases of improvement: 30%, 15/50<BR/>Rate and Cases of response: 22%, 11/50<BR/>Rate and Cases of no response: 28%, 14/50<BR/>Total effectiveness: 72% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.001</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 68.0%, 34/50<BR/>Rate and Cases of improvement: 10%, 5/50<BR/>Rate and Cases of response: 12%, 6/50<BR/>Rate and Cases of no response: 10%, 5/50<BR/>Total effectiveness: 90% </P>
<P>Control:<BR/>Rate and Cases of cure: 20%, 10/50<BR/>Rate and Cases of improvement: 30%, 15/50<BR/>Rate and Cases of response: 22%, 11/50<BR/>Rate and Cases of no response: 28%, 14/50<BR/>Total effectiveness: 72% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.001</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, pain scores reduced to '0', no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, and other symptoms disappeared or reduced, the scores reduced to as low as more than 1/2 of the scores before, capable of working without pain relieving medication. </P>
<P>Response: abdominal pain reduced, and other symptoms improved, the scores reduced to as low as more than 1/3 of the scores before, capable of working with pain relieving medication. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated. </P>
<P>4. Lab tests: stated. But no investigation nor data on the Controlrol group as a comparison </P>
<P>5. Use of additional medication: stated. </P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Li-2004">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 40 women<BR/>Control: 40 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 12-33 y<BR/>Control: 13-32 y </P>
<P>History: unstated </P>
<P>TCM Pattern: stated, only the pattern of 'retention of cold and blood stasis'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Nuan Gong ZHi Tong Tang) vs OTC (Yue Yue Shu) </P>
<P>Nuan Gong ZHi Tong Tang: <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 5 g, <BR/>Zhi Fu Zi (Radix Lateralis Aconiti Carmichaeli Praeparata) 3 g, <BR/>Zi Shi Ying (Fluoritum) 10 g, <BR/>San Leng (Rhizoma Sparganii Stoloniferi) 10 g, <BR/>Er Zhu (Rhizoma Curcumae Ezhu) 10 g, Dang Gui (Radix Angelicae Sinensis) 10 g, Xiang Fu (Rhizoma Cypri Rotundi) 10 g, Chuan Xiong (Radix Ligustici Chuanxiong) 6 g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 12 g, Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 12 g.<BR/>300ml of herbal decoction as daily dosage, 150ml, bid</P>
<P>Yue Yue Shu: 1 sachet (10g), bid</P>
<P>Both groups started from 5 days prior to bleeding for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Casess of cure: 21/40<BR/>Casess of improvement: 11/40<BR/>Casess of response: 5/40<BR/>Casess of no response: 3/40<BR/>Total effectiveness: 92.5% </P>
<P>Control:<BR/>Casess of cure: 14/40<BR/>Casess of improvement: 10/40<BR/>Casess of response: 7/40<BR/>Casess of no response: 9/40<BR/>Total effectiveness: 77.5% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05 </P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Casess of cure: 21/40<BR/>Casess of improvement: 11/40<BR/>Casess of response: 5/40<BR/>Casess of no response: 3/40<BR/>Total effectiveness: 92.5% </P>
<P>Control:<BR/>Casess of cure: 14/40<BR/>Casess of improvement: 10/40<BR/>Casess of response: 7/40<BR/>Casess of no response: 9/40<BR/>Total effectiveness: 77.5% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05 </P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapsed during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, and other symptoms disappeared or reduced, remained the efficacy during 3 cycles of follow up. </P>
<P>Response: abdominal pain reduced, and other symptoms improved, relapsed but less severe . </P>
<P>No response: abdominal pain, other symptoms not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2000">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised - method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 40 women<BR/>Control: 38 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-31</P>
<P>History: stated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OCT Chinese herbal formula (Xiao Yao Wan) + Piroxicam vs Prioxicam </P>
<P>Xiao Yao Wan: Dang Gui (Radix Angelicae Sinensis), Bai Shao (Radix Paeoniae Latiflorae), Chai Hu (Radix Bupleuri), Fu Ling (Sclerotium Poriae Cocos), Bai Zhu (Rhizoma Atractylodis Macrocephalae), Gan Cao (Radix Glycyrrhizae Uralensis), Wei Jiang (Rhizoma Phragmitis Communis), Bo He (Herba Menthae Haplocalcis), 9g, bid. in combination with Piroxicam: 20mg, once daily </P>
<P>Piroxicam: 20 mg, once daily</P>
<P>Both groups started from 2 days prior to bleed for a period of 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 70%, 28/40<BR/>Rate and Cases of improvement: 22.5%, 9/40<BR/>Rate and Cases of no response: 7.5%, 3/40<BR/>Total effectiveness: 92.5%</P>
<P>Control:<BR/>Rate and Cases of cure: 31.6%, 12/38<BR/>Rate and Cases of improvement: 52.6%, 20/38<BR/>Rate and Cases of no response: 15.8%, 6/38<BR/>Total effectiveness:84.2%<BR/>No significant difference between the Experimentalerimental and Controlrol groups in total efficacy P&gt;0.05. but different in rate of cure P&lt;0.001 </P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 10 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced or disappeared, no relapse during 3 cycles of follow up.</P>
<P>No response: relapsed as soon as cease of intervention.</P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: stated. no incidence in neither of groups</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2002">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 30 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 12-36</P>
<P>History: stated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Wen Tong Tang) vs OTC Chinese herbal formula (Gu Zhi Wan) </P>
<P>Wen Tong Tang: <BR/>Dang Gui (Radix Angelicae Sinensis) 10 g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 10 g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 10 g, <BR/>Chuan Niu Xi (Radix Cyathulae Officinalis) 15 g, <BR/>Pu Huang (Pollen Typhae) 10g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 10 g, <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 5 g, <BR/>Xiao Hui Xiang (Fructus Foeniculi Vulgaris) 5 g, <BR/>Pao Jiang (Quick-Fried Rhizoma Zingiberis Officinalis) 5 g, <BR/>Lu Jiao Shuang (Cornu Cerri Degelatinatium) 10 g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 10 g, Xiang Fu (Rhizoma Cypri Rotundi) 10 g. <BR/>Herbal decoction, one dose, bid</P>
<P>Gu Zhi Wan: 9g, bid</P>
<P>Both group started study material from the first day of cycle (bleeding) to the end of bleeding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 22/30<BR/>Cases of improvement: 6/30<BR/>Cases of no response: 2/30<BR/>Total effectiveness: 93.3%</P>
<P>Control:<BR/>Cases of cure: 12/30<BR/>Cases of improvement: 10/30<BR/>Cases of no response: 8/30<BR/>Total effectiveness: 73.3%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.05 </P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced or disappeared, but relapse during 3 cycles of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: stated but doesn't fit the criteria of outcomes. </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised - method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Parallel performance: yes</P>
<P>Duration: <BR/>2-3 days prior to bleeding or 1st day of bleeding for 7 days x 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 52 women<BR/>Control: 38 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-30</P>
<P>History: stated </P>
<P>TCM Pattern: specified, pattern of 'stagnation of blood' only</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Wen Jing Tang -&gt; oral administration +<BR/>Xin Jie San -&gt; external administration ) vs Indomethacin + Vit B6 + Hot water bottle </P>
<P>Wen Jing Tang: <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 3 g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 8 g, <BR/>Dangshen (Codonopsis Radix) 20 g, <BR/>Dang Gui (Radix Angelicae Sinensis) 10 g, Er Zhu (Rhizoma Curcumae Ezhu) 10 g, Dan Shen (Radix Salviae Miltrorrhizae) 15 g, Chuan Niu Xi (Radix Cyathulae Officinalis) 10 g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 10 g, Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 10 g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 6 g. Herbal decoction, one dose daily</P>
<P>Xin Jie San: Xi Xin (Asari Herba) 30 g, <BR/>Bai Jie Zi (Sinapis Semen) 30 g, <BR/>Mang Xiao (Natrii Sulfas) 30g. All ingredients were mixed, ground into powder and packed into a bag sized as 20x30cm, then sealed. Warmed up in microwave oven before applied on the lower abdominal region</P>
<P>Indomethacin: 25 mg, tid. Vit B6 20 mg, tid. Hot water bottle in the lower abdominal region</P>
<P>Both groups started from 2-3 days prior to bleeding or 1st day of bleeding for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure:90.4%, 47/52<BR/>Rate and Cases of improvement: 7.7%, 4/52<BR/>Rate and Cases of no response: 1.9%, 1/52<BR/>Total effectiveness: 98.1% </P>
<P>Control:<BR/>Rate and Cases of cure: 44.7%, 17/38<BR/>Rate and Cases of improvement: 31.6%, 12/38<BR/>Rate and Cases of no response: 23.7%, 9/38<BR/>Total effectiveness: 76.3% <BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.01 </P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Improved other symptoms: unstated</P>
<P>3. Adverse effect: unstated</P>
<P>4. Improvement in lab tests: unstated</P>
<P>5. Reduced additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. improvement in quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unclear how women assigned to different groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2004">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 45 women<BR/>Control: 40 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-18</P>
<P>History: stated </P>
<P>TCM Pattern: retention of coldness and stagnation of blood</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula administrated externally vs classic formula (Wen Jing Tang) administrated orally </P>
<P>Zi Ni Wai Fu Tong Jing Zhi Tong Fan: <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 30 g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 30 g, Ru Xiang (Gummi Olibanum) 30 g, <BR/>Mo Yao (Myrrha) 30 g, <BR/>Di Bie Chong (Eupolyphaga Seu Opisthaplatia) 30 g, <BR/>Wu Yao (Radix Linderae Strychnifoliae) 30 g. <BR/>All ingredients were dried and granted into powder, 20g each time, mixed with rice wine as paste for external use on navel. Change once daily</P>
<P>Wen Jing Tang: no details. One dose daily. </P>
<P>Both groups started from 3 days prior to bleeding for a period of 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 88.89%, 40/45<BR/>Rate and Cases of improvement: 6.67%, 3/45<BR/>Rate and Cases of response: 2.22%, 1/45<BR/>Rate and Cases of response: 2.22%, 1/45<BR/>Total effectiveness: 97.78%</P>
<P>Control:<BR/>Rate and Cases of cure: 47.50%, 19/40<BR/>Rate and Cases of improvement: 10.00%, 4/40 <BR/>Rate and Cases of response: 15.00%, 6/40<BR/>Rate and Cases of no response: 27.50%, 11/40<BR/>Total effectiveness: 72.50%</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 88.89%, 40/45<BR/>Rate and Cases of improvement: 6.67%, 3/45<BR/>Rate and Cases of response: 2.22%, 1/45<BR/>Rate and Cases of response: 2.22%, 1/45<BR/>Total effectiveness: 97.78%</P>
<P>Control:<BR/>Rate and Cases of cure: 47.50%, 19/40<BR/>Rate and Cases of improvement: 10.00%, 4/40 <BR/>Rate and Cases of response: 15.00%, 6/40<BR/>Rate and Cases of no response: 27.50%, 11/40<BR/>Total effectiveness: 72.50%</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, scores reduced to 0, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms significantly reduced, after intervention, scores reduced as 1/2 below as before</P>
<P>Response: abdominal pain and reduced, after intervention, scores reduced as 1/2 below as before</P>
<P>No response: abdominal pain, other symptoms. </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated </P>
<P>5. Use of additional medication: unstated </P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Liu-2005">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised - method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 30 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-30</P>
<P>History: stated </P>
<P>TCM Pattern: stated, retention of coldness and stagnation of blood</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Wen Jing Zhi Tong Yin) vs OTC Chinese herbal formula (Ai Fu Nuan Gong Tang) </P>
<P>Wen Jing Zhi Tong Yin: Pao Jiang (Quick-Fried Rhizoma Zingiberis Officinalis), Rou Gui (Cortex Cinnamomi Cassiae), Dang Gui (Radix Angelicae Sinensis), Chuan Xiong (Radix Ligustici Chuanxiong), Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), Pu Huang (Pollen Typhae), Bai Shao (Radix Paeoniae Latiflorae), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Huai Niu Xi (Radix Achyranthis Bidentatae), Xiao Hui Xiang (Fructus Foeniculi Vulgaris), Xiang Fu (Rhizoma Cypri Rotundi), Gan Cao (Radix Glycyrrhizae Uralensis) etc. No dosage in detail stated. Herbal decoction. 5 days prior to bleeding for a period of 7 days </P>
<P>Ai Fu Nuan Gong Tang: No dosage in detail stated. 3 days prior to bleeding for a period of 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Casess of cure: 7/30<BR/>Casess of improvement: 15/30<BR/>Casess of response: 6/30<BR/>Casess of no response: 2/30<BR/>Total effectiveness: 93.33% </P>
<P>Control:<BR/>Casess of cure: 6/30<BR/>Casess of improvement: 6/30<BR/>Casess of response: 11/30<BR/>Casess of no response: 7/30<BR/>Total effectiveness: 76.67% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05 </P>
<P>2. Overall symptoms: Experimental: <BR/>Casess of cure: 7/30<BR/>Casess of improvement: 15/30<BR/>Casess of response: 6/30<BR/>Casess of no response: 2/30<BR/>Total effectiveness: 93.33% </P>
<P>Control:<BR/>Casess of cure: 6/30<BR/>Casess of improvement: 6/30<BR/>Casess of response: 11/30<BR/>Casess of no response: 7/30<BR/>Total effectiveness: 76.67% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05 <BR/>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, other symptoms disappeared or reduced, the pain scores after intervention reduced as low as 1/2 of the scores before intervention. </P>
<P>Response: abdominal pain reduced, other symptoms improved, the pain scores after intervention reduced as low as between 1/2 to 3/4 of the scores before intervention. </P>
<P>No response: abdominal pain, or other symptoms not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lu-2002">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 45 women<BR/>Control: 41 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-32</P>
<P>History: stated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Fu Kang Bao) vs Ibuprofen </P>
<P>Fu Kang Bao: Dang Gui (Radix Angelicae Sinensis), E Jiao (Gelatinum Corii Asini), Chuan Xiong (Radix Ligustici Chuanxiong), Shao Yao (Radix Paeoniae Latiflorae), Shu Di (Radix Rehmanntae Glutinosae Conquitae) etc. No dosage, nor form of herbal preparation in detail stated. 10ml, bid, before meals</P>
<P>Ibuprofen: 300mg, bid </P>
<P>Both groups started from 5 days prior to bleeding to the end of bleeding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 66.7%, 30/45<BR/>Rate and Cases of improvement: 28.8%, 13/45<BR/>Rate and Cases of no response: 4.4%, 2/45<BR/>Total effectiveness: 95.6% </P>
<P>Control:<BR/>Rate and Cases of cure: 42.5%, 20/41<BR/>Rate and Cases of improvement: 26.8%, 11/41<BR/>Rate and Cases of no response: 24.3%, 10/41<BR/>Total effectiveness: 75.6% <BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.01 </P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Luo-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 31 women<BR/>Control: 31 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 13-40 </P>
<P>History: stated </P>
<P>TCM Pattern: Stagnation of Qi and Blood</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Tong Jing San) vs Indomethacin </P>
<P>Tong Jing San: <BR/>Pu Huang (Pollen Typhae) 15 g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 12 g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 15 g, Xiang Fu (Rhizoma Cypri Rotundi) 10 g, <BR/>Chuan Niu Xi (Radix Cyathulae Officinalis) 10 g, Pao Jiang (Quick-Fried Rhizoma Zingiberis Officinalis) 6 g, <BR/>Xi Xin (Herba cum Radice Asari) 3 g. Herbs were soaked for one hour, cooked for one hour, extracted into 200ml decoction, 100ml, bid. Started from 7 days prior to bleeding till 1st day of cycle</P>
<P>Indomethacin: 25 mg, tid. 3 days prior to bleeding till 1st day of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of improvement: 26/31<BR/>Cases of response: 5/31<BR/>Cases of no response: 0/31<BR/>Total effectiveness: 83.87% </P>
<P>Control:<BR/>Cases of improvement: 15/31<BR/>Cases of response: 11/31<BR/>Cases of no response: 4/31<BR/>Total effectiveness: 48.39% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Casess of improvement: 26/31<BR/>Casess of response: 5/31<BR/>Casess of no response: 0/31<BR/>Total effectiveness: 83.87% </P>
<P>Control:<BR/>Casess of improvement: 15/31<BR/>Casess of response: 11/31<BR/>Casess of no response: 4/31<BR/>Total effectiveness: 48.39% </P>
<P>Criteria: <BR/>Improvement: abdominal pain reduced obviously, and other symptoms disappeared or reduced, pain scores reduced as low as more then 1/2 of the scores before the intervention, capable of working without pain relieving medication. </P>
<P>Response: abdominal pain reduced, and other symptoms improved, pain scores reduced as low as between 1/2 to 3/4 of the scores before the intervention, capable of working with pain relieving medication. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: <BR/>Experimental: 26/31<BR/>Control: 15/31</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Miao-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design:<BR/>parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 36 women<BR/>Control: 27 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 12-20 y </P>
<P>History: stated </P>
<P>TCM Pattern: believed all clinical patterns related to 'deficiency of kidney and liver'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Niu Xi San) vs Acupuncture (LI 4, and SP 6 only) </P>
<P>Niu Xi San: Niu Xi (Chuan Niu Xi (Radix Cyathulae Officinalis) or Huai Niu Xi (Radix Achyranthis Bidentatae) (not clear), Rou Gui (Cortex Cinnamomi Cassiae), Chi Shao (Radix Paeoniae Rubrae), Tao Ren (Semen Persicae), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Dang Gui (Radix Angelicae Sinensis), Mu Xiang (Radix Aucklandiae Lappae), Dan Pi (Cortex Mouten Radicis) in a ration of 3:1:1:1:1:1:1:1:1, in a form of powder, 9g, mixed with warm water or wine, for a period of 5 days (unclear when started the intervention) </P>
<P>Acupuncture: needles remained for 30 minutes of each point, for a period of 5 days (unclear when started the intervention)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 47.3%, 17/36<BR/>Rate and Cases of improvement: 41.3%, 15/36<BR/>Rate and Cases of no response: 11.4%, 4/36<BR/>Total effectiveness: 88.6% </P>
<P>Control:<BR/>Rate and Cases of cure: 17.1%, 3/17<BR/>Rate and Cases of improvement: 47.1%, 8/17<BR/>Rate and Cases of no response: 34.8%, 6/17<BR/>Total effectiveness: 65.2%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.05 </P>
<P>Criteria: <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced or disappeared, but relapse during 3 cycle of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Niu-1996">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: single blinded </P>
<P>Trial design: parallel</P>
<P>Parallel performance: may not </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 32 women<BR/>Control: 21 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 17-47 ys<BR/>Control: 18-42yrs </P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Single herb (Glycyrrhiza uralensis Fisch) vs OTC (Yuan Hu Zhi Tong Pian) </P>
<P>Glycyrrhiza uralensis Fisch: no dosage of details stated </P>
<P>Yuan Hu Zhi Tong Pian: 6 tablets, tid</P>
<P>Both group took herb as soon as pain started for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 28.1%, 9/32<BR/>Rate and Cases of improvement: 40.6%, 13/32<BR/>Rate and Cases of response: 25.0%, 8/32<BR/>Rate and Cases of no response: 6.3%, 2/32<BR/>Total effectiveness: 93.8%</P>
<P>Control:<BR/>Rate and Cases of cure: 9.5%, 2/21<BR/>Rate and Cases of improvement: 23.8%, 5/21<BR/>Rate and Cases of response: 23.8%, 5/21<BR/>Rate and Cases of no response: 42.9%, 9/21<BR/>Total effectiveness: 57.1%</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 28.1%, 9/32<BR/>Rate and Cases of improvement: 40.6%, 13/32<BR/>Rate and Cases of response: 25.0%, 8/32<BR/>Rate and Cases of no response: 6.3%, 2/32<BR/>Total effectiveness: 93.8%</P>
<P>Control:<BR/>Rate and Cases of cure: 9.5%, 2/21<BR/>Rate and Cases of improvement: 23.8%, 5/21<BR/>Rate and Cases of response: 23.8%, 5/21<BR/>Rate and Cases of no response: 42.9%, 9/21<BR/>Total effectiveness: 57.1%</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, scores reduced to 0, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms significantly reduced, after intervention, scores reduced as 1/2 below as before, maintain daily activities with pain relieving medication. <BR/>Response: abdominal pain and reduced, after intervention, scores reduced as 1/2 to 3/4 below as before, pain relieving medication needed. <BR/>No response: abdominal pain, other symptoms. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Qin-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 60 women<BR/>Control: 60 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>average 14-40 y </P>
<P>History: unstated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Du Yi Wei Jiao Nang) vs OTC Formua (Yuan Hu Zhi Tong Jiao Nang) or added pain relieving medication if required </P>
<P>Du Yi Wei Jiao Nang: no details given. 3 pills, tid. </P>
<P>Yuan Hu Zhi Tong Jiao Nang: no details given. </P>
<P>Both group started herb from 1st day of cycle/bleeding for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate of cure: 81.67%, 49/60<BR/>Rate of improvement: 15.00%, 9/60<BR/>Rate of no response: 3.33%, 2/60<BR/>Total effectiveness: 96.66% </P>
<P>Control:<BR/>Rate of cure: 35.00%, 21/60<BR/>Rate of improvement: 48.33%, 29/60<BR/>Rate of no response: 16.66%, 10/60<BR/>Total effectiveness: 83.33%</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, but relapsed during 3 cycle of follow up.</P>
<P>No response: abdominal pain and other symptoms not changed at all.</P>
<P>2. Overall symptoms:<BR/>Experimental: <BR/>Rate of cure: 81.67%, 49/60<BR/>Rate of improvement: 15.00%, 9/60<BR/>Rate of no response: 3.33%, 2/60<BR/>Total effectiveness: 96.66% </P>
<P>Control:<BR/>Rate of cure: 35.00%, 21/60<BR/>Rate of improvement: 48.33%, 29/60<BR/>Rate of no response: 16.66%, 10/60<BR/>Total effectiveness: 83.33%</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shen-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 60 women<BR/>Control: 60 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 26.63 y<BR/>Control: 25.1 y </P>
<P>History: stated </P>
<P>TCM Pattern: stated, 'the retention of cold and stagnation of blood'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Wen Jing Jian Tong Jiao Nang) vs OCT Formua (Jiu Qi Jian Tong Wan) </P>
<P>Wen Jing Jian Tong Jiao Nang: Rou Gui (Cortex Cinnamomi Cassiae), Jiu Xiang Chong (Aspongopus), Xiao Hui Xiang (Fructus Foeniculi Vulgaris), Dang Gui (Radix Angelicae Sinensis), Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), Xiang Fu (Rhizoma Cypri Rotundi), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Bing Pian (Borneol), dosage of herbal ingredients unstated. 4 pills, bid </P>
<P>Jiu Qi Jian Tong Wan: no detail of dosage of herbal ingredient stated. 9g, bid</P>
<P>Both groups started herbs 7 days prior to period for a period of 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 14/60<BR/>Cases of improvement: 27/60<BR/>Cases of response: 16/60<BR/>Cases of no response: 3/60<BR/>Total effectiveness: 57 (95.00%) </P>
<P>Control:<BR/>Cases of cure: 8/60<BR/>Cases of improvement: 19/60<BR/>Cases of response: 28/60<BR/>Cases of no response: 5/60<BR/>Total effectiveness: 55 (91.67%)</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Cases of cure: 14/60<BR/>Cases of improvement: 27/60<BR/>Cases of response: 16/60<BR/>Cases of no response: 3/60<BR/>Total effectiveness: 57 (95.00%) </P>
<P>Control:<BR/>Cases of cure: 8/60<BR/>Cases of improvement: 19/60<BR/>Cases of response: 28/60<BR/>Cases of no response: 5/60<BR/>Total effectiveness: 55 (91.67%)</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, pain scores reduced to 0, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, other symptoms disappeared or reduced, no need to take pain relieving medication, the pain scores after intervention reduced was less than 1/2 of the scores before intervention. </P>
<P>Response: abdominal pain reduced, other symptoms improved, pain relieving medication needed, the pain scores after intervention reduced was between 1/2 to 4/3 of the scores before intervention. </P>
<P>No response: abdominal pain, or other symptoms not changed at all. </P>
<P>3. Adverse effect: stated, confirmed with lab tests such as blood and urine, excrement routine tests, ECG, ALT, BUN, Cr. </P>
<P>4. Lab tests: unreported</P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Song-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: single blinding </P>
<P>Trial design: parallel </P>
<P>Parallel performance: no </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 50 women<BR/>Control: 50 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 15-35,<BR/>Control: 14-36 </P>
<P>History: stated </P>
<P>TCM Pattern: stated, only the pattern of 'stagnation of Qi and Blood" was included.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Tong Jing Jiao Nang) vs Indomethacin </P>
<P>Tong Jing Jiao Nang: Xue Jie (Sanguis Draconis), Pu Huang (Pollen Typhae), Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), Chuan Niu Xi (Radix Cyathulae Officinalis), Xiang Fu (Rhizoma Cypri Rotundi), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Dang Gui (Radix Angelicae Sinensis), Bai Shao (Radix Paeoniae Latiflorae), Xi Xin (Herba cum Radice Asari), etc. in a form of capsule (no detailed dosage), 4 capsules, tid. 5 days prior to period for a period of 7 days</P>
<P>Indomethacin: 25 mg, tid. 3 days prior to period for a period of 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate of cure: 70%, 35/50<BR/>Rate of improvement: 20%, 10/50<BR/>Rate of no response: 10%, 5/50<BR/>Total effectiveness: 90% </P>
<P>Control:<BR/>Rate of cure: 20%, 10/50<BR/>Rate of improvement: 52%, 26/50<BR/>Rate of no response: 28%, 14/50<BR/>Total effectiveness: 72%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.005</P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, but relapsed during 3 cycles of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated</P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun-2006">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 46 women<BR/>Control: 45 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 13-35<BR/>Control: 12-35 </P>
<P>History: stated </P>
<P>TCM Pattern: specified, only the pattern of "stagnation of blood and retention of cold"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Tao Jing Ding Tong Tang) vs OTC Chinese herbal formula (Tian Qi Tong Jing Jiao Nang)</P>
<P>Tao Jing Ding Tong Tang: <BR/>Gui Zhi (Ramulus Cinnamomi Cassiae) 15 g, <BR/>Xiao Hui Xiang (Fructus Foeniculi Vulgaris) 10 g, Dang Gui (Radix Angelicae Sinensis) 10 g, Chuan Xiong (Radix Ligustici Chuanxiong) 15 g, Xiang Fu (Rhizoma Cypri Rotundi) 15 g, <BR/>Chai Hu (Radix Bupleuri) 10 g, <BR/>Yi Mu Cao (Herba Leonuri Herterophylli) 15 g,<BR/>Ze Lan (Herba Lycopi Lucidi) 15 g, <BR/>Wang Bu Liu Xing (Semen Vaccariae Segetalis) 20 g, <BR/>Lu Lu Tong (Fructus Liquidambaris Taiwanianae) 15 g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 15 g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 5 g. Herbal decoction, bid</P>
<P>Tian Qi Tong Jing Jiao Nang: 4 pills, tid, a half hour before meals </P>
<P>Both groups took herbs from 5 days prior to period for a period of 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 27/46<BR/>Cases of improvement: 12/46<BR/>Cases of response: 5/46<BR/>Cases of no response: 2/46<BR/>Total effectiveness: 95.65%</P>
<P>Control:<BR/>Cases of cure: 7/45<BR/>Cases of improvement: 18/45<BR/>Cases of response: 8/45<BR/>Cases of no response: 12/45<BR/>Total effectiveness: 73.33%</P>
<P>Significant difference in rate of cure between the two groups: P&lt;0.05</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Cases of cure: 27/46<BR/>Cases of improvement: 12/46<BR/>Cases of response: 5/46<BR/>Cases of no response: 2/46<BR/>Total effectiveness: 95.65%</P>
<P>Control:<BR/>Cases of cure: 7/45<BR/>Cases of improvement: 18/45<BR/>Cases of response: 8/45<BR/>Cases of no response: 12/45<BR/>Total effectiveness: 73.33%</P>
<P>Significant difference in rate of cure between the two groups: P&lt;0.05</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, scores reduced to 0, no relapse during 3 cycles of follow up.</P>
<P>Improvement: abdominal pain and other symptoms significantly reduced, after intervention, scores reduced as 1/2 below as before.</P>
<P>Response: abdominal pain and reduced, after intervention, scores reduced as 1/2 to 3/4 below as before. </P>
<P>No response: abdominal pain, other symptoms, lab tests not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: <BR/>unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun2004">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: randomised based on a random number table</P>
<P>Blinding: double-blinding </P>
<P>Trial design: parallel</P>
<P>Parallel performance: may not</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 30 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-23 </P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OTC formula (Gui Zhi Fu Ling Wan No1) vs Placebo </P>
<P>Gui Zhi Fu Ling Wan No1: Gui Zhi (Ramulus Cinnamomi Cassiae), Fu Ling (Sclerotium Poriae Cocos), Chi Shao (Radix Paeoniae Rubrae), Dan Pi (Cortex Mouten Radicis), Tao Ren (Semen Persicae). 3 pills, tid</P>
<P>Placebo: 3 pills, tid. no further details</P>
<P>Both groups started herbs/placebo from 3 days prior to period for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental 1: <BR/>Rate and Cases of cure: 10%, 3/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 46.7%, 14/30<BR/>Rate and Cases of no response: 10%, 3/30<BR/>Total effectiveness: 90.0%<BR/>Experimental 2: <BR/>Rate and Cases of cure: 6.7%, 2/30<BR/>Rate and Cases of improvement: 30.0%, 9/30<BR/>Rate and Cases of response: 50.0%, 15/30<BR/>Rate and Cases of no response: 13.3%, 4/30<BR/>Total effectiveness: 86.7%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/30<BR/>Rate and Cases of improvement: 3.3%, 1/30<BR/>Rate and Cases of response: 36.7%, 11/30<BR/>Rate and Cases of no response: 60%, 18/30<BR/>Total effectiveness: 60.0%</P>
<P>2. Overall symptoms: <BR/>Experimental 1: <BR/>Rate and Cases of cure: 10%, 3/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 46.7%, 14/30<BR/>Rate and Cases of no response: 10%, 3/30<BR/>Total effectiveness: 90.0%</P>
<P>Experimental 2: <BR/>Rate and Cases of cure: 6.7%, 2/30<BR/>Rate and Cases of improvement: 30.0%, 9/30<BR/>Rate and Cases of response: 50.0%, 15/30<BR/>Rate and Cases of no response: 13.3%, 4/30<BR/>Total effectiveness: 86.7%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/30<BR/>Rate and Cases of improvement: 3.3%, 1/30<BR/>Rate and Cases of response: 36.7%, 11/30<BR/>Rate and Cases of no response: 60%, 18/30<BR/>Total effectiveness: 60.0%</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, scores reduced to 0, no relapse during 3 cycles of follow up, lab tests within normal range. </P>
<P>Improvement: abdominal pain and other symptoms significantly reduced, after intervention, scores reduced as 1/2 below as before, maintain daily activities with pain relieving medication, lab tests significantly improved, closed to normal range. </P>
<P>Response: abdominal pain and reduced, after intervention, scores reduced as 1/2 to 3/4 below as before, pain relieving medication needed, lab tests improved. </P>
<P>No response: abdominal pain, other symptoms, lab tests not changed at all. </P>
<P>3. Adverse effect: stated </P>
<P>4. Lab tests: stated, including blood viscosity 200s/L, 30s/L and 1s/L; plasma viscosity (PV), blood viscosity at high and low shear rate, PGE2a in menstrual blood. </P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This trial had two Experimental groups,which is tabled separately, however the numbers of women in placebo group was only entered into analysis once.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sun2004-_x002d_2">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: randomised based on a random number table</P>
<P>Blinding: double-blinding </P>
<P>Trial design: parallel</P>
<P>Parallel performance: may not</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 30 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 15-23 </P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OTC formula (Gui Zhi Fu Ling Wan No2) vs Placebo </P>
<P>Gui Zhi Fu Ling Wan No2: Gui Zhi (Ramulus Cinnamomi Cassiae), Fu Ling (Sclerotium Poriae Cocos), Bai Shao (Radix Paeoniae Latiflorae), Dan Pi (Cortex Mouten Radicis), Tao Ren (Semen Persicae). 3 pills, tid </P>
<P>Placebo: 3 pills, tid. no further details</P>
<P>Both groups started herbs/placebo from 3 days prior to period for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental 1: <BR/>Rate and Cases of cure: 10%, 3/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 46.7%, 14/30<BR/>Rate and Cases of no response: 10%, 3/30<BR/>Total effectiveness: 90.0%<BR/>Experimental 2: <BR/>Rate and Cases of cure: 6.7%, 2/30<BR/>Rate and Cases of improvement: 30.0%, 9/30<BR/>Rate and Cases of response: 50.0%, 15/30<BR/>Rate and Cases of no response: 13.3%, 4/30<BR/>Total effectiveness: 86.7%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/30<BR/>Rate and Cases of improvement: 3.3%, 1/30<BR/>Rate and Cases of response: 36.7%, 11/30<BR/>Rate and Cases of no response: 60%, 18/30<BR/>Total effectiveness: 60.0%</P>
<P>2. Overall symptoms: <BR/>Experimental 1: <BR/>Rate and Cases of cure: 10%, 3/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 46.7%, 14/30<BR/>Rate and Cases of no response: 10%, 3/30<BR/>Total effectiveness: 90.0%</P>
<P>Experimental 2: <BR/>Rate and Cases of cure: 6.7%, 2/30<BR/>Rate and Cases of improvement: 30.0%, 9/30<BR/>Rate and Cases of response: 50.0%, 15/30<BR/>Rate and Cases of no response: 13.3%, 4/30<BR/>Total effectiveness: 86.7%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/30<BR/>Rate and Cases of improvement: 3.3%, 1/30<BR/>Rate and Cases of response: 36.7%, 11/30<BR/>Rate and Cases of no response: 60%, 18/30<BR/>Total effectiveness: 60.0%</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, scores reduced to 0, no relapse during 3 cycles of follow up, lab tests within normal range. </P>
<P>Improvement: abdominal pain and other symptoms significantly reduced, after intervention, scores reduced as 1/2 below as before, maintain daily activities with pain relieving medication, lab tests significantly improved, closed to normal range. </P>
<P>Response: abdominal pain and reduced, after intervention, scores reduced as 1/2 to 3/4 below as before, pain relieving medication needed, lab tests improved. </P>
<P>No response: abdominal pain, other symptoms, lab tests not changed at all. </P>
<P>3. Adverse effect: stated </P>
<P>4. Lab tests: stated, including blood viscosity 200s/L, 30s/L and 1s/L; plasma viscosity (PV), blood viscosity at high and low shear rate, PGE2a in menstrual blood. </P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tseng-2005">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated </P>
<P>Blinding: open trial </P>
<P>Trial design: parallel </P>
<P>Parallel performance: stated </P>
<P>Age: significant different in mean age and PSS scores (variable) between two groups, but adjusted. </P>
<P>Duration: 6 cycles of intervention + 0 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 70 adolescents <BR/>Control: 60 adolescents </P>
<P>Drop-outs/withdrawals: stated<BR/>21 out of 130 dropped out because of irregular course of menstruation, failure of compliance, withdrawal of school. 59 Experimental and 50 Control subjects completed the assessment. </P>
<P>Diagnosis of dysmenorrhoea: unstated</P>
<P>Age: adolescents/boarding school girls, age unspecified </P>
<P>History: stated </P>
<P>TCM Pattern: unstated, only mentioned stagnation Qi and blood as general condition. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rose tea vs no treatment </P>
<P>Rose tea: 2 teacups per day made from 6 dry rosebuds steeped in 300mL of hot water, taken for 12 days from one week prior to their menstrual period to the fifth menstrual day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Reduction in pain <BR/>The short-Form McGill Pain Questionnaire (SF-MPQ)<BR/>The Menstrual Distress Questionnaire Short Form (MDQ-SF) <BR/>Received Stress Scale (PSS) </P>
<P>Reduction in anxiety and psychophysiologic stress <BR/>Visual Analogue Scale for Anxiety (VASA) <BR/>The Psychophysiologic Life Adaptation Scale (PLAS) </P>
<P>Adverse Effects <BR/>Self report from subjects: two had mild diarrhoea after 1st course of rose tea, one quit the study, the other Controlinued and Experimentalerienced no further diarrhoea. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The results listed in a separate table</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-1996">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: randomised based on random number table </P>
<P>Blinding: stated, single blinded </P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 23 women <BR/>Control 1: 21 women<BR/>Control 2: 16 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>high school girls </P>
<P>History: stated </P>
<P>TCM Pattern: specified, 'retention of cold and stagnation of Qi'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Tong Jing Ling) rectal administration vs 1 OCT Chinese herbal formula (Tian Qi Tong Jing Jiao Nang) oral administration vs 2 Self-designed formula (Tong Jing Ling) oral administration </P>
<P>Tong Jing Ling: Gui Zhi (Ramulus Cinnamomi Cassiae), Wu Yao (Radix Linderae Strychnifoliae), Xiang Fu (Rhizoma Cypri Rotundi), Yan Hu Suo (Rhizoma Corydalis Yanhusuo), Mu Xiang (Radix Aucklandiae Lappae), Kun Cao, Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi), Chuan Xiong (Radix Ligustici Chuanxiong), etc. Either in suppository administration, 1 piece, rectal administration, bid. or in oral administration in capsule form, 5 pills, tid</P>
<P>Tian Qi Tong Jing Jiao Nang: 5 pills, tid</P>
<P>All groups started from 4-5 days prior to bleeding till day 2 of cycle (appx 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 8/23<BR/>Cases of improvement: 11/23<BR/>Cases of response: 2/23<BR/>Cases of no response: 2/23<BR/>Total effectiveness: 91.3%</P>
<P>Control 1:<BR/>Cases of cure: 7/21<BR/>Cases of improvement: 8/21<BR/>Cases of response: 2/21<BR/>Cases of no response: 4/21<BR/>Total effectiveness: 81.0%</P>
<P>Control 2:<BR/>Cases of cure: 4/16<BR/>Cases of improvement: 6/16<BR/>Cases of response: 3/16<BR/>Cases of no response: 3/16<BR/>Total effectiveness: 81.3%</P>
<P>No significant difference between the Experimentalerimental and Controlrol groups P&gt;0.05</P>
<P>2. Overall symptoms: <BR/>unstated </P>
<P>Criteria: <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, capable of working, no relapse during 3 cycles. </P>
<P>Response: abdominal pain reduced, capable of working, but relapsed </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: stated including PGF2a in menstrual blood, Lr(cp), Hr(cp), RE, ET(s), Hct(%), EsR (mm/h), VK, VP(cp) and Fbg(mg%) of 14 samples of each Experimentalerimental and Controlrol 1groups. </P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-13 10:17:37 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Wang-2000b">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-13 10:17:37 +1200" MODIFIED_BY="jane clarke">
<P>Number: Experimental: 50 women Control: 50 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age:<BR/>Experimental 14-35 years<BR/>Control 15-32 years</P>
<P>History: stated</P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Bu Shen Hua Yu Tang) vs OCT formula (Yue Yue Shu) </P>
<P>Bu Shen Hua Yu Tang: <BR/>Ba Jie Tian (Radix Morindae Officinalis) 15g, <BR/>Gou Qi Zi (Fructus Lycii) 15g, <BR/>Xian Ling Pi (Herba Epimedii) 15g, <BR/>Shu Di (Radix Rehmanntae Glutinosae Conquitae) 15g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 20g, <BR/>Dang Gui (Radix Angelicae Sinensis) 12g, <BR/>Hong Hua (Flos Carthami Tinctorii) 12g, <BR/>Pu Huang (Pollen Typhae) 12g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 12g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 6g, Xiang Fu (Rhizoma Cypri Rotundi) 9g, <BR/>Zhi Qiao (Fructus Aurantii) 9g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis)6g. Modification of formulation might be required. Herbal decoction, one dose daily, starting from 5 days prior to bleeding for a period of 7 days</P>
<P>Yue Yue Shu: no details of formula stated. 10g, bid, started from 7 days prior to bleeding for a period of 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 38%, 19/50<BR/>Rate and Cases of improvement: 50%, 25/50<BR/>Rate and Cases of response: 8%, 4/50<BR/>Rate and Cases of no response: 4%, 2/50<BR/>Total effectiveness: 48/50</P>
<P>Control:<BR/>Rate and Cases of cure: 16%, 8/50<BR/>Rate and Cases of improvement: 24%, 12/50<BR/>Rate and Cases of response: 50%, 25/50<BR/>Rate and Cases of no response: 10%, 5/50<BR/>Total effectiveness: 45/50</P>
<P>No significant difference between the Experimentalerimental and Controlrol groups P&gt;0.05<BR/>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 38%, 19/50<BR/>Rate and Cases of improvement: 50%, 25/50<BR/>Rate and Cases of response: 8%, 4/50<BR/>Rate and Cases of no response: 4%, 2/50<BR/>Total effectiveness: 48/50</P>
<P>Control:<BR/>Rate and Cases of cure: 16%, 8/50<BR/>Rate and Cases of improvement: 24%, 12/50<BR/>Rate and Cases of response: 50%, 25/50<BR/>Rate and Cases of no response: 10%, 5/50<BR/>Total effectiveness: 45/50</P>
<P>No significant difference between the Experimentalerimental and Controlrol groups P&gt;0.05<BR/>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>Criteria: <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, capable of working, no relapse during 3 cycles. </P>
<P>Response: abdominal pain reduced, capable of working, but relapse </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: open labelled comparison</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 52 women <BR/>Control: 51 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental 14-35 y<BR/>Control 15-32 y </P>
<P>History: stated </P>
<P>TCM Pattern: specified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tailored formulae based on clinical manifestation vs Acupuncture</P>
<P>Stagnation of Qi and Blood: <BR/>Chai Hu (Radix Bupleuri) 12g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 10g, <BR/>Qing Pi (Pericarpium Citri Reticulatae Viride) 12g, Zhi Shi (Fructis Immaturus Citri Aurantii) 10g, Chuan Lian Zi (Fructus Meliae Toosendan) 10g, Tao Ren (Semen Persicae) 10g, <BR/>Yu Jing (Tuber Curcumae) 10g, <BR/>Dang Gui (Radix Angelicae Sinensis) 10g, <BR/>Fu Ling (Sclerotium Poriae Cocos) 10g, <BR/>Bai Zhu (Rhizoma Atractylodis Macrocephalae) 10g, <BR/>Dan Pi (Cortex Mouten Radicis) 10g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 10g, <BR/>Yi Mu Cao (Herba Leonuri Herterophylli) 30g, <BR/>Nu Zhen Zi (Fructus Ligustri Lucidi) 10g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 10g</P>
<P>Retention of Cold and Blood Stasis: <BR/>Gui Zhi (Ramulus Cinnamomi Cassiae) 12g, Pao Jiang (Quick-Fried Rhizoma Zingiberis Officinalis) 10g, <BR/>Xiao Hui Xiang (Fructus Foeniculi Vulgaris) 10g, Chuan Xiong (Radix Ligustici Chuanxiong) 10g, Dang Gui (Radix Angelicae Sinensis) 20g, <BR/>Mo Yao (Myrrha) 10g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 10g, Xiang Fu (Rhizoma Cypri Rotundi) 12g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 10g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 10g, <BR/>Hong Hua (Flos Carthami Tinctorii) 10g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 6g.</P>
<P>Deficiency of Qi and Blood: <BR/>Huang Qi (Radix Astraguli Membranacei) 30g, Ren Shen (Radix Ginseng) 6g, <BR/>Bai Zhu (Rhizoma Atractylodis Macrocephalae) 10g, <BR/>Huang Jing (Rhizoma Polygonati) 15g, <BR/>Fu Ling (Sclerotium Poriae Cocos) 10g, <BR/>Dang Gui (Radix Angelicae Sinensis) 20g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 10g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 12g, <BR/>Chai Hu (Radix Bupleuri) 10g, <BR/>Zhi Qiao (Fructus Aurantii) 10g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 10g,<BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 6g.</P>
<P>Deficiency of Kidney and Liver: <BR/>Shu Di (Radix Rehmanntae Glutinosae Conquitae) 20g, <BR/>Shan Yu Rou (Fructus Corni Officinalis) 15g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 10g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 10g, <BR/>Gou Qi Zhi 10g, <BR/>Nu Zhen Zi (Fructus Ligustri Lucidi) 10g, <BR/>Han Lian Cao (Herba Ecliptue Prostratae) 10g, <BR/>Yi Mo Cao (Herba Leonuri Heterophylii) 15g, Xiang Fu (Rhizoma Cypri Rotundi) 15g, <BR/>Dang Gui (Radix Angelicae Sinensis) 20g, <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 12g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 10g</P>
<P>Herbal decoction, 1 dose daily, 3 days prior to bleeding for a period of 7 days </P>
<P>Acupuncture: L4 (Lie Que), bilateral, needles remaining for 30 minutes after achievement of sensation of 'arrival of Qi'; meanwhile, needling manipulation every 5 minutes; moxibustion on the same point for 10 minutes of each side. Once a day for 3 days (beginning of intervention was unstated)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 23/52<BR/>Cases of improvement: 25/52<BR/>Cases of no response: 4/52</P>
<P>Control:<BR/>Cases of cure: 15/51<BR/>Cases of improvement: 21/51<BR/>Cases of no response: 14/51</P>
<P>Criteria<BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, but relapse during 3 cycle of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author stated the selected point might not be suitable for two of four patterns based on Chinese medicine diagnostic approach which might influence the outcome for women diagnosed with these two patterns</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2006a">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 172 women <BR/>Control: 168 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-23 y </P>
<P>History: stated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OCT Chinese herbal formula (Su Xiao Jiu Xin Wan) vs Indomethacin </P>
<P>Su Xiao Jiu Xin Wan: sublingual adminstration, 2-5 pills, tid, as soon as pain started for 4 days</P>
<P>Indomethacin: 25mg, tid, as soon as pain started for 4 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 83.7%, 144/172<BR/>Rate and Cases of improvement: 14.0%, 24/172<BR/>Total effectiveness: 97.7%</P>
<P>Control:<BR/>Rate and Cases of cure: 50.0%, 84/168<BR/>Rate and Cases of improvement: 42.9%, 72/168<BR/>Total effectiveness: 92.7%</P>
<P>Criteria<BR/>Cure: abdominal pain disappeared within 15-30 mins</P>
<P>Improvement: abdominal pain reduced within 15-30 mins</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: <BR/>unstated </P>
<P>3. Adverse effect: stated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wang-2006b">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 32 women <BR/>Control: 24 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 14-29 y <BR/>Control: 15-30 y</P>
<P>History: stated </P>
<P>TCM Pattern: unspecified</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Modified self-designed formula (Tong Jing Ling) vs Indomethacin</P>
<P>Tong Jing Ling: <BR/>Dang Gui (Radix Angelicae Sinensis) 15g, <BR/>Bai Shao (Radix Paeoniae Latiflorae) 15g, <BR/>Sheng Di (Radix Rennanniae Glutinosae) 15g, Dan Shen (Radix Salviate Miltiorrhizae)15g, Chuan Xiong (Radix Ligustici Chuanxiong) 12g, Hong Hua (Flos Carthami Tinctorii) 12g, <BR/>Tao Ren (Semen Persicae) 9g, <BR/>Xiao Hui Xiang (Fructus Foeniculi Vulgaris) 9g, Guang Mu Xiang (Radix Aucklandiae Lappae) 6g. Modification of formulation might be required. Herbal decoction, 1 dose daily, 3 days prior to bleeding for a period of 6 days</P>
<P>Indomethacin: 50mg, bid, as soon as pain started for a period of 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 62.50%, 20/32<BR/>Rate and Cases of improvement: 31.25%, 10/32<BR/>Rate and Cases of no response: 6.25%, 2/32<BR/>Total effectiveness: 93.75%</P>
<P>Control:<BR/>Rate and Cases of cure: 8.33%, 2/24<BR/>Rate and Cases of improvement: 62.50%, 15/24<BR/>Rate and Cases of no response: 29.17%, 7/24<BR/>Total effectiveness: 70.83%</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 62.50%, 20/32<BR/>Rate and Cases of improvement: 31.25%, 10/32<BR/>Rate and Cases of no response: 6.25%, 2/32<BR/>Total effectiveness: 93.75%</P>
<P>Control:<BR/>Rate and Cases of cure: 8.33%, 2/24<BR/>Rate and Cases of improvement: 62.50%, 15/24<BR/>Rate and Cases of no response: 29.17%, 7/24<BR/>Total effectiveness: 70.83%</P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.01</P>
<P>Criteria<BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, relapse during 3 months follow-up. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: <BR/>unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wu-2006">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 45 women<BR/>Control: 45 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 13-27 ys <BR/>Control: 14-29 ys </P>
<P>History: stated </P>
<P>TCM Pattern: no specific statement</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Jia Wei Dang Gui Shao Yao San) vs Ibuprofen </P>
<P>Jia Wei Dang Gui Shao Yao San: <BR/>Dang Gui (Radix Angelicae Sinensis) 10-20g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 30g, Bai Shao (Radix Paeoniae Latiflorae) 15-30g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 10-20g, <BR/>Fu Ling (Sclerotium Poriae Cocos) 10-20g, <BR/>Ze Xie (Rhizoma Alismatis Orientalis) 10-20g, Bai Zhu (Rhizoma Atractylodis Macrocephalae) 10-20g, <BR/>Wu Yao (Radix Linderae Strychnifoliae) 10-20g, Xiang Fu (Rhizoma Cypri Rotundi) 10-20g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 10-20g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 5-10g. Herbal decoction, 300ml daily, 150ml bid </P>
<P>Ibuprofen: 200mg, tid </P>
<P>Both groups started from 3 days prior to bleeding for a period of 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 14/45<BR/>Cases of improvement: 27/45<BR/>Cases of no response: 4/45<BR/>Total effectiveness: 91.1%</P>
<P>Control:<BR/>Cases of cure: 1/45<BR/>Cases of improvement: 27/45<BR/>Cases of no response: 17/45<BR/>Total effectiveness: 60.2% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.05</P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain almost disappeared or reduced. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ye-2004">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 30 women<BR/>Control: 28 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 15-27 ys <BR/>Control: 14-28y </P>
<P>History: unstated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Nv Jin Jiao Nang) vs Indomethacin </P>
<P>Nv Jin Jiao Nang: Dang Gui (Radix Angelicae Sinensis), Bai Shao (Radix Paeoniae Latiflorae), Chuan Xiong (Radix Ligustici Chuanxiong), Shu Di (Radix Rehmanniae Glutinosae Conquitae), Rou Gui (Cortex Cinnamomi Cassiae), etc. 23 herbs in total, in a form of pills. 3pills, bid, 7 days prior to bleeding until the end of bleeding </P>
<P>Indomethacin: 50 mg, tid, 1 days prior to bleeding until the end of bleeding</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 40%, 12/30<BR/>Rate and Cases of improvement: 56.67%, 17/30<BR/>Rate and Cases of no response: 3.33%, 1/30<BR/>Total effectiveness: 96.67%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/28<BR/>Rate and Cases of improvement: 57.14%, 16/28<BR/>Rate and Cases of no response: 42.86%, 12/28<BR/>Total effectiveness: 57.14%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 40%, 12/30<BR/>Rate and Cases of improvement: 56.67%, 17/30<BR/>Rate and Cases of no response: 3.33%, 1/30<BR/>Total effectiveness: 96.67%</P>
<P>Control:<BR/>Rate and Cases of cure: 0%, 0/28<BR/>Rate and Cases of improvement: 57.14%, 16/28<BR/>Rate and Cases of no response: 42.86%, 12/28<BR/>Total effectiveness: 57.14%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yu-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 35 women<BR/>Control: 30 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 12-32 ys <BR/>Control: 13-30 ys </P>
<P>History: stated </P>
<P>TCM Pattern: both groups were diagnosed as 'retention of cold with blood stasis'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (Fu Mei Tong Jing Fang) vs OTC formula (Tian Qi Tong Jing Jiao Nang) </P>
<P>Fu Mei Tong Jing Fang: <BR/>Zhi Fu Zi (Radix Lateralis Aconiti Carmichaeli Praeparata) 6g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 12g, Dang Gui (Radix Angelicae Sinensis) 12g, <BR/>Mo Yao (Myrrha) 9g, <BR/>E Zhu (Rhizoma Curcumae Ezhu) 9g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 9g, <BR/>Pu Huang (Pollen Typhae) 9g, <BR/>Rou Gui (Cortex Cinnamomi Cassiae) 5g. Herbal decoction, extracted as 400 ml daily, 200 ml, bid. </P>
<P>Tian Qi Tong Jing Jiao Nang: no details of formulation provided, 4 pills, tid. </P>
<P>Both groups started from 3 days prior to bleeding for a period of 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 51.4%, 18/35<BR/>Rate and Cases of improvement: 28.6%, 10/35<BR/>Rate and Cases of response: 11.4%, 4/35<BR/>Rate and Cases of no response: 8.6%, 3/35<BR/>Total effectiveness: 91.4%</P>
<P>Control:<BR/>Rate and Cases of cure: 36.7%, 11/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 16.7%, 5/30<BR/>Rate and Cases of no response: 13.3%, 4/30 <BR/>Total effectiveness: 86.7% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.001</P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Rate and Cases of cure: 51.4%, 18/35<BR/>Rate and Cases of improvement: 28.6%, 10/35<BR/>Rate and Cases of response: 11.4%, 4/35<BR/>Rate and Cases of no response: 8.6%, 3/35<BR/>Total effectiveness: 91.4%</P>
<P>Control:<BR/>Rate and Cases of cure: 36.7%, 11/30<BR/>Rate and Cases of improvement: 33.3%, 10/30<BR/>Rate and Cases of response: 16.7%, 5/30<BR/>Rate and Cases of no response: 13.3%, 4/30 <BR/>Total effectiveness: 86.7% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.001</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain and other symptoms reduced, after intervention, the scores reduced as below as more than 1/2 of the scores before. </P>
<P>Response: abdominal pain and reduced, after intervention, the scores reduced as below as more than 1/3 of the scores before. </P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-2000">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 35 women<BR/>Control: 20 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 16-22 ys<BR/>Control: 15-23 </P>
<P>History: stated </P>
<P>TCM Pattern: unspecified, common patterns mentioned were 'deficiency of blood, blood stasis'.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self designed formula (modified Si Wu Tang) vs heat compression </P>
<P>Modified Si Wu Tang: Dang Gui (Radix Angelicae Sinensis), Chi Shao (Radix Paeoniae Rubrae), Shen Di, Chuan Xiong (Radix Ligustici Chuanxiong), etc. 2-3 days prior to bleeding for a period of 10 days</P>
<P>Heat compression: as soon as pain started till pain disappeared</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate of cure: 77.14%, 27/35<BR/>Rate of improvement: 11.43, 4/35<BR/>Rate of response: 8.57%, 3/35<BR/>Rate of no response: 2.86%, 1/35<BR/>Total effectiveness: 97.14%</P>
<P>Control:<BR/>Rate of cure: 0%, 0/20<BR/>Rate of improvement: 0%, 0/20<BR/>Rate of response: 10%, 2/20<BR/>Rate of no response: 90%, 18/20 <BR/>Total effectiveness: 10% </P>
<P>Significant difference between the two groups in the rate of cure P&lt;0.001</P>
<P>2. Overall symptoms: unstated </P>
<P>Criteria: <BR/>Cure: abdominal pain symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain symptoms reduced obviously, but relapsed </P>
<P>Response: abdominal pain reduced.</P>
<P>No response: abdominal pain not changed at all. </P>
<P>3. Adverse effect: stated. no incidence </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhang-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: paralleled </P>
<P>Duration: 3 - 5 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 60 women<BR/>Control: 40 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-26 y </P>
<P>History: stated </P>
<P>TCM Pattern: unstated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (oral administration) + self-designed formula (external administration) vs 2 different <BR/>OTC formulae (Yuan Hu Zhi Tong Pian and Tong Jing Wan, oral administration) </P>
<P>Self-designed formula (oral administration): <BR/>Gui Zhi (Ramulus Cinnamomi Cassiae) 9g, <BR/>Ru Xiang (Gummi Olibanum) 9g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 9g, <BR/>Ze Lan (Herba Lycopi Lucidi) 9g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 9g, <BR/>Xi Xin (Herba cum Radice Asari) 6g, <BR/>Xiao Hui Xiang (Fructus Foeniculi Vulgaris) 6g, Chuan Xiong (Radix Ligustici Chuanxiong) 6g, Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 6g, Yi Mu Cao (Herba Leonuri Herterophylli) 15g, Dang Gui (Radix Angelicae Sinensis) 15g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 15g. Herbal decoction, one dose daily, 7 days prior to period till postal menstruation</P>
<P>Self-designed formula (external administration): Bai Zhi (Radix Angelicae) 6g, <BR/>Dang Gui (Radix Angelicae Sinensis) 6g, <BR/>Chi Shao (Radix Paeoniae Rubrae) 6g, <BR/>Da Huang (Radix et Rhizoma Rhei) 6g, <BR/>Huang Dan (Minium) mixed with sesame oil, in a form of paste, applied on 'Guan Yuan' outpoint during menstruation</P>
<P>Yuan Hu Zhi Tong Pian: 4 tablets, bid, 1st OCT herbs started from 7 days prior to period for 7 days</P>
<P>Tong Jing Wan: 10 pills, bid, 2nd OCT herbs in menstruation period for 3-5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate and Cases of cure: 85%, 51/60<BR/>Rate and Cases of improvement: 11.67%, 7/60<BR/>Rate and Cases of no response: 3.33%, 2/60<BR/>Total effectiveness: 96.67%</P>
<P>Control:<BR/>Rate and Cases of cure: 25%, 10/40<BR/>Rate and Cases of improvement: 35%, 14/40<BR/>Rate and Cases of no response: 40%, 16/40<BR/>Total effectiveness: 60%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.05 </P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, but relapse during 3 cycles of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-2001">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, methods unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 78 women<BR/>Control: 39 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: <BR/>Experimental: 12-30, <BR/>Control: 12.5-28 </P>
<P>History: stated </P>
<P>TCM Pattern: stated, <BR/>'stagnation of Qi and Blood, retention of cold, deficiency of Qi and Blood, deficiency of Liver and Kindey'</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Dong Gui Ai Ye Tang) vs Indomethacin and Vitamin B6 </P>
<P>Dong Gui Ai Ye Tang: <BR/>Dang Gui (Radix Angelicae Sinensis) 30g, <BR/>Ai Ye (Folium Artemisiae Argyri) 15g, <BR/>Hong Tang (Caulis Sargentodoxae Cuneatae) 60g <BR/>600 ml herbal decoction daily, 3 days prior to bleeding for a period of 6 days </P>
<P>Indomethacin: 25 mg, tid, Vitamin B6 20 mg, tid, 3 days prior to bleeding till bleeding stopped</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Rate of cure: 71/78<BR/>Rate of improvement: 5/78<BR/>Rate of no response: 2/78<BR/>Total effectiveness: 97.4%</P>
<P>Control:<BR/>Rate of cure: 15/39<BR/>Rate of improvement: 16/39<BR/>Rate of no response: 8/39<BR/>Total effectiveness: 79.5%<BR/>significant difference between the Experimentalerimental and Controlrol groups P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced, but relapse during 3 cycle of follow up.</P>
<P>No response: abdominal pain not changed at all.</P>
<P>2. Overall symptoms: unstated </P>
<P>3. Adverse effect: unstated</P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-2002">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: paralleled </P>
<P>Parallel performance: no </P>
<P>Duration: 3 cycles of intervention + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 70 women<BR/>Control: 62 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 16-32, </P>
<P>History: stated </P>
<P>TCM Pattern: unstated <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula vs Indomethacin </P>
<P>Self-designed formula: <BR/>Dan Shen (Radix Salviate Miltiorrhizae)30g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 10-15g, <BR/>Sheng Jiang (fresh Rhizoma Zingiberis Officinalis) 6g, <BR/>Herbs were cooked and extracted into 300 ml decoction, mixed with brown sugar (no dose provided), bid, 1 day prior to bleeding until 3rd day of cycle</P>
<P>Indomethacin: 50 mg, tid, 3 days prior to bleeding until 3rd day of cycle</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases of cure: 48/70<BR/>Cases of improvement: 14/70<BR/>Cases of response: 6/70<BR/>Cases of no response: 2/70<BR/>Total effectiveness: 97.14%</P>
<P>Control:<BR/>Cases of cure: 18/62<BR/>Cases of improvement: 18/62<BR/>Cases of response: 2/62<BR/>Cases of no response: 2/62<BR/>Total effectiveness: 93.55 </P>
<P>Significant difference in rate of cure between the two groups: P&lt;0.01</P>
<P>2. Overall symptoms: <BR/>Cases of cure: 48/70<BR/>Cases of improvement: 14/70<BR/>Cases of response: 6/70<BR/>Cases of no response: 2/70<BR/>Total effectiveness: 97.14%</P>
<P>Control:<BR/>Cases of cure: 18/62<BR/>Cases of improvement: 18/62<BR/>Cases of response: 2/62<BR/>Cases of no response: 2/62<BR/>Total effectiveness: 93.55 </P>
<P>Significant difference in rate of cure between the two groups: P&lt;0.01</P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, other symptoms disappeared or reduced, no need to take pain relieving medication. </P>
<P>Response: Response: abdominal pain reduced, other symptoms improved, pain relieving medication needed. </P>
<P>No response: abdominal pain, or other symptoms not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: stated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-2003">
<CHAR_METHODS>
<P>Allocation concealment and randomisation: Randomised, method unstated</P>
<P>Blinding: unstated</P>
<P>Trial design: parallel</P>
<P>Duration: 3 cycles of intervention or 6 cycles or 9 cycles + 3 cycles of follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Number: <BR/>Experimental: 42 women<BR/>Control: 42 women</P>
<P>Drop-outs/withdrawals: unstated</P>
<P>Diagnosis of dysmenorrhoea: stated</P>
<P>Age: 14-32, </P>
<P>History: stated </P>
<P>TCM Pattern: unspecific, but mentioned 'stagnation of blood in the medians' was most common pattern <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Self-designed formula (Hua Yu Tong Mai Zhi Tong Tang) vs OCT (Yuan Hu Zhi Tong Jiao Nang) </P>
<P>Hua Yu Tong Mai Zhi Tong Tang: <BR/>Dang Gui (Radix Angelicae Sinensis) 10g, <BR/>Shi Shao 12g, Bai Shao (Radix Paeoniae Latiflorae) 12g, <BR/>Tao Ren (Semen Persicae) 10g, <BR/>Chuan Xiong (Radix Ligustici Chuanxiong) 10g, Hong Hua (Flos Carthami Tinctorii) 10g, <BR/>Xiang Fu (Rhizoma Cypri Rotundi) 12g, <BR/>Yan Hu Suo (Rhizoma Corydalis Yanhusuo) 15g, Yi Mu Cao (Herba Leonuri Herterophylli) 20g, <BR/>Ze Lan (Herba Lycopi Lucidi) 15g, <BR/>Xue Jie (Sanguis Draconis) 3g, <BR/>Wu Ling Zhi (Excrementum Trogopteri Seu Pteromi) 15g, <BR/>Gan Cao (Radix Glycyrrhizae Uralensis) 6g. Herbal decoction, one dose daily</P>
<P>Yuan Hu Zhi Tong Jiao Nang: 3 pills, tid</P>
<P>Both groups started from 4 days prior to bleeding for a period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Pain:<BR/>Experimental: <BR/>Cases and rate of cure: 12/42, 28.6%<BR/>Casess and rate of improvement: 23/42, 54.8%<BR/>Cases and rate of response: 4/42, 9.5%<BR/>Cases and rate of no response: 3/42, 7.1%<BR/>Total effectiveness: 92.9%</P>
<P>Control:<BR/>Cases and rate of cure: 9/42, 21.4%<BR/>Cases and rate of improvement: 18/42, 42.9%<BR/>Cases and rate of response: 8/42, 19.0%<BR/>Cases and rate of no response: 7/42, 16.7% <BR/>Total effectiveness: 83.3% </P>
<P>2. Overall symptoms: <BR/>Experimental: <BR/>Cases and rate of cure: 12/42, 28.6%<BR/>Cases and rate of improvement: 23/42, 54.8%<BR/>Cases and rate of response: 4/42, 9.5%<BR/>Cases and rate of no response: 3/42, 7.1%<BR/>Total effectiveness: 92.9%</P>
<P>Control:<BR/>Cases and rate of cure: 9/42, 21.4%<BR/>Cases and rate of improvement: 18/42, 42.9%<BR/>Cases and rate of response: 8/42, 19.0%<BR/>Casess and rate of no response: 7/42, 16.7% <BR/>Total effectiveness: 83.3% </P>
<P>Criteria <BR/>Cure: abdominal pain and other symptoms disappeared, no relapse during 3 cycles of follow up. </P>
<P>Improvement: abdominal pain reduced obviously, other symptoms disappeared or reduced, relapse during 3 cycles of follow up. </P>
<P>Response: Response: abdominal pain reduced, other symptoms improved. </P>
<P>No response: abdominal pain, or other symptoms not changed at all. </P>
<P>3. Adverse effect: unstated </P>
<P>4. Lab tests: unstated</P>
<P>5. Use of additional medication: <BR/>unstated</P>
<P>6. Satisfaction from patients: unstated </P>
<P>7. Quality of life: unstated</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Chen-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Du-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each treatment arm were very different, 56 women in herbal group vs 32 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ji-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each treatment arm are very different, 273 women in herbal group vs 70 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed cases of primary and secondary dysmenorrhoea in the trial, review is limited to primary dysmenorrhoea only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liao-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each treatment arm were very different, 79 women in herbal group vs 24 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was receieved.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lin-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed cases of primary and secondary dysmenorrhoea in data, Review is limited to primary dysmenorrhoea only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Liu-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each treatment arm were very different, 60 women in herbal group vs 30 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was receieved.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miao-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each treatment arm were very different, 58 women in herbal group vs 40 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ni-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 60 women in herbal group vs 30 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 76 women in herbal group vs 50 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shi-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 60 women in herbal group vs 40 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Song-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 120 women in herbal group vs 40 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sun-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised ('randomisation' based on hospital number allocation).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 150 women in herbal group vs 50 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 150 women in herbal group vs 50 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wei-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No 3 month of follow up, contaminated data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised ('randomisation' based on sequence hospital number)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wu-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 60 women in herbal group vs 30 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xu-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 60 women in herbal group vs 40 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yang-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised ('randomisation' based on odd and even day)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 50 women in herbal group vs 30 women in control group). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was received.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhang-Y-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>The experimental group was mixed herbs and acupuncture - contaminated data, which is not one of the interventions considered by this review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhao-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised (the numbers of women in each group were very different, 318 women in herbal group vs 132 women in control group 1 vs 116 women in control group 2). Attempts were made to contact the authors to clarify randomisation and allocation concealment however no response was recieved.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Mixed cases of primary and secondary dysmenorrhoea in the trial, review is limited to primary dysmenorrhoea only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deng-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Deng-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fan-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guo-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Huang-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kennedy-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kotani-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Li-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Liu-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lu-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luo-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miao-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Niu-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Qin-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shen-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Song-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sun-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sun2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sun2004-_x002d_2">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tseng-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Wang-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2000b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2006b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wu-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ye-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-06 14:21:42 +1200" MODIFIED_BY="jane clarke">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-05-06 14:20:07 +1200" MODIFIED_BY="jane clarke" NO="1">
<TITLE>Rose tea for relief of primary dysmenorrhoea</TITLE>
<TABLE COLS="5" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome measures</P>
</TH>
<TH>
<P>Exp group (SD)</P>
</TH>
<TH>
<P>Control group (SD)</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<TR>
<TD>
<P>Tseng 2005</P>
</TD>
<TD>
<P>The Sort-form McGill Pain Questionnaire (SF-MPQ) - means (SD)</P>
</TD>
<TD>
<P>1 month - 8.64 (8.35)<BR/>3 months - 7.02 (6.24)<BR/>6 months - 6.82 (7.07)<BR/>
</P>
</TD>
<TD>
<P>1 month - 11.86 (8.34)<BR/>3 months - 11.41 (7.72)<BR/>6 months - 9.52 (7.76)<BR/>
</P>
</TD>
<TD>
<P>P = 0.0443<BR/>P = 0.0010<BR/>P = 0.0629<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>The Menstrual Distress Questionnaire Short Form, mean (sd)</P>
</TD>
<TD>
<P>1 month - 24.23 (5.42)<BR/>3 months - 23.44 (5.78)<BR/>6 months - 22.75 (5.25)<BR/>
</P>
</TD>
<TD>
<P>1 month - 26.86 (5.78)<BR/>3 months - 26.02 (5.21)<BR/>6 months - 25.94 (6.26)<BR/>
</P>
</TD>
<TD>
<P>P = 0.0191<BR/>P = 0.0144<BR/>P = 0.0040<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Visual analogue scale for Anxiety (VASA), mean (sd)</P>
</TD>
<TD>
<P>1 month - 3.64 (1.74)<BR/>3 months - 3.14 (1.84)<BR/>6 months - 3.09 (1.88)<BR/>
</P>
</TD>
<TD>
<P>1 month - 4.04 (2.15)<BR/>3 months - 4.16 (1.82)<BR/>6 months - 3.65 (2.20)<BR/>
</P>
</TD>
<TD>
<P>P = 0.2546<BR/>P = 0.0037<BR/>P = 0.1537<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Received Stress scale (PSS), mean (sd)</P>
</TD>
<TD>
<P>1 month - 20.83 (5.69)<BR/>3 months - 20.81 (5.22)<BR/>6 months - 20.84 (4.61)<BR/>
</P>
</TD>
<TD>
<P>1 month - 17.76 (5.82)<BR/>3 months - 18.51 (5.12)<BR/>6 months - 19.12 (5.59)<BR/>
</P>
</TD>
<TD>
<P>P = 0.0063<BR/>P = 0.0195<BR/>P = 0.0817<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>The Psychophysiologic Life Adaptation scale (PLAS), means (sd)</P>
</TD>
<TD>
<P>3 months - 94.08 (15.00)<BR/>6 months - 95.25 (13.43)<BR/>
</P>
</TD>
<TD>
<P>3 months - 94.76 (13.13)<BR/>6 months - 95.64 (13.20)<BR/>
</P>
</TD>
<TD>
<P>P = 0.7972<BR/>P = 0.8789<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="2">
<TITLE>Analgesic effect of a herbal medicine for treatment of primary dysmenorrhoea</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome measures</P>
</TH>
<TH>
<P>Experimental group</P>
</TH>
<TH>
<P>Control group</P>
</TH>
<TH>
<P>Conclusion</P>
</TH>
</TR>
<TR>
<TD>
<P>Naoki 1997 <BR/>
<BR/>
</P>
</TD>
<TD>
<P>Visual analogue scale (VAS)</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Compared to placebo, herbs significantly reduced pain through 2 intervention cycles and 2 follow-up cycles (P&lt;0.05 for the 1st intervention cycle, P&lt;0.005 for subsequence cycles)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Pain relieving medication</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Significant reduction in pain relieving medication through intervention and follow-up in herbal group (P&lt;0.05, P&lt;0.01). Significant reduction in pain relieving medication only in 1st cycle of intervention in placebo group (P&lt;0.01), then faded out.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<BR/>
</P>
</TD>
<TD>
<P>Zung self-rating depression Scale <BR/>
<BR/>
</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>No significant difference between groups, nor within groups in Zung self-rating depression scale</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Improved biomedical parameters (FSH, LH, Prolactin, Esrtadiol, Blood count, Hepatic and renal function tests at each cycle)</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Data not available</P>
</TD>
<TD>
<P>Plasma levels of various hormones and chemical mediators changed during and after treatment.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="3">
<TITLE>RCT assessing a traditional Chinese medicine remedy in primay dysmenorrhoea</TITLE>
<TABLE COLS="8" ROWS="10">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Observation cycle SD</P>
</TH>
<TH>
<P>Treatment cycle 1 SD</P>
</TH>
<TH>
<P>Treatment cycle 2 SD</P>
</TH>
<TH>
<P>Treatment cycle 3 SD</P>
</TH>
<TH>
<P>Follow-up cycle SD</P>
</TH>
</TR>
<TR>
<TD>
<P>Kennedy 2006</P>
</TD>
<TD>
<P>The maximal pain scores (Cmax)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>76 (14)</P>
</TD>
<TD>
<P>67 (27)</P>
</TD>
<TD>
<P>57 (28)</P>
</TD>
<TD>
<P>61(31)</P>
</TD>
<TD>
<P>60 (30)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Herbs</P>
</TD>
<TD>
<P>77 (19)</P>
</TD>
<TD>
<P>59 (28)</P>
</TD>
<TD>
<P>58 (36)</P>
</TD>
<TD>
<P>51 (36)</P>
</TD>
<TD>
<P>61 (28)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Total pain area under the curve (AUC)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>186 (73)</P>
</TD>
<TD>
<P>123 (69)</P>
</TD>
<TD>
<P>115 (84)</P>
</TD>
<TD>
<P>134 (102)</P>
</TD>
<TD>
<P>138 (119)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Herbs</P>
</TD>
<TD>
<P>207 (84)</P>
</TD>
<TD>
<P>128 (83)</P>
</TD>
<TD>
<P>130 (97)</P>
</TD>
<TD>
<P>112 (88)</P>
</TD>
<TD>
<P>150 (84)</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Duration of pain (data not shown)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Total amount of rescure medication used (data not shown)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Global assessment of treatment (data not shown)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>Safety</P>
</TD>
<TD>
<P>Placebo (18 adverse events)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Herbs (13 adverse events)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2008-05-06 14:21:42 +1200" MODIFIED_BY="jane clarke" NO="4">
<TITLE>Quality features of included studies</TITLE>
<TABLE COLS="6" ROWS="60">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Allocation concealme</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>ITT</P>
</TH>
<TH>
<P>Follow-up</P>
</TH>
</TR>
<TR>
<TD>
<P>Deng 2003a</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Deng 2003a</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Fan 1999</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Guo 1997</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Huang 2000</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>2 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Jiang 2000</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Kotani 1997</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Double blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>2 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 1999</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Single blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Li 2004</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu 2000</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu 2002</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu 2004</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Liu 2005</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Lu 2002</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Luo 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Miao 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Niu 1996</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Single blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Qin 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Shen 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Song 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Single blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Sun 2006</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Sun 2004</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Random number table</P>
</TD>
<TD>
<P>Double blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Sun 2004-2</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Random number table</P>
</TD>
<TD>
<P>Double blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Tseng 2005</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Open trial</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 1996</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Random number table</P>
</TD>
<TD>
<P>Single blinded</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2000b</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Open labelled</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2006a</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2006b</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Wu 2006</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Ye 2004</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Yu 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhang 2000</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhang 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhu 2001</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhu 2002</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhu 2003</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>Unclear/Not stated</P>
</TD>
<TD>
<P>3 cycles</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-13 10:15:51 +1200" MODIFIED_BY="jane clarke">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-13 10:15:16 +1200" MODIFIED_BY="jane clarke" NO="1">
<NAME>Chinese herbal medicine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="97.86680500554516" CI_START="0.3193108512328477" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" METHOD="MH" MODIFIED="2008-05-13 10:00:30 +1200" MODIFIED_BY="jane clarke" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.238661077562625" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.17834007642179">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese herb</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.86680500554516" CI_START="0.3193108512328477" DF="0.0" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" NO="1" P_CHI2="1.0" P_Z="0.238661077562625" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.17834007642179">
<NAME>Methodological quality A - standard formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="97.86680500554516" CI_START="0.3193108512328477" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" ORDER="947" O_E="0.0" SE="1.4605364338759586" STUDY_ID="STD-Sun2004" TOTAL_1="60" TOTAL_2="30" VAR="2.133166674679102" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.09650194939715603" CI_END="20.050536278754386" CI_START="-16.410247585257892" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8201443467482474" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.7560685364712116" P_Q="0.7560685364712116" P_Z="0.8448565917926372" Q="0.09650194939715603" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="34" TOTAL_2="38" UNITS="" WEIGHT="200.0" Z="0.19568517120181178">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="19.950537748537933" CI_START="-17.950537748537933" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="0.9176254780248352" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0" Z="0.10342524368160841">
<NAME>Intensity of pain Cmax</NAME>
<CONT_DATA CI_END="19.950537748537933" CI_START="-17.950537748537933" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="60.0" ORDER="948" SD_1="28.0" SD_2="30.0" SE="9.668819375262686" STUDY_ID="STD-Kennedy-2006" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="78.76474588006964" CI_START="-54.76474588006964" DF="0.0" EFFECT_SIZE="12.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="0.7246318452797827" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0" Z="0.3522752540199756">
<NAME>Intensity of pain AUCt</NAME>
<CONT_DATA CI_END="78.76474588006964" CI_START="-54.76474588006964" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="150.0" MEAN_2="138.0" ORDER="949" SD_1="84.0" SD_2="119.0" SE="34.06427179616637" STUDY_ID="STD-Kennedy-2006" TOTAL_1="17" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="97.86680500554516" CI_START="0.3193108512328477" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" METHOD="MH" MODIFIED="2008-05-13 10:00:49 +1200" MODIFIED_BY="jane clarke" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.238661077562625" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.17834007642179">
<NAME>Overall symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese herb</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="97.86680500554516" CI_START="0.3193108512328477" DF="0.0" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" NO="1" P_CHI2="1.0" P_Z="0.238661077562625" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="30" WEIGHT="99.99999999999999" Z="1.17834007642179">
<NAME>Methodology quality A - standard formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="97.86680500554516" CI_START="0.3193108512328477" EFFECT_SIZE="5.590163934426229" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="1.990635410418469" LOG_CI_START="-0.49578632245500753" LOG_EFFECT_SIZE="0.7474245439817306" ORDER="950" O_E="0.0" SE="1.4605364338759586" STUDY_ID="STD-Sun2004" TOTAL_1="60" TOTAL_2="30" VAR="2.133166674679102" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0724953514793512" CI_START="0.6075130830136051" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8071895424836601" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.030395418496629543" LOG_CI_START="-0.21644436494045804" LOG_EFFECT_SIZE="-0.09302447322191425" METHOD="MH" MODIFIED="2008-05-13 10:08:35 +1200" MODIFIED_BY="jane clarke" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.1396030293597883" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="69" WEIGHT="100.0" Z="1.4772709217048225">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More incidents in CT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More incidents in CH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0724953514793512" CI_START="0.6075130830136051" DF="0.0" EFFECT_SIZE="0.8071895424836601" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.030395418496629543" LOG_CI_START="-0.21644436494045804" LOG_EFFECT_SIZE="-0.09302447322191425" NO="1" P_CHI2="1.0" P_Z="0.1396030293597883" STUDIES="3" TAU2="0.0" TOTAL_1="97" TOTAL_2="69" WEIGHT="100.0" Z="1.4772709217048225">
<NAME>Methodology quality A - standard formua</NAME>
<DICH_DATA CI_END="1.0724953514793512" CI_START="0.607513083013605" EFFECT_SIZE="0.8071895424836601" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.030395418496629543" LOG_CI_START="-0.21644436494045813" LOG_EFFECT_SIZE="-0.09302447322191425" ORDER="951" O_E="0.0" SE="0.1449949106675795" STUDY_ID="STD-Kennedy-2006" TOTAL_1="17" TOTAL_2="19" VAR="0.021023524119499357" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="952" O_E="0.0" SE="0.0" STUDY_ID="STD-Kotani-1997" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="953" O_E="0.0" SE="0.0" STUDY_ID="STD-Sun2004" TOTAL_1="60" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="84.49454980114871" CI_START="1.7042519350525294" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.9268286963150838" LOG_CI_START="0.2315337957801659" LOG_EFFECT_SIZE="1.0791812460476249" METHOD="MH" MODIFIED="2008-05-13 10:15:16 +1200" MODIFIED_BY="jane clarke" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.012584160158368232" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="30" WEIGHT="100.0" Z="2.4953255912903485">
<NAME>Use of additional medication</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Chinese herb</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="84.49454980114871" CI_START="1.7042519350525294" DF="0.0" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.9268286963150838" LOG_CI_START="0.2315337957801659" LOG_EFFECT_SIZE="1.0791812460476249" NO="1" P_CHI2="1.0" P_Z="0.012584160158368232" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="30" WEIGHT="100.0" Z="2.4953255912903485">
<NAME>Methodology quality A -standard formula</NAME>
<DICH_DATA CI_END="84.49454980114871" CI_START="1.7042519350525294" EFFECT_SIZE="12.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="1" LOG_CI_END="1.9268286963150838" LOG_CI_START="0.2315337957801659" LOG_EFFECT_SIZE="1.0791812460476249" ORDER="954" O_E="0.0" SE="0.9958246164193104" STUDY_ID="STD-Sun2004" TOTAL_1="60" TOTAL_2="30" VAR="0.9916666666666668" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-05-13 10:15:51 +1200" MODIFIED_BY="jane clarke" NO="2">
<NAME>Chinese herbal medicine versus conventional therapy (NSAIDs or OCP)</NAME>
<DICH_OUTCOME CHI2="71.13374255018921" CI_END="2.600077177448173" CI_START="1.5201354453392197" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9880818589928635" ESTIMABLE="YES" EVENTS_1="538" EVENTS_2="244" I2="81.72456624108072" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.41498623921790045" LOG_CI_START="0.18188228567026482" LOG_EFFECT_SIZE="0.29843426244408267" METHOD="MH" NO="1" P_CHI2="4.960731825320863E-10" P_Q="0.0" P_Z="5.206647039705325E-7" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.16187081667954462" TOTALS="YES" TOTAL_1="768" TOTAL_2="673" WEIGHT="100.0" Z="5.018536985248051">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Conventional</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="32.099434402904" CI_END="5.93753695492976" CI_START="0.8773316304004345" DF="3.0" EFFECT_SIZE="2.2823647774252382" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="53" I2="90.65404093310569" ID="CMP-002.01.01" LOG_CI_END="0.7736063256682288" LOG_CI_START="-0.05683621275845746" LOG_EFFECT_SIZE="0.3583850564548857" NO="1" P_CHI2="4.98697700135331E-7" P_Z="0.09070687214316243" STUDIES="4" TAU2="0.6022718356689455" TOTAL_1="160" TOTAL_2="152" WEIGHT="22.984941374907763" Z="1.691680690104585">
<NAME>Methodological quality B - standard formula - up to 3 month's follow-up</NAME>
<DICH_DATA CI_END="1.2935836778568301" CI_START="0.9327304928624716" EFFECT_SIZE="1.0984375" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="32" LOG_CI_END="0.11179452710441105" LOG_CI_START="-0.03024382503253755" LOG_EFFECT_SIZE="0.04077535103593677" ORDER="955" O_E="0.0" SE="0.08343403114642621" STUDY_ID="STD-Liu-2000" TOTAL_1="40" TOTAL_2="38" VAR="0.006961237553342818" WEIGHT="11.105025960715082"/>
<DICH_DATA CI_END="1.9896455342034747" CI_START="0.93874901115264" EFFECT_SIZE="1.3666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="20" LOG_CI_END="0.2987757114592162" LOG_CI_START="-0.027450507459070097" LOG_EFFECT_SIZE="0.13566260200007305" ORDER="956" O_E="0.0" SE="0.19162689583842893" STUDY_ID="STD-Lu-2002" TOTAL_1="45" TOTAL_2="41" VAR="0.03672086720867209" WEIGHT="9.440900588326782"/>
<DICH_DATA CI_END="102.03228144066136" CI_START="1.9209606727649917" EFFECT_SIZE="14.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="2.0087375975806667" LOG_CI_START="0.2835184737758092" LOG_EFFECT_SIZE="1.146128035678238" ORDER="957" O_E="0.0" SE="1.013402253295367" STUDY_ID="STD-Wu-2006" TOTAL_1="45" TOTAL_2="45" VAR="1.026984126984127" WEIGHT="1.577050552087773"/>
<DICH_DATA CI_END="377.3468885548922" CI_START="1.4494787478443176" EFFECT_SIZE="23.387096774193548" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5767407733309624" LOG_CI_START="0.16121185214247977" LOG_EFFECT_SIZE="1.368976312736721" ORDER="958" O_E="0.0" SE="1.4188936453671155" STUDY_ID="STD-Ye-2004" TOTAL_1="30" TOTAL_2="28" VAR="2.0132591768631816" WEIGHT="0.8619642737781239"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.13441930241369" CI_END="2.66167026139666" CI_START="1.702165957954847" DF="8.0" EFFECT_SIZE="2.1285216724877793" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="107" I2="39.091330832343274" ID="CMP-002.01.02" LOG_CI_END="0.4251542522934789" LOG_CI_START="0.23100190070176185" LOG_EFFECT_SIZE="0.3280780764976204" NO="2" P_CHI2="0.10730772268977629" P_Z="3.4988414190231846E-11" STUDIES="9" TAU2="0.04230330405882987" TOTAL_1="436" TOTAL_2="353" WEIGHT="65.91802747456748" Z="6.623882829961512">
<NAME>Methodological quality B - tailored formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="2.5656939039671554" CI_START="1.0452875477961492" EFFECT_SIZE="1.6376470588235295" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.4092048423165676" LOG_CI_START="0.01923577680393355" LOG_EFFECT_SIZE="0.21422030956025057" ORDER="959" O_E="0.0" SE="0.22906975946012828" STUDY_ID="STD-Fan-1999" TOTAL_1="50" TOTAL_2="48" VAR="0.05247295469912103" WEIGHT="8.747090401544018"/>
<DICH_DATA CI_END="15.772588438916594" CI_START="0.9096811070185779" EFFECT_SIZE="3.787878787878788" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.1979029712294418" LOG_CI_START="-0.04111082496910402" LOG_EFFECT_SIZE="0.5783960731301689" ORDER="960" O_E="0.0" SE="0.7278028371042323" STUDY_ID="STD-Huang-2000" TOTAL_1="33" TOTAL_2="25" VAR="0.5296969696969697" WEIGHT="2.711063734013078"/>
<DICH_DATA CI_END="2.3147092111036582" CI_START="0.6507073717433731" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.36449643987003655" LOG_CI_START="-0.18661427319647433" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="961" O_E="0.0" SE="0.3237251608972954" STUDY_ID="STD-Jiang-2000" TOTAL_1="40" TOTAL_2="36" VAR="0.10479797979797982" WEIGHT="7.030760141504189"/>
<DICH_DATA CI_END="2.9084094785871644" CI_START="1.4034690109933328" EFFECT_SIZE="2.020361990950226" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="17" LOG_CI_END="0.46365555135189707" LOG_CI_START="0.14720282772701201" LOG_EFFECT_SIZE="0.3054291895394545" ORDER="962" O_E="0.0" SE="0.18588589632350302" STUDY_ID="STD-Liu-2003" TOTAL_1="52" TOTAL_2="38" VAR="0.03455356645199212" WEIGHT="9.545069279925112"/>
<DICH_DATA CI_END="2.572882499394129" CI_START="1.1677348052823793" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.41041995293014055" LOG_CI_START="0.06734422490013292" LOG_EFFECT_SIZE="0.23888208891513676" ORDER="963" O_E="0.0" SE="0.20152438089706928" STUDY_ID="STD-Luo-2001" TOTAL_1="31" TOTAL_2="31" VAR="0.04061207609594707" WEIGHT="9.259470365903452"/>
<DICH_DATA CI_END="6.271822086401477" CI_START="1.9531804045526688" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="10" LOG_CI_END="0.7973937301626697" LOG_CI_START="0.2907423585378816" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="964" O_E="0.0" SE="0.297609523657138" STUDY_ID="STD-Song-2003" TOTAL_1="50" TOTAL_2="50" VAR="0.08857142857142858" WEIGHT="7.486294268677445"/>
<DICH_DATA CI_END="29.039995708711842" CI_START="1.9369837573056288" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.4629965478516476" LOG_CI_START="0.28712597893175257" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="965" O_E="0.0" SE="0.6907121928367367" STUDY_ID="STD-Wang-2006b" TOTAL_1="32" TOTAL_2="24" VAR="0.47708333333333336" WEIGHT="2.934301851266298"/>
<DICH_DATA CI_END="3.5414568754798457" CI_START="1.5815838814505385" EFFECT_SIZE="2.3666666666666667" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="15" LOG_CI_END="0.5491819577382011" LOG_CI_START="0.19909223026062461" LOG_EFFECT_SIZE="0.37413709399941286" ORDER="966" O_E="0.0" SE="0.20564443889242842" STUDY_ID="STD-Zhu-2001" TOTAL_1="78" TOTAL_2="39" VAR="0.042289635247381725" WEIGHT="9.183386535253828"/>
<DICH_DATA CI_END="3.5956172526418246" CI_START="1.5514983137344789" EFFECT_SIZE="2.361904761904762" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="18" LOG_CI_END="0.5557734556105536" LOG_CI_START="0.1907513079020029" LOG_EFFECT_SIZE="0.37326238175627824" ORDER="967" O_E="0.0" SE="0.21441581645277497" STUDY_ID="STD-Zhu-2002" TOTAL_1="70" TOTAL_2="62" VAR="0.04597414234511008" WEIGHT="9.020590896480062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9746993915283426" CI_START="1.4197997303437697" DF="0.0" EFFECT_SIZE="1.6744186046511629" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="84" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.2955009923488281" LOG_CI_START="0.15222708935453577" LOG_EFFECT_SIZE="0.22386404085168193" NO="3" P_CHI2="1.0" P_Z="9.077007077811428E-10" STUDIES="1" TAU2="0.0" TOTAL_1="172" TOTAL_2="168" WEIGHT="11.097031150524755" Z="6.124848256843806">
<NAME>Methodological quality B - standard formula - immediate efficacy</NAME>
<DICH_DATA CI_END="1.9746993915283426" CI_START="1.4197997303437697" EFFECT_SIZE="1.6744186046511629" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="84" LOG_CI_END="0.2955009923488281" LOG_CI_START="0.15222708935453577" LOG_EFFECT_SIZE="0.22386404085168193" ORDER="968" O_E="0.0" SE="0.08415979983610526" STUDY_ID="STD-Wang-2006a" TOTAL_1="172" TOTAL_2="168" VAR="0.007082871908453303" WEIGHT="11.097031150524755"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.056163722518104" CI_END="2.733775736399414" CI_START="1.725099695139919" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1716435456684726" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="63" I2="58.52743778967463" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4367628846140107" LOG_CI_START="0.23681419842264165" LOG_EFFECT_SIZE="0.33678854151832616" METHOD="MH" NO="2" P_CHI2="0.03402631400639422" P_Q="0.0" P_Z="4.0393184122967854E-11" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="253" TOTAL_2="229" WEIGHT="100.0" Z="6.60262814780311">
<NAME>Overall symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Conventional</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="377.3468885548919" CI_START="1.449478747844318" DF="0.0" EFFECT_SIZE="23.387096774193548" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="2.576740773330962" LOG_CI_START="0.1612118521424799" LOG_EFFECT_SIZE="1.368976312736721" NO="1" P_CHI2="1.0" P_Z="0.026311764431924095" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="0.784978932578887" Z="2.221579087806791">
<NAME>Methodological quality B - standard formula - up to 3month follow up</NAME>
<DICH_DATA CI_END="377.3468885548922" CI_START="1.4494787478443176" EFFECT_SIZE="23.387096774193548" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.5767407733309624" LOG_CI_START="0.16121185214247977" LOG_EFFECT_SIZE="1.368976312736721" ORDER="969" O_E="0.0" SE="1.4188936453671155" STUDY_ID="STD-Ye-2004" TOTAL_1="30" TOTAL_2="28" VAR="2.0132591768631816" WEIGHT="0.784978932578887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.826470962246247" CI_END="2.5208319161403976" CI_START="1.592795883114832" DF="4.0" EFFECT_SIZE="2.0037890852215208" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="63" I2="48.89139665507716" ID="CMP-002.02.02" LOG_CI_END="0.4015438887838071" LOG_CI_START="0.2021601245037694" LOG_EFFECT_SIZE="0.30185200664378825" NO="2" P_CHI2="0.0981458196280196" P_Z="2.9478581216148548E-9" STUDIES="5" TAU2="0.0" TOTAL_1="223" TOTAL_2="201" WEIGHT="99.21502106742112" Z="5.934475796655457">
<NAME>Methodology quality B - tailored formula - up to 3month follow up</NAME>
<DICH_DATA CI_END="2.5656939039671554" CI_START="1.0452875477961492" EFFECT_SIZE="1.6376470588235295" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.4092048423165676" LOG_CI_START="0.01923577680393355" LOG_EFFECT_SIZE="0.21422030956025057" ORDER="970" O_E="0.0" SE="0.22906975946012828" STUDY_ID="STD-Fan-1999" TOTAL_1="50" TOTAL_2="48" VAR="0.05247295469912103" WEIGHT="26.35544803260252"/>
<DICH_DATA CI_END="2.3147092111036582" CI_START="0.6507073717433731" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.36449643987003655" LOG_CI_START="-0.18661427319647433" LOG_EFFECT_SIZE="0.08894108333678108" ORDER="971" O_E="0.0" SE="0.3237251608972954" STUDY_ID="STD-Jiang-2000" TOTAL_1="40" TOTAL_2="36" VAR="0.10479797979797982" WEIGHT="17.592057572226327"/>
<DICH_DATA CI_END="2.572882499394129" CI_START="1.1677348052823793" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.41041995293014055" LOG_CI_START="0.06734422490013292" LOG_EFFECT_SIZE="0.23888208891513676" ORDER="972" O_E="0.0" SE="0.20152438089706928" STUDY_ID="STD-Luo-2001" TOTAL_1="31" TOTAL_2="31" VAR="0.04061207609594707" WEIGHT="22.789710945838653"/>
<DICH_DATA CI_END="29.039995708711842" CI_START="1.9369837573056288" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.4629965478516476" LOG_CI_START="0.28712597893175257" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="973" O_E="0.0" SE="0.6907121928367367" STUDY_ID="STD-Wang-2006b" TOTAL_1="32" TOTAL_2="24" VAR="0.47708333333333336" WEIGHT="3.4727178584135086"/>
<DICH_DATA CI_END="3.5956172526418246" CI_START="1.5514983137344789" EFFECT_SIZE="2.361904761904762" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="18" LOG_CI_END="0.5557734556105536" LOG_CI_START="0.1907513079020029" LOG_EFFECT_SIZE="0.37326238175627824" ORDER="974" O_E="0.0" SE="0.21441581645277497" STUDY_ID="STD-Zhu-2002" TOTAL_1="70" TOTAL_2="62" VAR="0.04597414234511008" WEIGHT="29.0050866583401"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.14950028534588605" CI_START="5.789760289767153E-4" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.009303605835397744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.8253579784163042" LOG_CI_START="-3.237339416753816" LOG_EFFECT_SIZE="-2.03134869758506" METHOD="MH" MODIFIED="2008-05-13 10:15:51 +1200" MODIFIED_BY="jane clarke" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="9.62284978359201E-4" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0" Z="3.301327467970295">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More incidents in CM</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More incidents in CH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.14950028534588605" CI_START="5.789760289767153E-4" DF="0.0" EFFECT_SIZE="0.009303605835397744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="52" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.8253579784163042" LOG_CI_START="-3.237339416753816" LOG_EFFECT_SIZE="-2.03134869758506" MODIFIED="2008-05-13 10:15:51 +1200" MODIFIED_BY="jane clarke" NO="1" P_CHI2="1.0" P_Z="9.62284978359201E-4" STUDIES="2" TAU2="0.0" TOTAL_1="212" TOTAL_2="206" WEIGHT="100.0" Z="3.301327467970295">
<NAME>Methodology quality B</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="975" O_E="0.0" SE="0.0" STUDY_ID="STD-Liu-2000" TOTAL_1="40" TOTAL_2="38" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.14950028534588614" CI_START="5.789760289767153E-4" EFFECT_SIZE="0.009303605835397744" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="52" LOG_CI_END="-0.8253579784163039" LOG_CI_START="-3.237339416753816" LOG_EFFECT_SIZE="-2.03134869758506" ORDER="976" O_E="0.0" SE="1.416809836380132" STUDY_ID="STD-Wang-2006a" TOTAL_1="172" TOTAL_2="168" VAR="2.0073501124634965" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.30522931033791056" CI_END="1.9313937082640005" CI_START="1.2991656758526289" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.584045584045584" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.28587081230759365" LOG_CI_START="0.11366453792487308" LOG_EFFECT_SIZE="0.19976767511623336" METHOD="MH" MODIFIED="2008-05-13 10:15:12 +1200" MODIFIED_BY="jane clarke" NO="4" P_CHI2="0.580622632418518" P_Q="0.0" P_Z="5.43365596752671E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="93" WEIGHT="100.0" Z="4.5473075810576065">
<NAME>Use of additional medication</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours conventional</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.572882499394129" CI_START="1.1677348052823793" DF="0.0" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.41041995293014055" LOG_CI_START="0.06734422490013292" LOG_EFFECT_SIZE="0.23888208891513676" NO="1" P_CHI2="1.0" P_Z="0.006344425489800594" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="28.205128205128204" Z="2.729428243226878">
<NAME>Methodological quality B - standard formula - up to 3-month follow up</NAME>
<DICH_DATA CI_END="2.572882499394129" CI_START="1.1677348052823793" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.41041995293014055" LOG_CI_START="0.06734422490013292" LOG_EFFECT_SIZE="0.23888208891513676" ORDER="977" O_E="0.0" SE="0.20152438089706928" STUDY_ID="STD-Luo-2001" TOTAL_1="31" TOTAL_2="31" VAR="0.04061207609594707" WEIGHT="28.205128205128204"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9153777787193673" CI_START="1.2148180378736817" DF="0.0" EFFECT_SIZE="1.5253968253968253" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="36" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.2822544446400329" LOG_CI_START="0.08451123178989435" LOG_EFFECT_SIZE="0.18338283821496362" NO="2" P_CHI2="1.0" P_Z="2.7770300949169527E-4" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="62" WEIGHT="71.7948717948718" Z="3.635257595985929">
<NAME>Methodological quality B - tailored followup - up to 3 month follow up</NAME>
<DICH_DATA CI_END="1.9153777787193673" CI_START="1.2148180378736817" EFFECT_SIZE="1.5253968253968253" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="36" LOG_CI_END="0.2822544446400329" LOG_CI_START="0.08451123178989435" LOG_EFFECT_SIZE="0.18338283821496362" ORDER="978" O_E="0.0" SE="0.1161553420728616" STUDY_ID="STD-Zhu-2002" TOTAL_1="70" TOTAL_2="62" VAR="0.013492063492063493" WEIGHT="71.7948717948718"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-13 10:15:09 +1200" MODIFIED_BY="jane clarke" NO="3">
<NAME>Experimental Chinese herbal formula versus OTC Chinese herbal formula</NAME>
<DICH_OUTCOME CHI2="24.19827751162973" CI_END="2.3642659362593443" CI_START="1.7963618598284947" CI_STUDY="95" CI_TOTAL="95" DF="17.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.060843796697846" ESTIMABLE="YES" EVENTS_1="422" EVENTS_2="185" I2="29.747065708169625" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.3736963250663328" LOG_CI_START="0.2543938255924888" LOG_EFFECT_SIZE="0.3140450753294108" METHOD="MH" NO="1" P_CHI2="0.11414708987014832" P_Q="0.0" P_Z="5.8067129241935175E-25" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="801" TOTAL_2="726" WEIGHT="100.0" Z="10.318594159928054">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OTC formula</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4358111314547566" CI_END="2.698231418550316" CI_START="1.6210643110179377" DF="4.0" EFFECT_SIZE="2.09141259809709" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="51" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.43107919496129193" LOG_CI_START="0.2098002445623887" LOG_EFFECT_SIZE="0.3204397197618403" NO="1" P_CHI2="0.656165559761752" P_Z="1.3743986926853781E-8" STUDIES="5" TAU2="0.0" TOTAL_1="197" TOTAL_2="183" WEIGHT="26.752414518510697" Z="5.676548165264867">
<NAME>Methodological quality B - standard formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="5.0274383552139215" CI_START="1.211097192671155" EFFECT_SIZE="2.4675324675324677" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7013467541261508" LOG_CI_START="0.08317899743454342" LOG_EFFECT_SIZE="0.39226287578034713" ORDER="979" O_E="0.0" SE="0.3631148002603965" STUDY_ID="STD-Deng-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.13185235816814764" WEIGHT="3.791117565457398"/>
<DICH_DATA CI_END="2.9881059404079755" CI_START="1.1248299685961627" EFFECT_SIZE="1.8333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="12" LOG_CI_END="0.47539599090740947" LOG_CI_START="0.05108687864175319" LOG_EFFECT_SIZE="0.2632414347745814" ORDER="980" O_E="0.0" SE="0.2492412729088265" STUDY_ID="STD-Liu-2002" TOTAL_1="30" TOTAL_2="30" VAR="0.062121212121212126" WEIGHT="6.203646925293924"/>
<DICH_DATA CI_END="12.338866106656118" CI_START="0.706786765513287" EFFECT_SIZE="2.953125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.0912752515733624" LOG_CI_START="-0.15071159119464828" LOG_EFFECT_SIZE="0.470281830189357" ORDER="981" O_E="0.0" SE="0.7295492193759537" STUDY_ID="STD-Niu-1996" TOTAL_1="32" TOTAL_2="21" VAR="0.5322420634920635" WEIGHT="1.2485327145245633"/>
<DICH_DATA CI_END="3.3614300270943476" CI_START="1.619681028776516" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="21" LOG_CI_END="0.5265240752328371" LOG_CI_START="0.20942949535635166" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="982" O_E="0.0" SE="0.18626292586293283" STUDY_ID="STD-Qin-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.03469387755102041" WEIGHT="10.856382119264367"/>
<DICH_DATA CI_END="2.8255334989632774" CI_START="0.6291830475306932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4511004605734531" LOG_CI_START="-0.2012229873568532" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="983" O_E="0.0" SE="0.38317802236740667" STUDY_ID="STD-Zhu-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.1468253968253968" WEIGHT="4.652735193970443"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.794246309357536" CI_END="2.514309327036219" CI_START="1.7993576046512416" DF="11.0" EFFECT_SIZE="2.127002963808035" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="127" I2="38.182265161658556" ID="CMP-003.01.02" LOG_CI_END="0.40041870642907773" LOG_CI_START="0.25511748368628" LOG_EFFECT_SIZE="0.32776809505767884" NO="2" P_CHI2="0.08647929986413949" P_Z="9.359302703984285E-19" STUDIES="12" TAU2="0.0" TOTAL_1="565" TOTAL_2="522" WEIGHT="68.54315322980808" Z="8.842508679111507">
<NAME>Methodological quality B - tailored formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="3.4757202079557237" CI_START="1.228842040085616" EFFECT_SIZE="2.066666666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="15" LOG_CI_END="0.5410448089067836" LOG_CI_START="0.08949606065039943" LOG_EFFECT_SIZE="0.31527043477859146" ORDER="984" O_E="0.0" SE="0.2652419699281528" STUDY_ID="STD-Deng-2005" TOTAL_1="70" TOTAL_2="70" VAR="0.07035330261136712" WEIGHT="7.754558656617405"/>
<DICH_DATA CI_END="4.27929294445658" CI_START="1.3036251961985756" EFFECT_SIZE="2.361904761904762" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.631372017684272" LOG_CI_START="0.11515274582828439" LOG_EFFECT_SIZE="0.37326238175627824" ORDER="985" O_E="0.0" SE="0.3032297556148146" STUDY_ID="STD-Guo-1997" TOTAL_1="35" TOTAL_2="31" VAR="0.09194828469022016" WEIGHT="4.934719145120167"/>
<DICH_DATA CI_END="2.135209766919564" CI_START="0.5298412978326383" EFFECT_SIZE="1.0636363636363637" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.3294405473425697" LOG_CI_START="-0.27585419416669643" LOG_EFFECT_SIZE="0.026793176587936632" ORDER="986" O_E="0.0" SE="0.3555531274198364" STUDY_ID="STD-Li-1999" TOTAL_1="44" TOTAL_2="36" VAR="0.1264180264180264" WEIGHT="5.686676348186097"/>
<DICH_DATA CI_END="6.109469494294453" CI_START="1.892144647059081" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="10" LOG_CI_END="0.7860035006348189" LOG_CI_START="0.27695433344969134" LOG_EFFECT_SIZE="0.5314789170422551" ORDER="987" O_E="0.0" SE="0.2990180006385608" STUDY_ID="STD-Li-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.08941176470588236" WEIGHT="5.16970577107827"/>
<DICH_DATA CI_END="2.510503050812248" CI_START="0.896234720476454" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.39976075347380713" LOG_CI_START="-0.04757823536244458" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="988" O_E="0.0" SE="0.2627691364061218" STUDY_ID="STD-Li-2004" TOTAL_1="40" TOTAL_2="40" VAR="0.06904761904761905" WEIGHT="7.237588079509578"/>
<DICH_DATA CI_END="2.6338362225250918" CI_START="1.329593764605088" EFFECT_SIZE="1.871345029239766" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="19" LOG_CI_END="0.42058876612120905" LOG_CI_START="0.12371896973429522" LOG_EFFECT_SIZE="0.27215386792775215" ORDER="989" O_E="0.0" SE="0.1743827879268656" STUDY_ID="STD-Liu-2004" TOTAL_1="45" TOTAL_2="40" VAR="0.030409356725146185" WEIGHT="10.400231610051579"/>
<DICH_DATA CI_END="3.0649506760372986" CI_START="0.4440890751530474" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4864234898504567" LOG_CI_START="-0.3525299105892302" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="990" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Liu-2005" TOTAL_1="30" TOTAL_2="30" VAR="0.24285714285714288" WEIGHT="3.101823462646962"/>
<DICH_DATA CI_END="3.861857369581218" CI_START="0.7930121977374059" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.586796229891926" LOG_CI_START="-0.10072013251933722" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="991" O_E="0.0" SE="0.4038505145412571" STUDY_ID="STD-Shen-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.1630952380952381" WEIGHT="4.135764616862616"/>
<DICH_DATA CI_END="7.772316783709215" CI_START="1.831851731085897" EFFECT_SIZE="3.7732919254658386" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.8905504932418395" LOG_CI_START="0.26289031923516065" LOG_EFFECT_SIZE="0.5767204062385001" ORDER="992" O_E="0.0" SE="0.36869069317949305" STUDY_ID="STD-Sun-2006" TOTAL_1="46" TOTAL_2="45" VAR="0.13593282723717506" WEIGHT="3.658561007224622"/>
<DICH_DATA CI_END="4.91415192300244" CI_START="1.147832848552574" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6914485787418917" LOG_CI_START="0.059878649179879034" LOG_EFFECT_SIZE="0.3756636139608854" ORDER="993" O_E="0.0" SE="0.3709873029462982" STUDY_ID="STD-Wang-2000b" TOTAL_1="50" TOTAL_2="50" VAR="0.13763157894736844" WEIGHT="4.135764616862616"/>
<DICH_DATA CI_END="2.4800216900966503" CI_START="0.7932509145499902" EFFECT_SIZE="1.4025974025974026" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.3944554791520607" LOG_CI_START="-0.10058941852312506" LOG_EFFECT_SIZE="0.14693303031446783" ORDER="994" O_E="0.0" SE="0.290791823406169" STUDY_ID="STD-Yu-2003" TOTAL_1="35" TOTAL_2="30" VAR="0.08455988455988456" WEIGHT="6.124112990354258"/>
<DICH_DATA CI_END="5.87647526855622" CI_START="1.9671656004161406" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="10" LOG_CI_END="0.7691169127418487" LOG_CI_START="0.29384092134266143" LOG_EFFECT_SIZE="0.5314789170422551" ORDER="995" O_E="0.0" SE="0.2791794700019832" STUDY_ID="STD-Zhang-2001" TOTAL_1="60" TOTAL_2="40" VAR="0.07794117647058824" WEIGHT="6.203646925293924"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9866047408423881" CI_START="0.428908171011337" DF="0.0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.2981114675392316" LOG_CI_START="-0.36763568005765546" LOG_EFFECT_SIZE="-0.03476210625921192" NO="3" P_CHI2="1.0" P_Z="0.8378223511239585" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="21" WEIGHT="4.704432251681226" Z="0.20467973926961314">
<NAME>Methodological quality C - tailored formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="1.9866047408423881" CI_START="0.428908171011337" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.2981114675392316" LOG_CI_START="-0.36763568005765546" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="996" O_E="0.0" SE="0.39106316999994123" STUDY_ID="STD-Wang-1996" TOTAL_1="39" TOTAL_2="21" VAR="0.15293040293040291" WEIGHT="4.704432251681226"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.443563329296175" CI_END="2.3886569299920737" CI_START="1.7417161668341947" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.039696642147486" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="141" I2="20.94170989788482" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.37815377883719486" LOG_CI_START="0.2409773830361311" LOG_EFFECT_SIZE="0.309565580936663" METHOD="MH" MODIFIED="2008-05-13 10:04:38 +1200" MODIFIED_BY="jane clarke" NO="2" P_CHI2="0.22600472503420932" P_Q="0.0" P_Z="9.063895490908463E-19" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="602" TOTAL_2="565" WEIGHT="100.0" Z="8.846090261315556">
<NAME>Overall symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OTC formula</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0712289390860588" CI_END="2.916866628590354" CI_START="1.6133672310851492" DF="3.0" EFFECT_SIZE="2.169326401446655" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="39" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.4649165718054961" LOG_CI_START="0.20773323179163447" LOG_EFFECT_SIZE="0.3363249017985652" NO="1" P_CHI2="0.5577552851141079" P_Z="2.956720300415482E-7" STUDIES="4" TAU2="0.0" TOTAL_1="167" TOTAL_2="153" WEIGHT="27.349596019940172" Z="5.126185036663959">
<NAME>Methodological quality B - standard formula - up to 3 month' follow up</NAME>
<DICH_DATA CI_END="5.0274383552139215" CI_START="1.211097192671155" EFFECT_SIZE="2.4675324675324677" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7013467541261508" LOG_CI_START="0.08317899743454342" LOG_EFFECT_SIZE="0.39226287578034713" ORDER="997" O_E="0.0" SE="0.3631148002603965" STUDY_ID="STD-Deng-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.13185235816814764" WEIGHT="5.0458273669699745"/>
<DICH_DATA CI_END="12.338866106656118" CI_START="0.706786765513287" EFFECT_SIZE="2.953125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.0912752515733624" LOG_CI_START="-0.15071159119464828" LOG_EFFECT_SIZE="0.470281830189357" ORDER="998" O_E="0.0" SE="0.7295492193759537" STUDY_ID="STD-Niu-1996" TOTAL_1="32" TOTAL_2="21" VAR="0.5322420634920635" WEIGHT="1.6617476062748457"/>
<DICH_DATA CI_END="3.3614300270943476" CI_START="1.619681028776516" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="21" LOG_CI_END="0.5265240752328371" LOG_CI_START="0.20942949535635166" LOG_EFFECT_SIZE="0.36797678529459443" ORDER="999" O_E="0.0" SE="0.18626292586293283" STUDY_ID="STD-Qin-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.03469387755102041" WEIGHT="14.449414732686746"/>
<DICH_DATA CI_END="2.8255334989632774" CI_START="0.6291830475306932" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4511004605734531" LOG_CI_START="-0.2012229873568532" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="1000" O_E="0.0" SE="0.38317802236740667" STUDY_ID="STD-Zhu-2003" TOTAL_1="42" TOTAL_2="42" VAR="0.1468253968253968" WEIGHT="6.192606314008605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.87901435925514" CI_END="2.399681499931053" CI_START="1.6517485488889387" DF="9.0" EFFECT_SIZE="1.9908968921837085" ESTIMABLE="YES" EVENTS_1="217" EVENTS_2="102" I2="35.15389661659653" ID="CMP-003.02.02" LOG_CI_END="0.3801536033776314" LOG_CI_START="0.2179439339396845" LOG_EFFECT_SIZE="0.2990487686586579" NO="2" P_CHI2="0.12669452309480111" P_Z="4.946692563457046E-13" STUDIES="10" TAU2="0.0" TOTAL_1="435" TOTAL_2="412" WEIGHT="72.65040398005982" Z="7.226755571636759">
<NAME>Methodological quality B - tailored formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="4.27929294445658" CI_START="1.3036251961985756" EFFECT_SIZE="2.361904761904762" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="9" LOG_CI_END="0.631372017684272" LOG_CI_START="0.11515274582828439" LOG_EFFECT_SIZE="0.37326238175627824" ORDER="1001" O_E="0.0" SE="0.3032297556148146" STUDY_ID="STD-Guo-1997" TOTAL_1="35" TOTAL_2="31" VAR="0.09194828469022016" WEIGHT="6.567915787584885"/>
<DICH_DATA CI_END="2.135209766919564" CI_START="0.5298412978326383" EFFECT_SIZE="1.0636363636363637" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.3294405473425697" LOG_CI_START="-0.27585419416669643" LOG_EFFECT_SIZE="0.026793176587936632" ORDER="1002" O_E="0.0" SE="0.3555531274198364" STUDY_ID="STD-Li-1999" TOTAL_1="44" TOTAL_2="36" VAR="0.1264180264180264" WEIGHT="7.568741050454962"/>
<DICH_DATA CI_END="6.109469494294453" CI_START="1.892144647059081" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="10" LOG_CI_END="0.7860035006348189" LOG_CI_START="0.27695433344969134" LOG_EFFECT_SIZE="0.5314789170422551" ORDER="1003" O_E="0.0" SE="0.2990180006385608" STUDY_ID="STD-Li-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.08941176470588236" WEIGHT="6.880673682231784"/>
<DICH_DATA CI_END="2.510503050812248" CI_START="0.896234720476454" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.39976075347380713" LOG_CI_START="-0.04757823536244458" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="1004" O_E="0.0" SE="0.2627691364061218" STUDY_ID="STD-Li-2004" TOTAL_1="40" TOTAL_2="40" VAR="0.06904761904761905" WEIGHT="9.632943155124497"/>
<DICH_DATA CI_END="2.6338362225250918" CI_START="1.329593764605088" EFFECT_SIZE="1.871345029239766" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="19" LOG_CI_END="0.42058876612120905" LOG_CI_START="0.12371896973429522" LOG_EFFECT_SIZE="0.27215386792775215" ORDER="1005" O_E="0.0" SE="0.1743827879268656" STUDY_ID="STD-Liu-2004" TOTAL_1="45" TOTAL_2="40" VAR="0.030409356725146185" WEIGHT="13.84229646660747"/>
<DICH_DATA CI_END="3.0649506760372986" CI_START="0.4440890751530474" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4864234898504567" LOG_CI_START="-0.3525299105892302" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="1006" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Liu-2005" TOTAL_1="30" TOTAL_2="30" VAR="0.24285714285714288" WEIGHT="4.12840420933907"/>
<DICH_DATA CI_END="3.861857369581218" CI_START="0.7930121977374059" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.586796229891926" LOG_CI_START="-0.10072013251933722" LOG_EFFECT_SIZE="0.24303804868629442" ORDER="1007" O_E="0.0" SE="0.4038505145412571" STUDY_ID="STD-Shen-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.1630952380952381" WEIGHT="5.504538945785427"/>
<DICH_DATA CI_END="7.772316783709215" CI_START="1.831851731085897" EFFECT_SIZE="3.7732919254658386" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.8905504932418395" LOG_CI_START="0.26289031923516065" LOG_EFFECT_SIZE="0.5767204062385001" ORDER="1008" O_E="0.0" SE="0.36869069317949305" STUDY_ID="STD-Sun-2006" TOTAL_1="46" TOTAL_2="45" VAR="0.13593282723717506" WEIGHT="4.869399836656339"/>
<DICH_DATA CI_END="4.91415192300244" CI_START="1.147832848552574" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6914485787418917" LOG_CI_START="0.059878649179879034" LOG_EFFECT_SIZE="0.3756636139608854" ORDER="1009" O_E="0.0" SE="0.3709873029462982" STUDY_ID="STD-Wang-2000b" TOTAL_1="50" TOTAL_2="50" VAR="0.13763157894736844" WEIGHT="5.504538945785427"/>
<DICH_DATA CI_END="2.4800216900966503" CI_START="0.7932509145499902" EFFECT_SIZE="1.4025974025974026" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.3944554791520607" LOG_CI_START="-0.10058941852312506" LOG_EFFECT_SIZE="0.14693303031446783" ORDER="1010" O_E="0.0" SE="0.290791823406169" STUDY_ID="STD-Yu-2003" TOTAL_1="35" TOTAL_2="30" VAR="0.08455988455988456" WEIGHT="8.150951900489959"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More incidents in CT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More incidents in CH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="60" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Completed data</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1011" O_E="0.0" SE="0.0" STUDY_ID="STD-Shen-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5422720032473106" CI_END="1.865651920466714" CI_START="1.3383858919912746" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5801779044522415" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="92" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.27083061951675585" LOG_CI_START="0.1265813500533872" LOG_EFFECT_SIZE="0.1987059847850715" METHOD="MH" MODIFIED="2008-05-13 10:15:09 +1200" MODIFIED_BY="jane clarke" NO="4" P_CHI2="0.9692574713279031" P_Q="0.0" P_Z="6.672569352378267E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="210" TOTAL_2="192" WEIGHT="100.0" Z="5.399771869072857">
<NAME>Use of additional medication</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.34176690192659875" CI_END="2.430318716259255" CI_START="1.2077010092014893" DF="1.0" EFFECT_SIZE="1.713212878280913" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="22" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.3856632314732856" LOG_CI_START="0.08195942921383018" LOG_EFFECT_SIZE="0.2338113303435579" NO="1" P_CHI2="0.558811285037131" P_Z="0.0025459962498234445" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="51" WEIGHT="25.37016267607808" Z="3.0178205425250195">
<NAME>Methodological quality B - standard formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="2.348958239818553" CI_START="1.0570694256996216" EFFECT_SIZE="1.5757575757575757" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.370875295884639" LOG_CI_START="0.024103511629184327" LOG_EFFECT_SIZE="0.19748940375691165" ORDER="1012" O_E="0.0" SE="0.20369546261967028" STUDY_ID="STD-Deng-2003" TOTAL_1="33" TOTAL_2="30" VAR="0.04149184149184149" WEIGHT="16.496547892207808"/>
<DICH_DATA CI_END="3.7892830576632246" CI_START="1.0228786035557444" EFFECT_SIZE="1.96875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.578557048080394" LOG_CI_START="0.009824094186957531" LOG_EFFECT_SIZE="0.29419057113367575" ORDER="1013" O_E="0.0" SE="0.33407655239053047" STUDY_ID="STD-Niu-1996" TOTAL_1="32" TOTAL_2="21" VAR="0.11160714285714285" WEIGHT="8.873614783870272"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.015787506122044104" CI_END="1.8517672650469392" CI_START="1.272341886330255" DF="2.0" EFFECT_SIZE="1.5349531116794544" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="70" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.2675864025093544" LOG_CI_START="0.10460382467419539" LOG_EFFECT_SIZE="0.18609511359177489" NO="2" P_CHI2="0.9921373209515723" P_Z="7.612130845409728E-6" STUDIES="3" TAU2="0.0" TOTAL_1="145" TOTAL_2="141" WEIGHT="74.62983732392192" Z="4.475812386618007">
<NAME>Methodological quality B - tailored formula - up to 3month follow up</NAME>
<DICH_DATA CI_END="2.1047882224890357" CI_START="1.105496244263042" EFFECT_SIZE="1.5253968253968253" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="18" LOG_CI_END="0.3232084049549115" LOG_CI_START="0.04355727147501584" LOG_EFFECT_SIZE="0.18338283821496362" ORDER="1014" O_E="0.0" SE="0.16426846010152704" STUDY_ID="STD-Guo-1997" TOTAL_1="35" TOTAL_2="31" VAR="0.026984126984126985" WEIGHT="20.041260662434276"/>
<DICH_DATA CI_END="2.1351379018610706" CI_START="1.1397858648281118" EFFECT_SIZE="1.56" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="25" LOG_CI_END="0.3294259299854976" LOG_CI_START="0.056823266723425664" LOG_EFFECT_SIZE="0.1931245983544616" ORDER="1015" O_E="0.0" SE="0.16012815380508713" STUDY_ID="STD-Li-2001" TOTAL_1="50" TOTAL_2="50" VAR="0.025641025641025637" WEIGHT="26.244508010330602"/>
<DICH_DATA CI_END="2.1090753931462953" CI_START="1.0933219829774614" EFFECT_SIZE="1.5185185185185186" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="27" LOG_CI_END="0.32409210474762923" LOG_CI_START="0.03874808037386719" LOG_EFFECT_SIZE="0.1814200925607482" ORDER="1016" O_E="0.0" SE="0.1676124923928486" STUDY_ID="STD-Shen-2001" TOTAL_1="60" TOTAL_2="60" VAR="0.028093947606142724" WEIGHT="28.344068651157052"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-05-13 10:07:21 +1200" MODIFIED_BY="jane clarke" NO="4">
<NAME>Chinese herbal medicine versus acupuncture</NAME>
<DICH_OUTCOME CHI2="0.9145283129815854" CI_END="2.8205302006553428" CI_START="1.0887236465920203" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.752363525465081" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.45033075426802327" LOG_CI_START="0.03691765570510367" LOG_EFFECT_SIZE="0.24362420498656345" METHOD="MH" NO="1" P_CHI2="0.3389159067430785" P_Q="0.0" P_Z="0.02088747418309072" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="68" WEIGHT="99.99999999999999" Z="2.310012281641315">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours acupuncture</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.906666920325815" CI_START="0.9056381953607644" DF="0.0" EFFECT_SIZE="2.675925925925926" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.8979934439054589" LOG_CI_START="-0.043045269366262545" LOG_EFFECT_SIZE="0.4274740872695981" NO="1" P_CHI2="1.0" P_Z="0.07496842217786906" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="17" WEIGHT="21.20311070448307" Z="1.7806574874260739">
<NAME>Methodological quality B - standard formula with 3 month follow up</NAME>
<DICH_DATA CI_END="7.906666920325815" CI_START="0.9056381953607644" EFFECT_SIZE="2.675925925925926" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="3" LOG_CI_END="0.8979934439054589" LOG_CI_START="-0.043045269366262545" LOG_EFFECT_SIZE="0.4274740872695981" ORDER="1017" O_E="0.0" SE="0.5527707983925666" STUDY_ID="STD-Miao-2001" TOTAL_1="36" TOTAL_2="17" VAR="0.3055555555555555" WEIGHT="21.20311070448307"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.538059624219617" CI_START="0.8910559991801749" DF="0.0" EFFECT_SIZE="1.5038461538461538" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.4045018203455292" LOG_CI_START="-0.05009500149543144" LOG_EFFECT_SIZE="0.17720340942504884" NO="2" P_CHI2="1.0" P_Z="0.12651217909736487" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="51" WEIGHT="78.79688929551692" Z="1.528001445343617">
<NAME>Methodological quality B - tailored formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="2.538059624219617" CI_START="0.8910559991801749" EFFECT_SIZE="1.5038461538461538" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.4045018203455292" LOG_CI_START="-0.05009500149543144" LOG_EFFECT_SIZE="0.17720340942504884" ORDER="1018" O_E="0.0" SE="0.2670324234399406" STUDY_ID="STD-Wang-2003" TOTAL_1="52" TOTAL_2="51" VAR="0.07130631516820775" WEIGHT="78.79688929551692"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-05-13 10:15:03 +1200" MODIFIED_BY="jane clarke" NO="5">
<NAME>Chinese versus heat compression</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="499.1780943897061" CI_START="2.0620702097039065" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="32.083333333333336" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="2.698255518792933" LOG_CI_START="0.3143034481288187" LOG_EFFECT_SIZE="1.506279483460876" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.013257635462143527" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="20" WEIGHT="100.0" Z="2.476772561465536">
<NAME>Reduction of pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CHM</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="499.1780943897061" CI_START="2.0620702097039065" DF="0.0" EFFECT_SIZE="32.083333333333336" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="2.698255518792933" LOG_CI_START="0.3143034481288187" LOG_EFFECT_SIZE="1.506279483460876" NO="1" P_CHI2="1.0" P_Z="0.013257635462143527" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="100.0" Z="2.476772561465536">
<NAME>Methodological quality B - standard formula - up to 3 month follow up</NAME>
<DICH_DATA CI_END="499.1780943897061" CI_START="2.0620702097039065" EFFECT_SIZE="32.083333333333336" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="0" LOG_CI_END="2.698255518792933" LOG_CI_START="0.3143034481288187" LOG_EFFECT_SIZE="1.506279483460876" ORDER="1019" O_E="0.0" SE="1.4003452470611706" STUDY_ID="STD-Zhang-2000" TOTAL_1="35" TOTAL_2="20" VAR="1.9609668109668108" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-13 10:15:03 +1200" MODIFIED_BY="jane clarke" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>More incidents in CT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>More incidents in CH</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Methodology quality B - standard formula</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1020" O_E="0.0" SE="0.0" STUDY_ID="STD-Zhang-2000" TOTAL_1="35" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown">
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of trials comparing CHM with conventional therapy for the outcome of reduction of pain</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of trials comparing CHM with conventional therapy for the outcome of overall symptoms</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of trials comparing CHM (self-desogned) with CHM (over-the-counter) for the outcome of reduction of pain</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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</FILE>
</FIGURE>
<FIGURE FILENAME="Other figure.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2008-05-05 12:48:13 +1200" MODIFIED_BY="Julie A Brown" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of trials comparing CHM (self-desogned) with CHM (over-the-counter) for the outcome of overall symptoms</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAAAAAFUAAKoAAP8AJAAA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-13 09:56:28 +1200" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2008-05-13 09:55:03 +1200" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-05-13 09:54:17 +1200" MODIFIED_BY="jane clarke">MEDLINE search</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-13 09:55:03 +1200" MODIFIED_BY="jane clarke">
<P/>
<P>1. randomised controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomised controlled trials/<BR/>4. random allocation/<BR/>5. double-blind method/<BR/>6. single-blind method/<BR/>7. or/1-6<BR/>8. clinical trial.pt.<BR/>9. exp clinical trials/<BR/>10. (clin$ adj25 trial$).tw.<BR/>11. ((singl$ or doubl$ or treb$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>12. placebos/<BR/>13. placebo$.tw.<BR/>14. random$.tw.<BR/>15. research design/<BR/>16. or/8-15<BR/>17. animal/ not (human/ and animal/)<BR/>18. 7 or 16<BR/>19. 18 not 17<BR/>20 exp Menstruation disturbances/<BR/>21 Pelvic pain/<BR/>22 (pelvic adj5 pain).tw.<BR/>23 Dysmenorrhoea/<BR/>24 dysmenorrh$.tw.<BR/>25 (painful adj5 menstrua$).tw.<BR/>26 (painful adj5 period$).tw.<BR/>27 menstrual disorder.tw.<BR/>28 or/20-27<BR/>29 19 and 28<BR/>30 complementary medicine.mp<BR/>21 Alternative Medicine/<BR/>32 alternative medicine.mp.<BR/>33 herbal medicine.mp.<BR/>34 Medicine, Herbal/<BR/>35 Chinese adj 5 herbal.mp.<BR/>36 Medicine, Chinese Traditional/<BR/>37 Drugs, Chinese Herbal/<BR/>38 Medicine, Oriental Traditional/<BR/>39 or/30-38<BR/>40 29 and 39</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-05-13 09:56:28 +1200" MODIFIED_BY="jane clarke" NO="2">
<TITLE MODIFIED="2008-05-13 09:55:31 +1200" MODIFIED_BY="jane clarke">Chinese database search</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-13 09:56:28 +1200" MODIFIED_BY="jane clarke">
<P>1. Tong Jing (period pain).<BR/>2. Yuan Fa Xing Tong Jing (primary dysmenorrhoea).<BR/>3. 1 or 2.<BR/>4. Lin Chuang (clinical).<BR/>5. Lin Chuang Yun Yong (clinical application).<BR/>6. Lin Chuang Zhi Liao (clinical treatment).<BR/>7. Lin Chuang Yan Jiu (clinical research).<BR/>8. Lin Chuang Guan Cha (clinical observation).<BR/>9. Lin Chuang Dui Zhao (clinical comparison).<BR/>10. 4 or 5 or 6 or 7 or 8 or 9.<BR/>11. 3 and 10.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>